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2. List of abbreviations 
4E-BP1 (eIF4EBP1) eIF4E binding protein 1  
AAA+ ATPase ATPases associated with diverse cellular activities 
ADRM1 Adhesion regulating molecule 1 
Akt (PKB) Thymoma viral proto-oncogene (Protein kinase B) 
ALP Autophagy-lysosomal pathway 
AMBRA1 Autophagy and beclin-1 regulator 1 
ANOVA Analysis of variance 
ARE Antioxidant response element 
Atf4 Activating transcription factor 4 
ATG Autophagy related proteins 
ATG12 Autophagy related 12 
ATG5 Autophagy related 5 
ATP Adenosine triphosphate 
ATPase Adenosinetriphosphatase 
 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 
BECN1 Beclin1, autophagy related 
BNIP3 BCL2/adenovirus E1B interacting protein 3 
BTZ Bortezomib 
C. elegans Caenorhabditis elegans 
CASTOR1 Cytosolic arginine sensor for mTORC1 subunit 1 
CASTOR2 Cytosolic arginine sensor for mTORC1 subunit 2 
CDK Cyclin-dependent kinase 
CL Cleaved 
CNC Cap-n-collar [Drosophila melanogaster] 
CNC-bZIP Cap’n’collar basic-region leucine zipper 
CP 26S proteasome core particle 
CSA Cross-sectional area 
CTSL Cathepsin L 
D-BSSE Department of Biosystems Science and Engineering 
DDI2 DNA-damage inducible protein 2 
DE Differentially expressed 
DES Desmin 
DMEM Glutamax Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DNM1 Dynamin 1 
DUB Deubiquitinase 
EDL Musculus extensor digitorum longus 
EGFP Enhanced green fluorescent protein 
eIF4E Eukaryotic translation initiation factor 4E 
EpRE Electrophile response element 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERt2 Human estrogen receptor type 2 
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Fbxo21 / Smart F-box protein 21 / Specific of muscle atrophy and regulated by 
transcription 
Fbxo30 / Musa1 F-box protein 30 / Muscle ubiquitin ligase of SCF complex in atrophy 1  
Fbxo32 / Atrogin-1 F-box protein 32 / Atrogin-1 
FBXW7 F-box and WD-40 domain protein 7 
FKBP1A / FKBP12  FK506-binding protein 1a 
FL Full-length 
FLCN Folliculin 
FNIP2 Folliculin interacting protein 2 
FoxO Forkhead box O 
FTH1 Ferritin heavy polypeptide 1 
FTL1 Ferritin light polypeptide 1 
GABARAPL1 Gamma-aminobutyric acid (GABA) receptor-associated protein-like 1 
Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 
GAP GTPase-activating proteins 
GAST Musculus gastrocnemius 
GATOR1 GTPase-activating protein complex 1 
GATOR2 GTPase-activating protein complex 2 
GCLC Glutamate-cysteine ligase, catalytic subunit 
GCLM Glutamate-cysteine ligase, modifier subunit 
GDP Guanosine diphosphate 
GEF Guanosine triphosphate exchange factors 
GlcNAc O-linked N-acetylglucosamine 
GSS Glutathione synthetase 
GST Glutathione S-transferase 
GTP Guanosine triphosphate 
 GTPase Guanosinetriphosphatase 
HAS Human skeletal ɑ-actin 
HCFC1 Host cell factor C1 
HIF1A Hypoxia-inducible factor 1α 
HMOX1 Heme oxygenase 1 
HRP Horseradish peroxidase-conjugated 
IGF Insulin-like growth factor 
IRS1 Insulin-receptor substrate 1 
iTSCmKO Inducible TSC1 muscle specific knockout 
IκB Inhibitor of kappa light polypeptide gene enhancer in B cells 
JUN Jun proto-oncogene 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KO Knockout 
LAMA2-MD Laminin-α2-related muscular dystrophy 
LC3 / Map1lc3a Microtubule-associated protein 1 light chain 3 alpha 
LCR-F1 / Nrf1β Locus control region-factor 1 
m7GTP-cap 7-methylguanosine 5'-triphosphate cap 
Maf Musculoaponeurotic fibrosarcoma proteins 
MCL Mantle-cell lymphoma 
ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic 
ME2 Malic enzyme 2, NAD(+)-dependent, mitochondrial 
MEF Mouse embryonic fibroblast 
  | List of abbreviations | 
 
  7 
MerCreMer Cre recombinase containing two mutated estrogen receptor ligand-
binding domains 
MLST8 mTOR associated protein, LST8 homolog 
MT1 Metallothionein 1 
MT2 Metallothionein 2 
mTOR Mammalian (or mechanistic) target of rapamycin 
mTORC1 Mammalian (or mechanistic) target of rapamycin complex 1 
mTORC2 Mammalian (or mechanistic) target of rapamycin complex 2 
MyHC / Myh Myosin heavy chain 
NASH Non-alcoholic steatohepatitis 
NFE2 Nuclear factor-erythroid 2 
NFE2L1 / Nrf1 Nuclear factor, erythroid derived 2, -like 1 
NFE2L2 / Nrf2 Nuclear factor, erythroid derived 2, -like 2 
NFE2L2 / Nrf3 Nuclear factor, erythroid derived 2, -like 3 
NF-κB Nuclear factor of kappa light polypeptide gene enhancer in B cells 
NGLY1 N-glycanase 1 
Nhb1 N-terminal homology box 1 
NIBR Novartis Institutes for BioMedical Research, Cambridge, MA, USA 
NMJ Neuromuscular junction 
NQO1 NAD(P)H dehydrogenase, quinone 1 
OGT O-linked GlcNAc transferase 
p97 / VCP ATPase p97 / Valosin containing protein 
PA Proteasome activator 
PA200 / PSME4 Proteasome activator 200 / Proteasome activator subunit 4 
PACE Proteasome associated control element 
PCA Principal component analysis 
PDK1 3-phosphoinositide dependent protein kinase 1 
Pen/strep Penicillin-streptomycin 
PI3K Phosphoinositide-3-kinase 
PLA Musculus plantaris 
PNK Polynucleotide kinase 
PPARGC1A / PGC-1α Peroxisome proliferator–activated receptor γ coactivator 1α 
Ppp1r15a Protein phosphatase 1, regulatory subunit 15A 
PRAS40 / Akt1s1 Proline-rich Akt substrate of 40 kDa / Akt1 substrate 1 (proline-rich) 
PRDX1 Peroxiredoxin 1 
PSM Proteasome (prosome, macropain) 26S subunit 
PSME1 Proteasome activator subunit 1 / PA28 alpha 
PSME2 Proteasome activator subunit 2 / PA28 beta 
PSME3 Proteasome activator subunit 3 / PA28 gamma 
QGF Quantitative Genomics Facility 
QUAD Musculus quadriceps femoris 
Rag Ras-related small G proteins 
Raptor / RPTOR Regulatory-associated protein of mTOR, complex 1 
RB1CC1 / FIP200 RB1-inducible coiled-coil 1 
RHEB Ras homolog enriched in brain 
Rictor RPTOR independent companion of mTOR, complex 2 
RLU Relative luminescence units 
RP 26S proteasome regulatory particle 
RPN4 Stress-regulated transcription factor RPN4 [Saccharomyces cerevisiae] 
RPS6 / S6 Ribosomal protein S6 
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S6K1 / RPS6KB1 Ribosomal protein S6 kinase, polypeptide 1 
 SBMA Spinal and bulbar muscular atrophy 
SEM Standard error of the mean 
SEM1 SEM1, 26S proteasome complex subunit 
SESN2 Sestrin 2 
SFP1 Split finger protein 1 
SIN1 / MAPKAP1 Mitogen-activated protein kinase associated protein 1 
SKN-1 Protein skinhead-1 [Caenorhabditis elegans] 
SLC38A9 Solute carrier family 38, member 9 
SMA Spinal muscular atrophy 
SMN1 Survival motor neuron 1 
SOL Musculus soleus 
SQSTM1 / p62 Sequestosome 1 
SREBP1 / SREBF1 Sterol regulatory element binding transcription factor 1 
SYVN1 / Hrd1 Synovial apoptosis inhibitor 1, synoviolin 
TA Musculus tibialis anterior 
TBC1D7 TBC1 domain family, member 7 
TMT Tandem Mass Tag 
Trim63 / MuRF1 Tripartite motif-containing 63 / Muscle ring finger 1  
TRP53 / p53 Transformation related protein 53 
TSA Trichostatin A 
TSC1 TSC complex subunit 1 / tuberous sclerosis complex 1 
TSC2 TSC complex subunit 2 / tuberous sclerosis complex 2 
TSCmKO TSC1 muscle specific knockout 
TXN1 Thioredoxin 1 
Ub Ubiquitin 
UBC Ubiquitin C 
UBE4B Ubiquitination factor E4B 
UCHL5 Ubiquitin carboxyl-terminal esterase L5 
ULK1 Unc-51 like kinase 1 
UPS Ubiquitin-proteasome system 
USP14 Ubiquitin specific peptidase 14 
v-ATPase Vacuolar adenosinetriphosphatase 
VPS34 Vacuolar protein sorting 34 
WCL Whole-cell lysates 
β-TrCP beta-transducin repeat containing protein 
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3. Abstract 
Skeletal muscle is crucial for human daily life. It is essential for locomotion and breathing and 
it affects whole-body metabolism. Preservation of muscle mass is thus critical to maintain body 
function and health. Current views indicate that muscle mass is controlled by the tight balance 
between protein synthesis and protein degradation, called proteostasis. Perturbation of this 
balance by extrinsic factors, as for example seen in cachexia (i.e., muscle loss as a secondary 
consequence of e.g. cancer, AIDS, or cardiac and kidney disease) or in sarcopenia (i.e., loss 
of muscle mass and function as a consequence of aging), is a main cause of loss of life quality 
and increased mortality. Thus, a better molecular understanding of muscle proteostasis is of 
fundamental importance to develop possible treatment strategies to counteract the above 
diseases.  
Two major regulators of muscle proteostasis are the mammalian (or mechanistic) target of 
rapamycin complex 1 (mTORC1) and the forkhead box O (FoxO) transcription factors. While 
mTORC1 controls proteostasis by increasing translation and protein synthesis, FoxO regulates 
catabolic processes by increasing the expression of genes encoding for proteins involved in 
protein degradation. Thus, increased activation of FoxO causes muscle loss (atrophy), 
whereas activation of mTORC1 is associated with muscle gain (hypertrophy). However and in 
striking contrast to the expected outcome of muscle gain, sustained activation of mTORC1 in 
muscle by knockout of its upstream inhibitor TSC1 (TSCmKO mice) results in atrophy. This 
phenotype is observed despite the marked increase in protein synthesis. Hence, the 
mechanisms involved in muscle atrophy in TSCmKO mice remain unresolved.  
The purpose of this thesis was to provide new insights on the role of mTORC1 in regulating 
muscle proteostasis. Particularly, to characterize the mechanism of this mTORC1-driven 
atrophy observed in TSCmKO mice. Furthermore, the aim was to investigate if sustained 
activation of mTORC1 increases overall protein degradation via the thymoma viral proto-
oncogene (Akt)-FoxO-signaling or by distinct other catabolic pathways. 
In this thesis, it was established that sustained activation of mTORC1 in muscles of TSCmKO 
mice leads to a significant increase of the ubiquitin-proteasome system (UPS). This was 
characterized by increased expression of ubiquitin-E3-ligases, increased ubiquitinylation, 
increased proteasomal biosynthesis and increased proteasome activity. The increase of the 
UPS was reversed by short-term treatment with the mTORC1-inhibitor rapamycin. 
Interestingly, the same increase of the UPS was observed upon acute muscle-specific deletion 
of Tsc1 for 3 weeks. Surprisingly, constitutive activation of Akt in muscle resulted in a similar 
induction of proteasomal biosynthesis and proteasome activity as observed in TSCmKO mice. 
Hence, this suggests a mechanism, which is independent of the activation of FoxO 
transcription factors. Finally, it was established that the increased UPS activity was 
  | Abstract | 
 
  10 
accompanied by a concomitant increase of the transcription factor “nuclear factor, erythroid-
derived 2,-like 1” (NFE2L1, hereafter called Nrf1). 
In short, this thesis demonstrated that mTORC1 activation is a major driver of the ubiquitin-
proteasome system in skeletal muscle and identified Nrf1, together with FoxO transcription 
factors, as a key mediator of this pathway. Both, mTORC1 signaling as well as the UPS are 
considered as potential treatment targets in a large variety of distinct muscle wasting diseases. 
Therefore, understanding the underlying regulatory mechanisms of how mTORC1 controls 
muscle mass is of fundamental importance to eventually develop new therapeutic agents that 
could slow-down the massive muscle wasting observed in cachexia and sarcopenia. 
  | Introduction | 
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4. Introduction 
Muscle tissue is the largest organ in most mammalian organisms and accounts for up to 50% 
of total body mass in humans. Generally, muscle tissue is divided into two subcategories based 
on its structure and its contractile properties. Smooth muscle tissue is an integral part of hollow 
organs such as blood vessels, the respiratory tract and the digestive tract. Regulated by the 
autonomic nervous system, smooth muscles contract and relax to adjust the diameter of the 
lumen. Striated muscle tissue includes cardiac (myocardium) and skeletal muscle tissue. 
Skeletal muscles are required for voluntary locomotion controlled by the somatic nervous 
system. Their main function is to generate mechanical force, which enables locomotion, 
precise movements and respiration and to allow keeping an upright posture. Skeletal muscles 
are composed of multiple muscle fiber bundles, which in turn are formed by differentiated, post-
mitotic myofibers. Each myofiber consists of longitudinally arranged myofibrils, composed of 
large proteins such as titin, myosin and actin, whereas the latter two are organized into thick 
and thin myofilaments, respectively. Innervating motor neurons provide neuronal stimuli by 
generating electric signals in the form of action potentials, which triggers the release of calcium 
ions by the sarcoplasmatic reticulum (Calderon et al., 2014; Kahn and Sandow, 1950; Sandow, 
1952). The free calcium enables the formation of cross-bridges between the heads of myosin 
molecules with the active sites on actin filaments (Calderon et al., 2014). According to the 
sliding filament theory, hydrolysis of adenosine triphosphate (ATP), which provides the energy 
for releasing the myosin heads from actin, the thick (myosin) and the thin (actin) filaments slide 
along each other causing the muscle to contract (Huxley and Niedergerke, 1954; Huxley and 
Hanson, 1954). 
 
Skeletal muscle fiber type classification and composition 
Skeletal muscles (hereafter, simply referred to as muscle) were initially classified as being fast 
or slow based on their shortening velocity (Buller et al., 1960). This classification corresponds 
to morphological but also metabolic differences observed between these two types of muscle. 
Slow muscles appear red because of their high myoglobin content giving them a higher 
oxidative capacity compared to the white fast muscles, which preferentially rely on anaerobic 
glycolysis for ATP production. (Schiaffino, 2010; Scott et al., 2001). Most muscles are a 
heterogeneous mixture of different muscle fiber types. Zooming from the level of the whole 
muscle into the level of single fibers, reveals three distinct groups of fiber types, differing in 
their twitch characteristics, fatigue resistance and histochemical features: fast-twitch, fatigable, 
glycolytic fibers; fast-twitch, fatigue-resistant, glycolytic-oxidative fibers; and slow-twitch, 
fatigue-resistant, oxidative fibers (Barnard et al., 1971; Burke et al., 1971). In parallel, the 
correlation found between the speed of muscle fiber shortening and their myosin 
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adenosinetriphosphatase (ATPase) activity led to the division into type II (fast) fibers and type 
I (slow) fibers (Barany, 1967). The myosin ATPase activity correlates with the particular myosin 
heavy chain (MyHC or Myh) isoform (Scott et al., 2001). The three MyHC isoforms that were 
originally identified in humans (four in rodents), MyHC-I, MyHC-IIa and MyHC-IId/x (MyHC-IIb 
/ MyHC-IId/x in rodents) can be identified by myosin ATPase staining and led to the general 
classification of type I, IIa and IId/x (IIb / IId/x in smaller mammals), respectively (Brooke and 
Kaiser, 1970). Muscle fibers that contain only one MyHC-isoform are referred to as “pure” fibers 
(Staron and Pette, 1993). The following classification and functional description for these 
muscle fibers have commonly been accepted (Brooke and Kaiser, 1970; Peter et al., 1972; 
Schiaffino, 2011): 
• Type I fibers: slow-twitch-oxidative 
• Type IIa fibers: fast-twitch-oxidative-glycolytic 
• Type IIx fibers: fast-intermediate-twitch-glycolytic 
• Type IIb fibers: fast-twitch-glycolytic 
The fact that each muscle fiber can express more than one MyHC-isoform explains the 
existence of intermediate – so called “hybrid” muscle fibers – possessing intermediate fiber 
characteristics (Hamalainen and Pette, 1995; Pierobon-Bormioli et al., 1981; Staron and Pette, 
1993). 
A previous study examined the fiber type composition and percentage of MyHC-isoforms of 
most hindlimb muscles in male C57BL6J mice (Augusto, 2004). They showed that the slow-
twitch, oxidative soleus (SOL) muscle is composed of the more oxidative MyHC-isoforms, i.e. 
MyHC-I (42%) and -IIa (58%). In contrast, the same study demonstrated that the fast-twitch 
glycolytic muscles extensor digitorum longus (EDL), tibialis anterior (TA) and gastrocnemius 
(GAST) are mainly composed of glycolytic fibers, namely type IIb (~60%) and hybrid type IIb/IIx 
(25%) fibers (Augusto, 2004). Other studies showed that the hindlimb, fast-twitch muscles 
plantaris (PLA) and quadriceps (QUAD) are majorly composed of type IIb and IIx fibers (Gentry 
et al., 2011; Waters et al., 2004). Muscle is a highly plastic tissue and has a remarkable 
capacity to undergo fiber type changes in response to external stimuli and changing 
environmental conditions. For example, type II fiber loss has been observed in patients 
suffering from cancer, diabetes and chronic heart failure. Moreover, age-dependent changes 
in motor unit composition seem to have similar consequences in elderly people characterized 
by a fast-to-slow fiber type shift (Ciciliot et al., 2013; Lexell, 1995). In contrast, a reduction in 
type I fibers and a concomitant increase in type II fibers occurs upon muscle disuse, inactivity 
and denervation (Wang and Pessin, 2013). In the case of denervation, for example due to 
spinal cord injury, the loss of neuronal input leads to the activation of the nerve activity-
independent, default “fast gene program” resulting in a slow-to-fast fiber type switch (Ciciliot et 
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al., 2013). Another external stimulus, which has been shown to cause a fiber type switch, is 
exercise. In humans, heavy resistance exercise leads to an increase in type IIa fibers and a 
reduction in type IIx fibers (Kraemer et al., 1995; Staron et al., 1994). In rodents, the 
transcriptional regulator peroxisome proliferator–activated receptor γ coactivator 1α 
(PPARGC1A, hereafter called PGC-1α) seems to coordinate an exercise-stimulated fast-to-
slow fiber type switch (Handschin et al., 2007; Lin et al., 2002). A fiber type switch to more 
oxidative, slow-type-I fibers correlates with an increase in oxidative capacity and fatigue-
resistance (Crow and Kushmerick, 1982; Szentesi et al., 2001) and with improved endurance 
performance and exercise efficiency (Coyle et al., 1992; Horowitz et al., 1994). Interestingly, a 
recent study showed that inorganic nitrate increases exercise efficiency and performance by 
induction of PGC-1α and that this leads to a similar fast-to-slow fiber type switch, as found in 
transgenic PGC-1α overexpressing mice (Lin et al., 2002; Roberts et al., 2017). In contrast, 
muscle specific PGC-1α knockout (KO) mice exhibit a switch from oxidative type I and type IIa 
fibers towards type IIx and IIb fibers, resulting in reduced endurance capacity (and fiber 
damage) (Handschin et al., 2007). Therefore, the fiber type composition of a muscle largely 
determines its physiological properties. The high plastic potential of muscle, i.e. its ability to 
alter its structural and functional properties, enables the adaptation to changes in physiological 
requirements in distinct environmental conditions. 
 
Muscle proteostasis maintains muscle mass and physiology 
The fact that muscle is a highly plastic tissue, also explains why its function is often 
compromised in pathological conditions as for example seen in cachexia or in sarcopenia. 
Generally speaking, muscle mass is controlled by the tight balance between protein synthesis 
and protein degradation, termed proteostasis. Perturbation of this balance can lead to a decline 
in muscle mass and ultimately to muscle wasting. Muscle wasting has severe consequences 
on the individual level by reducing quality of life and increasing mortality, but also puts a huge 
burden on healthcare systems. Cachexia describes a complex metabolic syndrome 
characterized by the loss of muscle mass that occurs as a sequelae of primary diseases such 
as cancer, AIDS and cardiac or kidney disease (Evans et al., 2008), whereas sarcopenia 
describes the age-associated loss of muscle mass and function (Fielding et al., 2011). 
Preserving muscle mass is critical in these conditions to maintain metabolic and functional 
capacities, which helps to maintain quality of life and increases chances of survival. 
Unfortunately, besides exercise, there is at this time no effective and safe treatment option 
available to counteract muscle wasting in cachexia (Furrer and Handschin, 2019) or 
sarcopenia (Leuchtmann and Handschin, 2019). Therefore, a better molecular understanding 
of muscle proteostasis is of fundamental importance to develop novel and effective treatment 
strategies to counteract the development of sarcopenia and other muscle wasting diseases. 
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mTORC1 regulates muscle proteostasis by affecting protein synthesis 
As described above, muscle proteostasis determines muscle size: if overall rates of protein 
degradation are lower than the overall rates in protein synthesis muscle will grow 
(hypertrophy); if overall rates of protein degradation outstrips the overall rates in protein 
synthesis muscle shrinks (atrophy) (Sandri, 2013). 
Therefore, muscle size is tightly controlled and dependent on regulators of protein synthesis 
and degradation. The mammalian (or mechanistic) target of rapamycin (mTOR) is a serine / 
threonine protein kinase and a highly conserved regulator of cell growth (Laplante and 
Sabatini, 2012). Rapamycin, clinically termed sirolimus, was isolated from the bacteria 
Streptomyces Hygroscopicus and was discovered because of its anti-proliferative properties 
in yeast (Laplante and Sabatini, 2012). Rapamycin forms a complex with the FK506-binding 
protein 1a (FKBP1A, also FKBP12), which binds to the mediators TOR1 and TOR2 (Cafferkey 
et al., 1993; Kunz et al., 1993). Later, mTOR was identified as the homologous protein in 
mammals (Brown et al., 1994; Sabatini et al., 1994; Sabers et al., 1995). mTOR assembles 
into two structurally and functionally distinct multi-protein complexes, called mTORC1 and 
mTORC2 (Laplante and Sabatini, 2012; Shimobayashi and Hall, 2014). The essential core 
components of mTORC1 are regulatory-associated protein of mTOR, complex 1 (Raptor) and 
mTOR associated protein, LST8 homolog (MLST8), whereas those of mTORC2 are RPTOR 
independent companion of mTOR, complex 2 (Rictor), mitogen-activated protein kinase 
associated protein 1 (SIN1, also MAPKAP1) and MLST8 (Shimobayashi and Hall, 2014). 
Studies in mice have shown that mTOR function in skeletal muscle is largely based on the 
activity of mTORC1 and not mTORC2 (Bentzinger et al., 2008; Risson et al., 2009). Rapamycin 
directly interacts and inhibits mTORC1 (Brown et al., 1994; Sabatini et al., 1994). 
 
mTORC1 involves amino acid sensing to localize at the lysosomal surface 
mTORC1 is activated by different cellular inputs, such as amino acids, insulin, growth factors 
and energy status, to drive cell growth through increasing protein translation and lipid synthesis 
or by activating energy metabolism, ATP production and glycolytic flux (Laplante and Sabatini, 
2012). Activation of mTORC1 depends on its translocation to the lysosomal surface. Upon 
amino acid stimulation, mTORC1 co-localizes and anchors at the lysosomal surface through 
direct interactions between the Ras-related small G proteins (Rag) and Raptor (Bar-Peled et 
al., 2013; Bar-Peled et al., 2012; Sancak et al., 2010; Sancak et al., 2008) (Figure 1). The Rag 
guanosine triphosphatases (GTPases) form heterodimeric complexes comprised of RagA or 
RagB bound to RagC or RagD (Sancak et al., 2008) and they are held at the lysosomal surface 
by the Ragulator protein complex (Sancak et al., 2010) (Figure 1). Amino acid sensing by 
mTORC1 initiates from within the lysosomal lumen and depends on the interplay between 
multiple distinct factors, including the vacuolar adenosine triphosphatase (v-ATPase) (Zoncu 
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et al., 2011), the lysosomal amino acid transporter solute carrier family 38, member 9 
(SLC38A9) (Rebsamen et al., 2015) and the Ragulator complex but also on the nucleotide 
state of the Rag GTPases (Bar-Peled et al., 2012; Sancak et al., 2010) (Figure 1). Distinct 
GTPase-activating proteins (GAPs) or Guanosine triphosphate exchange factors (GEFs) 
regulate the state of the Rag GTPases. Amongst them, a complex composed of folliculin 
(FLCN) and folliculin interacting protein 2 (FNIP2) which is a GAP for RagC/RagD (Petit et al., 
2013; Tsun et al., 2013). Regulator is a GEF for the RagA/RagB GTPases (Bar-Peled et al., 
2012). The GTPase-activating protein complex 1 (GATOR1) has GAP activity on RagA/RagB 
and is a critical negative regulator of mTORC1, whereas GATOR2 binds to GATOR1 and is a 
positive regulator of mTORC1 (Bar-Peled et al., 2013) (Figure 1). 
 
 
Figure 1: The mTORC1-Akt-FoxO signaling in skeletal muscle regulates muscle proteostasis. By the 
stimulation with amino acids and growth factors or insulin, mTORC1 is localized at the lysosomal surface in its 
active form. The left side of the signaling illustrates the role of mTORC1 in regulating anabolic processes. The right 
side of the signaling depicts the catabolic processes mainly regulated by Akt-FoxO signaling in a continual crosstalk 
with mTORC1. Important mTORC1-driven mechanisms to regulate catabolic processes are the feedback-loop via 
S6K1 and IRS1 to dampen Akt activity, the blockage of autophagy induction by phosphorylation of ULK1 and the 
transcriptional induction of Nrf1 to increase proteasomal subunits. Important note: Not all of those interactions have 
been confirmed in skeletal muscle! 
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Particularly two amino acids, leucine and arginine, are known to induce mTORC1 localization 
and to support its activation at the lysosomal surface by the help of specific sensors. Sestrin 2 
(SESN2) is a leucine sensor and interacts with GATOR2 to inhibit mTORC1-signaling in the 
absence of leucine (Chantranupong et al., 2014; Saxton et al., 2016b; Wolfson et al., 2016) 
(Figure 1). SLC38A9 is a lysosomal arginine sensor, which forms a supercomplex with 
Ragulator, to transmit arginine sufficiency to mTORC1 (Jung et al., 2015; Rebsamen et al., 
2015; Wang et al., 2015) (Figure 1). SLC38A9 functions in parallel with cytosolic arginine 
sensor for mTORC1 subunit 1 (CASTOR1) to regulate mTORC1 in response to arginine. 
CASTOR1 heterodimerizes with CASTOR2 to interact with GATOR2 and negatively regulate 
mTORC1 activtiy (Figure 1). Arginine disrupts this interaction by binding to CASTOR1, which 
leads to the activation of the mTORC1 pathway (Chantranupong et al., 2016; Saxton et al., 
2016a). 
 
mTORC1 activation by growth factors and insulin 
Although essential, the dynamic regulation of mTORC1 localization by amino acid availability 
is not sufficient for the activation of mTORC1, which also requires the presence of the GTPase 
Ras homolog enriched in brain (RHEB) (Sancak et al., 2010). The guanosine triphosphate 
(GTP) / guanosine diphosphate (GDP) loading state of RHEB is controlled by the presence of 
growth factors and GTP-bound RHEB is a direct activator of mTORC1 (Dibble and Manning, 
2013; Long et al., 2005) (Figure 1). A protein complex (the TSC complex) comprising TSC1, 
TSC2 (tuberous sclerosis complex 1 and 2) and TBC1D7 (TBC1 domain family, member 7) 
functions as GAP for RHEB (Long et al., 2005). Therefore, the TSC complex functions as an 
upstream inhibitor of mTORC1 and is essential for the growth factor-induced mTORC1 
activation (Inoki et al., 2002; Manning et al., 2002) (Figure 1). Binding of growth factors, 
including insulin and insulin-like growth factors (IGF), to its cell-surface receptors promotes the 
intracellular recruitment of the insulin-receptor substrate 1 (IRS1), the subsequent activation 
of the phosphoinositide-3-kinase (PI3K) and the recruitment of the protein kinase B (PKB, 
hereafter called Akt) to the plasma membrane (Laplante and Sabatini, 2009) (Figure 1). At the 
plasma membrane, Akt is activated by 3-phosphoinositide dependent protein kinase 1 (PDK1) 
through phosphorylation at threonine 308 (Alessi et al., 1997; Stokoe et al., 1997; Wick et al., 
2000). Akt phosphorylates TSC2, which disrupts its interaction with TSC1 and TBC1D7, which 
in turn leads to the dissociation of the TSC complex from the lysosomal surface, allowing GTP-
loaded RHEB to bind to the lysosomal surface and activate mTORC1 (Inoki et al., 2002; 
Manning et al., 2002; Menon et al., 2014; Potter et al., 2002) (Figure 1). Akt also activates 
mTORC1 independently from the TSC complex, by phosphorylating and inactivating proline-
rich Akt substrate of 40kDa (PRAS40) at threonine 246, which functions as an inhibitor through 
its binding to raptor (Sancak et al., 2007; Vander Haar et al., 2007). 
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mTORC1 regulates translation initiation and protein synthesis 
mTORC1 functions as a central regulator of cell growth by controlling key players in protein 
translation and degradation. Active mTORC1 phosphorylates its targets S6 kinase 1 (S6K1) 
and 4E-binding protein 1 (4E-BP1) (Ma and Blenis, 2009) (Figure 1). Phosphorylation of 4E-
BP1 leads to its dissociation from eukaryotic translation initiation factor 4E (eIF4E), which is 
essential to start the signaling cascade resulting in the assembly of the 48S pre-initiation 
complex (Ma and Blenis, 2009) (Figure 1). Phosphorylation of S6K1 promotes protein 
synthesis by activating ribosomal protein S6 and therefore ribosome biogenesis but also by 
regulating translation initiation factors (Ma and Blenis, 2009). These activities make mTORC1 
a major hub to control mammalian cell size, particularly also in regulating muscle fiber growth. 
 
mTORC1 activation also affects protein catabolism in muscle 
Based on the function of mTORC1 in controlling protein synthesis, stimulation of mTORC1 
activity was described as mediator of muscle hypertrophy (Bodine et al., 2001; Ruegg and 
Glass, 2011; Sandri, 2013) and recently proposed as a possible treatment option for muscle 
wasting conditions (Yoon, 2017). 
The results obtained from studies using mice in which TSC1 is specifically deleted in skeletal 
muscle fibers (called TSCmKO mice), which leads to constantly active mTORC1, however, 
challenges this concept as most muscles are already atrophic at young age (Bentzinger et al., 
2013) and because the mice develop a severe myopathy causing death at the age of 
approximately one year (Castets et al., 2013). The phenotypic similarity between skeletal 
muscles of mice that are deficient for autophagy related 7 (Atg7), a gene essential for 
macroautophagy (hereafter called autophagy) (Masiero et al., 2009), and of the TSCmKO mice 
suggested that impairment of autophagy might be responsible for the late-onset myopathy in 
TSCmKO mice. 
 
The role of mTORC1 in regulating the autophagy-lysosomal pathway 
Autophagy is the preferred degradation route for large, cytoplasmic molecules (such as protein 
aggregates, organelles, lipid droplets or invading bacteria) and is a process that is essential 
for the clearing of aberrant proteins and cell organelles by delivering the cytosolic substrates 
to the lysosome for degradation (Dikic, 2017). The autophagy-lysosome pathway (ALP) starts 
with the engulfment of cellular material, targeted for degradation, by a double-membrane 
structure called the phagophore, which closes to form the autophagosome (Lamb et al., 2013). 
Autophagosomes fuse with lysosomes, which provides degradative lysosomal proteases, 
converting it into an autolysosome (Lamb et al., 2013). The lysosomal proteases degrade the 
sequestered cytoplasmic material into amino acids and macromolecules that are transported 
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across the lysosomal membrane to the cytosol for reuse, for example, in the production of new 
proteins (Lamb et al., 2013). In this context, autophagy provides molecular building blocks 
during periods of nutrient deprivation but also eliminates unwanted cellular contents. The core 
machinery that is necessary and sufficient to drive this highly complex process involves more 
than 30 autophagy-related (ATG) proteins that function sequentially in the formation of the 
autophagosome (Wang and Klionsky, 2003). The unc-51 like kinase 1 (ULK1) is the most 
upstream kinase within the autophagy core machinery and its phosphorylation status is the 
main determinant of autophagy activation. ULK1 is part of a multiprotein complex with ATG13, 
ATG101 and RB1-inducible coiled-coil 1 (RB1CC1, also known as FIP200) which induces 
autophagosome formation together with another multiprotein complex composed of vacuolar 
protein sorting 34 (VPS34), Beclin1, autophagy related (BECN1) and autophagy and beclin-1 
regulator 1 (AMBRA1) (Ganley et al., 2009; Hara et al., 2008; He and Levine, 2010; Hosokawa 
et al., 2009) (Figure 1). The formation of the phagophore requires two ubiquitin-like 
conjugation systems: the conjugation of ATG12 and ATG5, which are localized to the 
phagophore and the conjugation to phosphatidylethanolamine of microtubule-associated 
protein 1 light chain 3 (Map1lc3a, hereafter called LC3) and gamma-aminobutyric acid (GABA) 
receptor-associated protein-like 1 (GABARAPL1) which are localized to both the phagophore 
and the autophagosomal membrane (Weidberg et al., 2010). Therefore, LC3 and GABARAPL1 
family members have a dual function in contributing to the maturation of the phagophore and 
interacting with selective autophagy adaptors to facilitate substrate sequestration (Dikic, 2017). 
Because of all these distinct steps, monitoring of autophagy is very complex and challenging. 
Importantly, one has to distinguish measurements that monitor the numbers of autophagic 
elements (such as autophagosomes or autolysosomes), from measurements that measure 
autophagic flux as the complete process (Klionsky et al., 2012). An important measurement is 
the accumulation of sequestosome 1 (SQSTM1, hereafter called p62), an ubiquitin receptor 
for facilitating the degradation of ubiquitinylated proteins in autophagosomes (Rogov et al., 
2014), which is used as a readout for autophagy impairment. Another important measurement 
is the rate of conversion of soluble LC3I to autophagosome-associated LC3II, which is 
representative of the accumulation of autophagosomes (Klionsky et al., 2012).  
mTORC1 phosphorylates and inactivates ULK1 at serine 757, thereby blocking autophagy 
induction (Kim et al., 2011) (Figure 1). Indeed, autophagy induction was completely blocked 
in TSCmKO mice due to the phosphorylation of ULK1, and inhibition of mTORC1 activation by 
rapamycin alleviated this blockage (Castets et al., 2013). The impairment of autophagy 
induction in TSCmKO mice was further supported and characterized by accumulations of p62, 
increased levels of LC3I and LC3II and increased expression of genes involved in the ALP, 
such as Gabarapl1, LC3b, cathepsin L (Ctsl) and BCL2/adenovirus E1B interacting protein 3 
(Bnip3) (Castets et al., 2013). While inhibition of autophagy can explain the late-onset 
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myopathy in the TSCmKO mice, the muscle atrophy observed in young TSCmKO mice cannot 
be explained by this mechanism. Instead, overall protein degradation rates may exceed the 
rates in protein synthesis, resulting in an imbalanced proteostasis. One possibility for the 
increased protein degradation could be an overall dampening of Akt signaling as a 
consequence of sustained mTORC1 activation. This inhibition of Akt could be based on a well-
described feedback loop from mTORC1 via S6K1 and IRS1 to Akt (Bentzinger et al., 2008; 
Harrington et al., 2004) (Figure 1). Inhibition of Akt result in the activation of forkhead box O 
(FoxO) pathways, which in turn could result in the activation of the ubiquitin-proteasome-
system (UPS) (Figure 1).  
 
The crosstalk between mTORC1 and Akt-FoxO-signaling to regulate muscle proteostasis 
The discovery that sustained activation of mTORC1 in muscle leads to decreased Akt activity, 
and that mTORC1 therefore regulates both, muscle anabolism and catabolism in parallel, 
further highlights the importance of mTORC1 in regulating muscle proteostasis. The protein 
kinase Akt was established as the major hub at the crossroad in between protein synthesis or 
protein breakdown. Under nutrient-rich conditions, Akt activates mTORC1 and promotes 
protein synthesis. In parallel, when the IRS1-PI3K-Akt signaling pathway is active, FoxO 
transcription factors are inactive and sequestered in the cytosol (Sandri et al., 2004). In 
contrast, in catabolic states where Akt activity is inhibited, the FoxO transcription factors enter 
the nucleus and become transcriptionally active (Sandri et al., 2004). 
The FoxO transcription factor family is a subclass of forkhead transcription factors 
characterized by a winged helix deoxyribonucleic acid (DNA)-binding domain known as a 
forkhead box (Kaestner et al., 2000). The mammalian FoxO family comprises four members: 
FoxO1, FoxO3, FoxO4 and FoxO6. FoxO transcription factors are involved in several 
physiological and pathological processes, including aging, cancer and neurological diseases 
(Greer and Brunet, 2008; Maiese et al., 2008; Webb and Brunet, 2014). Emerging evidence 
from multiple systems indicate that FoxO transcription factors orchestrate the expression of 
genes involved in cellular quality control, and in particular the proteostasis network (Kikis et 
al., 2010). In muscle, activation of FoxO transcription factors induces autophagy and causes 
atrophy in various catabolic conditions, such as denervation or starvation (Sandri et al., 2004; 
Zhao et al., 2007). Muscle atrophy involves a transcriptional regulation of a set of genes that 
are commonly increased or decreased in atrophying muscles during different catabolic 
conditions and that are named atrogenes (Lecker et al., 2004; Sacheck et al., 2007). These 
genes are involved in protein degradation (ALP and UPS), antioxidant stress response, DNA 
repair, mitochondrial function and energy balance pathways (Lecker et al., 2004; Sacheck et 
al., 2007). Initially, FoxO1, 3 and 4 (hereafter together referred to as FoxO) were identified as 
the main transcription factors regulating the expression of the atrogenes and ubiquitin-E3-
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ligases F-box protein 32 (Fbxo32, hereafter called Atrogin-1) and muscle ring finger 1 (MuRF1, 
also called Trim63) (Sacheck et al., 2004; Sandri et al., 2004) (Figure 1). Importantly, FoxO 
regulates the transcription of various genes involved in autophagy (i.e. LC3b, Gabarapl1, 
Beclin1, Bnip3 and Ctsl) and thereby induces autophagy (Mammucari et al., 2007; Zhao et al., 
2007). Recently, FoxO was shown to be required for the induction of several atrogenes and 
the newly identified ubiquitin-E3-ligases F-box protein 30 (Fbxo30, also called Musa1) and F-
box protein 21 (Fbxo21, also called Smart) (Milan et al., 2015; Sartori et al., 2013). 
In muscles, the two major degradation systems, the ALP and the UPS, are coordinately 
regulated to remove proteins and organelles upon atrophy (Mammucari et al., 2007; Sandri, 
2010; Zhao et al., 2007). Besides regulating the increase of autophagy-related genes and 
various ubiquitin-E3-ligases, FoxO induces the transcription of some additional atrogenes, 
which are involved in the UPS. Amongst them are few genes encoding for proteasomal 
subunits (Figure 1), such as protease (prosome, macropain) 26S subunit, alpha type 1 
(Psma1), Psmc4, Psmd11 and Psme4, the ubiquitin C gene (Ubc), the deubiquitinating 
enzyme ubiquitin specific peptidase 14 (Usp14) and the E3/E4 enzyme ubiquitination factor 
E4B (Ube4b) (Milan et al., 2015). These genes are critical in several steps of the UPS and 
might have an important role in the control of the proteasome degradation. Therefore, current 
views indicate that FoxO is the major transcription factor involved in regulating catabolic 
processes and driving muscle atrophy. Nevertheless, further work is necessary to understand 
the interplay between the autophagy-lysosomal and the ubiquitin-proteasome degradation 
system. 
Further investigations are also required to understand the crosstalk between mTORC1 and 
FoxO in regulating muscle proteostasis. This includes not only the regulation of Akt-FoxO-
signaling upon sustained activation of mTORC1 mentioned above, but also the regulation of 
autophagy and of the UPS, both essential processes allowing muscle fibers to adapt to cellular 
stress and nutritional restrictions. For example, autophagy is associated with both, mTORC1- 
and FoxO-signaling. While FoxO was shown to be required to induce and sustain autophagic 
flux, mTORC1 was shown to block autophagy induction completely (Castets et al., 2013; 
Mammucari et al., 2007; Milan et al., 2015). Under low nutrient condition, mTORC1 is inactive 
and therefore does not block autophagy induction, while FoxO is essential to induce autophagy 
to overcome the lack of amino acid and cellular stress (Milan et al., 2015). In contrast, 
sustained activation of mTORC1 blocks basal and starvation-induced autophagy irrespective 
of whether FoxO and its autophagy-related target genes are increased or not (Castets et al., 
2013). Altogether, these findings suggest that mTORC1 is the dominant regulator of autophagy 
induction in muscle. Nevertheless, mTORC1 as well as FoxO are essential for maintaining 
muscle proteostasis and the interplay between both of them ensures a tight coordination of 
metabolic pathways. Even though, mTORC1 and FoxO both were found to increase the 
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expression of proteasomal genes, their role in regulating the UPS remains to be resolved. 
(Milan et al., 2015; Zhang et al., 2014). A further understanding of this mechanism might be 
important to understand another aspect of the crosstalk between mTORC1 and FoxO in 
regulating muscle proteostasis. 
 
The ubiquitin-proteasome system 
Besides the ALP, the UPS is responsible for maintaining cellular homeostasis. The UPS is the 
primary degradation system for short-lived, misfolded and damaged proteins (Dikic, 2017). The 
protein degradation through the UPS starts from attaching a chain of multiple ubiquitin (Ub) 
molecules to the target proteins of the proteasome (Figure 2). Ubiquitin is a highly conserved 
small protein with 76-amino acids, which can be covalently coupled to a lysine within a 
substrate protein (Dikic, 2017). Ubiquitination is both inducible and reversible and requires a 
cascade of three enzymatic reactions: In the first step, the Ub-activating enzyme (E1) activates 
Ub and transfers it to the Ub conjugating enzyme (E2), which cooperates with ubiquitin-E3-
ligases to attach it to the substrate protein (Dikic, 2017) (Figure 2). Ubiquitin itself contains 
seven lysine residues that can be targeted in recurrent rounds of this cascade, giving rise to 
differently linked and branched Ub chains (poly-ubiquitinylation) (Dikic, 2017). The action of 
ubiquitin-E3-ligases can be reversed by specific deubiquitinases (DUBs) that can cleave Ub 
from substrates or process different types of Ub chains. (Dikic, 2017) (Figure 2). The key 
component of the UPS for degradation is the 26S proteasome (Figure 2). 
 
Proteasome structure and function 
The 26S proteasome recognizes ubiquitinylated proteins that, upon ATP hydrolysis, 
translocate into the 20S core particle where they are degraded to short peptides and amino 
acids (Finley et al., 2016). The 26S proteasome is a multi-catalytic, ATP-dependent protein 
complex, composed of various subunits that are assembled into two distinct subcomplexes - 
the 20S proteasome core particle (CP, red in Figure 2) and the 19S proteasome regulatory 
particle (RP, blue in Figure 2), which is attached to one or both ends of the 20S proteasome 
(Finley et al., 2016). In the CP, four stacked heptameric rings of subunits are assembled into 
an α7β7β7α7 architecture. Thus, the outer rings are formed by the α-subunits and the inner 
rings are formed by β-subunits (Finley et al., 2016) (Figure 2). Three out of the seven β-
subunits are proteolytically active including chymotrypsin-like (cleavage after hydrophobic 
amino acids, mediated by the β5 subunit), caspase-like (cleavage after acidic residues, 
mediated by the β1 subunit), and trypsin-like (cleavage after basic residues, mediated by the 
β2 subunit) activities (Groll et al., 2000) (Figure 2). Because of its closed architecture, the CP 
requires activators to facilitate gate opening and substrate degradation. The most 
comprehensively characterized proteasome activator (PA) is the 19S RP, also termed PA700. 
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Figure 2: The ubiquitin-proteasome system (UPS) for the degradation of misfolded and short-lived proteins 
and peptide fragments. The UPS involves attaching of free Ubiquitin (Ub) to substrates using the Ub-activating 
enzyme (E1), the Ub conjugating enzyme (E2) and the ubiquitin-E3-ligases. The 26S proteasome recognizes K48-
linked poly-ubiquitinylated substrates and degrades them to short peptide fragments and amino acids. 
 
The 19S RP regulates proteasome function by identification, binding, deubiquitination, 
unfolding and translocation of substrates to the proteolytic chamber of the CP (Livneh et al., 
2016). The RP is divided into two additional subcomplexes: the “base” and the “lid” (Livneh et 
al., 2016). The “base” consists of a hexameric ring of six proteasomal ATPases associated 
with diverse cellular activities (AAA)-family ATPase subunits (PSMC1-PSMC6) (Finley et al., 
2016) as well as three ubiquitin receptor subunits, recognizing substrates targeted to the 
proteasome (PSMD2, PSMD4 and adhesion regulating molecule 1 (ADRM1)) and PSMD1 
(Diaz-Villanueva et al., 2015; Fu et al., 1998; Husnjak et al., 2008; Shi et al., 2016). The 
ATPase ring assists the gate opening of the 20S CP and converts energy from ATP hydrolysis 
into mechanical force which leads to the unfolding and translocation of proteasome substrates 
(Maillard et al., 2011; Nyquist and Martin, 2014; Rabl et al., 2008). The “lid” consists of nine 
different proteasomal subunits (PSMD3, PSMD6, PSMD7, PSMD8, PSMD11, PSMD12, 
PSMD13, PSMD14 and SEM1, 26S proteasome complex subunit (SEM1)) which form a 
horseshoe-shaped structure (Livneh et al., 2016). A main function of the lid is deubiquitination 
of recognized substrates, which is carried out by the DUBs and particularly by PSMD14 and 
by proteins that transiently associate with the RP, such as the ubiquitin carboxyl-terminal 
esterase L5 (UCHL5) and USP14 (Leggett et al., 2002; Verma et al., 2002). 
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Alternative proteasome activators binding to the core particle 
The degradation of ubiquitinylated proteins relies on the 26S proteasomes. Nevertheless, 
some additional proteins can compete with the 19S RP for the occupancy of the ends of the 
20S CP, including proteasome activator subunit 1 (PSME1, also PA28α), PSME2 (PA28β), 
PSME3 (PA28γ) and proteasome activator 200 (PA200, also PSME4) (Finley et al., 2016). 
PA28α/β/γ are oligomeric ring complexes, belonging to the 11S family of proteasome activators 
(Stadtmueller and Hill, 2011). PA28α/β assemble into hetero-heptameric, PA28γ into homo-
heptameric ring structures with the ability to open the CP by docking to it (Stadtmueller and 
Hill, 2011). They do not have ATPase activity for substrate translocation into the CP (Finley et 
al., 2016). However, this does not exclude a role in promoting protein degradation, particularly 
for substrates that have little or no tertiary structure, such as the cyclin-dependent kinase 
(CDK) inhibitors p16, p19 and p21, which can diffuse into the CP if the gate is open 
(Voutsadakis, 2017). Interestingly, PA28α/β/γ do not recognize ubiquitin, which provides an 
ubiquitin-independent way for protein degradation (Finley et al., 2016). The 20S CP can 
associate at the same time with either one or two 11S activators, or in combination with 19S 
RP and a second activator, creating hybrid proteasomes (Tanahashi et al., 2000). PA200 is a 
200 kDa monomer that folds into a toroidal shape and promotes only partial opening of the 
20S gate (Iwanczyk et al., 2006; Sadre-Bazzaz et al., 2010). PA200 is believed to promote 
degradation of peptides, but not full-sized proteins and it does not have ATPase activity for 
translocation (Stadtmueller and Hill, 2011). PA200 is implicated in a variety of processes, 
including DNA repair (Ustrell et al., 2002), spermatogenesis (Khor et al., 2006), ribosome 
biogenesis (Lopez et al., 2011), proteasome inhibition and histone degradation (Qian et al., 
2013) and mitochondrial fission (Tar et al., 2014). PA200 forms either hybrid proteasomes 
(19S-20S-PA200), or single / double-capped complexes (PA200-20S and PA200-20S-PA200) 
(Qian et al., 2013). Reported targets of PA200 are dynamin 1 (DNM1), acetylated histones 
(Qian et al., 2013) and the transcriptional activator split finger protein 1 (SFP1) (Lopez et al., 
2011). 
 
p97 is an essential factor driving the turnover of ubiquitinylated proteins 
The chaperone-related, ubiquitin-selective ATPase p97 (also known as VCP) has emerged as 
an important motor and regulator of many ubiquitin-controlled cellular processes. (Buchberger 
et al., 2015). p97 is involved in the proteasomal degradation of protein quality control targets, 
cell cycle regulators, transcription factors and DNA repair proteins, but also in non-proteasomal 
proteolysis through macroautophagy and the endolysosomal pathway (Meyer et al., 2012). Its 
involvement in three major cellular proteolysis pathways makes p97 a central element of 
proteostasis (Buchberger et al., 2015). p97 is a member of the family of AAA ATPases and 
forms homo-hexameric, ring-structured complexes (Hanson and Whiteheart, 2005) It uses 
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energy derived from ATP hydrolysis to extract or segregate ubiquitinylated target proteins from 
stable protein assemblies, membranes and chromatin (Buchberger et al., 2015). p97 was also 
suggested as proteasome activator but the exact mechanism needs further investigations 
(Barthelme et al., 2015; Barthelme and Sauer, 2012). Importantly, p97 was found to play a 
critical role during muscle atrophy in the accelerated degradation of muscle proteins via the 
proteasomal and autophagy pathway (Piccirillo and Goldberg, 2012). In the same study, they 
showed that the expression of p97 in muscles and myotubes helps to limit muscle growth by 
promoting protein degradation (Piccirillo and Goldberg, 2012). 
 
Nrf1 induces transcription of proteasomal biogenesis 
In yeast, the main transcriptional regulator of proteasome biogenesis is stress-regulated 
transcription factor RPN4 (RPN4), which binds to the promoters of most PSM genes via the 
conserved proteasome-associated control element (PACE) motif (Mannhaupt et al., 1999). 
RPN4 is itself rapidly degraded by the proteasome. When RPN4 degradation is compromised, 
its stabilization and accumulation leads to elevated levels of proteasome synthesis. Therefore, 
RPN4 is involved in a negative feedback loop, which promotes transcription from most PSM 
genes (Xie and Varshavsky, 2001). A similar mechanism was described in Caenorhabditis 
elegans (C. elegans) for Protein skinhead-1 (SKN-1). When proteasome gene expression and 
activity are blocked, SKN-1 activates multiple classes of proteasome subunit genes in a 
compensatory response, thereby maintaining UPS activity (Li et al., 2011).  In contrast, when 
translation elongation is impaired, SKN-1 does not upregulate proteasome genes which  
results in reduced UPS activity (Li et al., 2011). Altogether, these studies in yeast and C. 
elegans support a model that protein synthesis and degradation may be coupled processes. 
Mammals lack an RPN4 orthologue but have one of SKN-1. The transcription factor nuclear 
factor, erythroid derived 2, -like 1 (NFE2L1 and TCF11, hereafter called Nrf1) provides a 
comparable feedback mechanism, which is also activated by proteasome inhibitors, such as 
bortezomib (Radhakrishnan et al., 2010; Steffen et al., 2010). 
 
The CNC-bZIP family of transcription factors 
Nrf1 is a member of the cap’n’collar basic-region leucine zipper (CNC-bZIP) family of 
transcription factors that further comprises the activators nuclear factor-erythroid 2 (NFE2) 
p45, NFE2L2 (hereafter called Nrf2), NFE2L3 and locus control region-factor 1 (LCR-F1 or 
Nrf1β), and the repressors BACH1 and BACH2 (BTB and CNC homology 1, basic leucine 
zipper transcription factor 1 and 2) and the founding member Drosophila melanogaster CNC 
protein (Zhang and Xiang, 2016). Several other important transcriptional regulators belong to 
the CNC-bZIP family, such as jun proto-oncogene (Jun, also AP-1), hypoxia-inducible factor 
1α (Hif1α), nuclear factor κB (NF-κB) and transformation-related protein 53 (p53) (Zhang and 
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Xiang, 2016). The CNC domain that characterizes this family of proteins binds to the 
antioxidant or electrophile response element (ARE or EpRE), a DNA element with the 
consensus sequence 5′-TGACNNNGC-3′ (Rushmore et al., 1991). The ARE/EpRE element is 
found in the enhancers of promoters of many enzymes involved in antioxidant responses, 
xenobiotic metabolism and inflammatory responses (Hayes et al., 1999; Nguyen et al., 2003; 
Rushmore et al., 1991). In response to oxidative stress, transcriptional expression of 
ARE/EpRE-driven genes is regulated primarily by CNC–bZIP family factors, aiming to maintain 
an appropriate redox homoeostasis. Amongst others, ARE/EpRE-target genes encoding for 
NAD(P)H dehydrogenase, quinone 1 (NQO1), heme oxygenase 1 (HMOX1), metallothionein 
1 and 2 (MT1, MT2), glutamate-cysteine ligase (GCLC, GCLM), glutathione synthetase (GSS), 
glutathione S-transferases (GSTs), ferritin (FTH1, FTL1), peroxiredoxin 1 (PRDX1), 
thioredoxin 1 (TXN1) and malic enzymes (ME1 and ME2) (Bugno et al., 2015; Zhang and 
Xiang, 2016). 
 
Transcriptional activity is different between Nrf1 and Nrf2 
Of the CNC transcription factors, Nrf1 and Nrf2 represent the primary factors that 
heterodimerize with the small musculoaponeurotic fibrosarcoma (Maf) proteins (MafF, MafG, 
MafK) in the nucleus and bind to the ARE/EpRE (Biswas and Chan, 2010; Itoh et al., 1997; 
Jaiswal, 2004). Altough, both Nrf1 and Nrf2, similarly regulate an ARE/EpRE-driven 
transcriptional programm against cellular stress, Nrf1 fullfils some unique functions that are 
distinct of Nrf2. Nrf1, but not Nrf2, is indispensable for development and healthy growth, 
demonstrated by a global knockout of Nrf1 in mice causing embryonic lethality (Chan et al., 
1998; Chan et al., 1996; Leung et al., 2003). Conditional KO of Nrf1 in liver results in oxidative 
stress, non-alcoholic steatohepatitis (NASH) and hepatic cancer (Ohtsuji et al., 2008; Xu et al., 
2005). Importantly, Nrf2 is not able to compsensate for a loss of Nrf1 function in liver, 
suggesting an independent activation of ARE/EpRE-target genes (Ohtsuji et al., 2008). In 
contrast, Nrf2 appears to be dispensable for the expression of most ARE/EpRE-driven 
cytoprotective genes and Nrf2 KO mice develop normally (Chan et al., 1996). Moreover, tissue-
specific loss of Nrf1 in mouse pancreas, brain and bone results in pathologies of diabetes 
(Zheng et al., 2015), neurodegeneration (Kobayashi et al., 2011; Lee et al., 2011) and reduced 
bone formation (Kim et al., 2010). These remarkable phenotypic changes are accompanied by 
significant disorders of glucose, lipid and protein metabolism, in addition to severe endogenous 
oxidative stress (Zhang and Xiang, 2016). Together, these findings demonstrate that Nrf1 fulfils 
a unique and indispensable biological function in regulating antioxidative response, which is 
distinct from that of Nrf2. 
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Nrf1 is a critical regulator of genes encoding for 26S proteasomal subunits 
The funciton of Nrf1 and its role as transcription factor received even more attention when it 
was shown that it is involved in the regulation of proteasomal biogenesis (Radhakrishnan et 
al., 2010; Steffen et al., 2010). Besides neurodegeneration, mice lacking Nrf1 in brain 
displayed an impaired proteasome function, which was accompanied by a coordinated down-
regulation of various genes encoding for 26S proteasomal subunits (Lee et al., 2011). Although 
Nrf2 knockout brains showed evidence of oxidative stress, impairment in proteasome activity 
was not detected and the regulation of proteasomal genes was shown to be Nrf1-specfific (Lee 
et al., 2011). Tissue-specific Nrf1 KO in liver revealed a similar reduced expression of PSM 
genes as found in the brain KO and also diminished proteasome activity (Lee et al., 2013). 
Nrf2 has also been reported to activate the expression of proteasomal subunits, but only upon 
exposure to oxidative stress (Kwak et al., 2003). It is important to note that Nrf1 regulates PSM 
gene expression through the activation of the ARE in the promoter region of the PSM genes 
(Radhakrishnan et al., 2010; Steffen et al., 2010). In addition to the coordinated induction of 
all proteasomal subunits, Nrf1 also regulates p97 (Sha and Goldberg, 2014) and p62 (Sha et 
al., 2018), which are both essential for the UPS. 
 
Figure 3: Nrf1 is the mammalian regulator of the “bounce-back” response to increase proteasomal 
biosynthesis upon proteasomal perturbation. Left: Under normal conditions, Nrf1 is a short-lived protein and 
maintained at low levels. ER-anchored Nrf1 is ubiquitinylated (Hrd1/SYVN1), retrotranslocated (p97) and degraded 
by the proteasome. In the nucleus, Nrf1 is ubiquitinylated (β-TrCP and FBXW7) and degraded by the proteasome. 
Right: When proteasome function is compromised, Nrf1 is stabilized and transcriptionally active. Nrf1 is glycosylated 
(G) in the ER and retrotranslocated (p97). In the cytosol, polysaccharides attached to Nrf1 are removed by NGLY1 
to generate the full-length Nrf1 (F, also Nrf1 FL), which is cleaved by DDI2 and produces the cleaved, processed 
Nrf1 (P, also Nrf1 CL). Processed Nrf1 translocates from the ER into the nucleus and promotes the expression of 
target genes including genes encoding for proteasomal subunit. (Koizumi et al., 2018) 
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Importantly, Nrf1 was identified as the mammalian regulator of a, in higher eukaryotes well 
conserved (Lundgren et al., 2005; Meiners et al., 2003; Mitsiades et al., 2002), positive-
feedback circuit (also called “bounce-back” response), which increases proteasomal 
biosynthesis upon proteasomal pertubation (i.e. with proteasomal inhibitors as 
chemotherapeutic drugs) (Radhakrishnan et al., 2010; Sha and Goldberg, 2014; Steffen et al., 
2010). Nrf1 is ubiquitously expresssed as an endoplasmic reticulum (ER) transmembrane 
protein possessing a long C-terminal portion with N-linked glycosylation in the ER lumen and 
a short N-terminal portion in the cytosol (Figure 3) (Radhakrishnan et al., 2014; Zhang et al., 
2007). Thus, newly synthesized Nrf1 is anchored and embedded into the ER membrane with 
its N-terminal homology box 1 (Nhb1) domain (Zhang et al., 2007). Nrf1 is a short-lived protein, 
which is generally maintained at low levels by subjecting it to ER-associated degradation 
(ERAD) (Koizumi et al., 2018). Under normal conditions, Nrf1 is constitutively ubiquitinylated 
by the ER-resident ubiquitin-E3-ligase Hrd1 (also called synovial apoptosis inhibitor 1, 
synoviolin (SYVN1)), the luminal portion of Nrf1 is retrotranslocated to the cytoplasm by the 
p97 ATPase and then degraded by the proteasome (Radhakrishnan et al., 2014; Steffen et al., 
2010) (Figure 3). In the nucleus, Nrf1 stability is regulated through ubiquitinylation by beta-
transducin repeat containing protein (β-TrCP) and  F-box and WD-40 domain protein 7 
(FBXW7) and then degraded by the proteasome (Biswas et al., 2011; Tsuchiya et al., 2011) 
(Figure 3). Nrf1 is stabilized and accumulates to high levels when proteasome function is 
compromised resulting in a release of processed Nrf1 (P) from the ER into the nucleus and 
transcriptional activation of PSM genes (Radhakrishnan et al., 2014). During this process, the 
glycosylated (G) luminal part of Nrf1 is rapidly exported into the cytosol by p97 (Radhakrishnan 
et al., 2014) and subsequently deglycosylated by N-glycanase 1 (NGLY1) (Tomlin et al., 2017) 
to generate full-length Nrf1 (F, also Nrf1 FL) (Figure 3). Cleavage of Nrf1 FL at leucine 104 by 
the aspartic protease DNA-damage inducible protein 2 (DDI2) (Koizumi et al., 2016) produces 
the processed, cleaved Nrf1 (P, also Nrf1 CL), which translocates to the nucleus (Figure 3). 
In the nucleus, processed Nrf1 (P) heterodimerizes with small Maf proteins and binds to ARE 
in the promoter region of PSM genes, to upregulate their expression  (Koizumi et al., 2016; 
Radhakrishnan et al., 2014; Radhakrishnan et al., 2010; Steffen et al., 2010) (Figure 3). In 
addition to N-linked glycosylation, O-linked glycosylation was described as an important post-
translational modification involved in Nrf1 transcription activity (Han et al., 2017; Sekine et al., 
2018). O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) is a positive regulator of 
Nrf1 transcription activity by increasing the stability of Nrf1 (Sekine et al., 2018). Ogt interacts 
with Nrf1 via host cell factor C1 (HCFC1) and modifies Nrf1 with GlcNAc polysaccharides, 
which attenuates the ubiquitination of Nrf1 prior to degradation resulting in the stabilization and 
increased transcriptional activity of Nrf1 (Han et al., 2017; Sekine et al., 2018). 
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mTORC1-dependent activation of Nrf1 upon proteasome inhibition 
Besides regulating various processes involved in protein synthesis, mTORC1 was also 
implicated in the regulation of lipid synthesis via the sterol regulatory element binding 
transcription factor 1 (SREBF1, also known as SREBP1) (Duvel et al., 2010). More recently, it 
was shown that mTORC1 induces Nrf1 transcription through the posttranslational activation of 
SREBF1, which activates the transcription of proteasomal genes (Zhang et al., 2014) (Figure 
1). This mechanism was studied in TSC2-deficient mouse embryonic fibroblasts (MEFs) and 
in brain and liver tissue. Whether mTORC1 regulates Nrf1 also in muscle tissue and whether 
this would lead to a similar activation of proteasomal genes has yet to be investigated. Since 
the “bounce-back” response links protein synthesis to proteasome degradation, this could be 
a novel mechanism by which mTORC1 additionally regulates catabolic processes to maintain 
muscle proteostasis. 
 
Proteasome inhibition as a therapeutic mean 
Proteasome inhibition has mainly been studied in the context of cancer treatment and 
neurodegenerative diseases because of its anti-inflammatory activity. Effective proteasome 
inhibition is achieved by either using proteasome inhibitors, drugs that chemically block the 
action of proteasomes or by inactivating specific subunits and the assembly of the proteasome. 
In the latter case, few publications showed that inactivation of subunits or proteasomal 
assembly in distinct tissues leads to a dysregulation of the proteasome, to the accumulation of 
damaged and misfolded proteins and even leads to embryonic lethality in mice (Ding et al., 
2006; Sasaki et al., 2010; Stohwasser et al., 1996). 
 
Proteasome inhibitors 
More promising is the usage of reversible proteasome inhibitors that chemically block the 
proteolitically active enzymes of the proteasome. One of the most widely used proteasome 
inhibitors is MG132. MG132 is largely used in in vitro experiments and is a very potent and 
reversible proteasome inhibitor of the chymotrypsin-like activity (Lee and Goldberg, 1998). 
MG132 belongs to the class of synthetic peptide aldehydes, which also inhibit certain 
lysosomal cysteine proteases and the calpains (Lee and Goldberg, 1998). The first non-
peptidic proteasome inhibitor discovered was lactacystin, which irreversibly inhibited trypsin-
like, chymotrypsin-like and caspase-like activity but also inhibits proteases other than the 
proteasome, namely cathepsin A and tripeptidyl peptidase II. (Craiu et al., 1997; Fenteany et 
al., 1995). The first specific, natural proteasome inhibitor found was epoxomicin, which 
irreversibly inhibits all three proteolytically active enzymes of the proteasome and which 
demonstrates anti-inflammatory activity (Meng et al., 1999). The newest group of proteasome 
inhibitors, which are further developed until today belong to the group of dipeptidyl boronic 
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acids. These inhibitors bind reversibly to the chymotryptic enzyme of the proteasome, show 
much higher potency and do not inhibit other cellular proteases (Adams et al., 1998). PS-341 
(hereafter called bortezomib, marketed as Velcade) was one of this dipeptidyl boronic acids 
and was the first proteasome inhibitor that entered clinical trials for cancer treatment (Adams 
et al., 1999). Bortezomib was the first proteasome inhibitor, that was approved for the treatment 
of adult patients with multiple myeloma, a particular white blood cell cancer (Adams and 
Kauffman, 2004). Two other proteasome inhibitors were approved for the treatment of multiple 
myeloma: Carfilzomib (marketed as Kyprolis) an analog of epoxomicin (Meng et al., 1999; 
Wang et al., 2013) and ixazomib (marketed as Ninlaro) a boronic acid derivative which was 
developed by Takeda. 
 
Proteasome inhibitors in cancer treatment 
Cancer cells produce proteins that promote both cell survival and proliferation, and/or inhibit 
mechanisms of cell death. Amongst other functions, the UPS prevents the accumulation of 
misfolded, damaged or deleterious proteins. Therefore, preclinical testing of proteasome 
inhibitors aimed to shift the equilibrium of proteostasis towards cell death (Manasanch and 
Orlowski, 2017). Initially, proteasome inhibitors were developed to prevent cancer-related 
cachexia (Manasanch and Orlowski, 2017). Then, preclinical studies demonstrated that 
proteasome inhibitors induce apoptosis in various cancer cell lines and murine models of 
cancer and were postulated as chemotherapeutics (Manasanch and Orlowski, 2017; Mitsiades 
et al., 2002). One of the earliest findings was, that proteasome inhibitors with a boronic acid 
(i.e. bortezomib) could inhibit NF-κB-signaling by blocking the degradation of the NF-κB 
inhibitor IκB, thereby preventing nuclear translocation of NF-κB, and repressing its 
transcriptional activity to induce inflammatory mediators, inhibitors of apoptosis and oncogenic 
proteins (Lee and Goldberg, 1998; Palombella et al., 1994). As mentioned above, bortezomib, 
carfilzomib and ixazomib are currently approved for the treatment of multiple myeloma or 
mantle-cell lymphoma (MCL). Full regulatory approval of bortezomib occurred in 2005, 
following the publication of results from a large phase III trial in patients with relapsed multiple 
myeloma comparing dexamethasone and bortezomib treatment (Richardson et al., 2005). 
Therefore, one of the nowadays most widely used combination treatment options for patients 
with newly diagnosed multiple myeloma comprises bortezomib, lenalidomide and 
dexamethasone (Richardson et al., 2010). Unfortunately, up to 80% of patients with newly 
diagnosed multiple myeloma treated with bortezomib develop any grade of neuropathy, but 
the exact underlying mechanisms are not fully understood (Richardson et al., 2010). In contrast 
to the boronates (i.e. bortezomib and ixazomib), carfilzomib is an epoxyketone that irreversibly 
binds to the chymotrypsin-like enzyme of the proteasome, which prolongs the duration of 
proteasome inhibition (Alsina et al., 2012). The possibility of a long-duration inhibition provided 
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the rationale for phase I studies of carfilzomib, which revealed that this agent is both tolerable 
and active against relapsed and/or refractory multiple myeloma (Alsina et al., 2012). 
Carfilzomib seems to have distinctly different adverse effects compared to that of bortezomib. 
Whereas the rates of peripheral neuropathy are lower with carfilzomib, a few patients have 
developed cardiovascular complications (Korde et al., 2015). The major advantage of 
ixazomib, which is the newest approved proteasome inhibitor, compared to previous 
proteasome inhibitors is that it can be distributed orally (Richardson et al., 2014). Ixazomib in 
combination with lenalidomide and dexamethasone demonstrated less neuropathy and 
improved progression-free survival (the length of time during and after the treatment of the 
cancer  that a patient lives with the disease but it does not get worse) in patients with relapsed 
or refractory myeloma (Richardson et al., 2015). Additional studies of ixazomib using several 
distinct settings are underway. 
 
Nrf1 mediates resistance to proteasome inhibitors in malignant cells 
Importantly, promising preclinical data, obtained with bortezomib in models of solid tumors, 
failed to demonstrate any efficacy in clinical studies in patients (Frankland-Searby and 
Bhaumik, 2012; Johnson, 2015). Therefore, investigations into the mechanisms of resistance 
are essential to improve the efficacy and the utility of proteasome inhibitors. Interestingly, 
amongst many other candidates, Nrf1 was associated as mediator of proteasome inhibitor 
resistance in malignant cells. The observation that therapeutic proteasome inhibition promptly 
triggers the upregulation of proteasome genes in malignant cells (Mitsiades et al., 2002), was 
associated with the Nrf1-induced “bounce-back” response (Radhakrishnan et al., 2010; Steffen 
et al., 2010). Therefore, Nrf1 received significant medical relevance as regulator of an 
important compensatory response that promotes tumor cell survival and attenuates therapeutic 
efficacy (Dikic, 2017; Weyburne et al., 2017). Interestingly, increased protein O-linked 
glycosylation was described in a wide range of cancers and it got attention as a new target in 
cancer treatments (Fardini et al., 2013). As mentioned earlier, a recent study has revealed that 
O-linked glycosylation by OGT makes a critical contribution to the proteasome bounce-back 
response via increasing the stability and transcriptional activity of Nrf1 (Han et al., 2017; Sekine 
et al., 2018). The discovery of the interaction between Nrf1 and the OGT/HCFC1 complex has 
added a new regulatory axis to the proteasome bounce-back response and identified OGT as 
a new therapeutic target for sensitizing cancer cells to proteasome inhibitors (Sekine et al., 
2018). Interestingly, recent studies demonstrate that increased levels of OGT and O-linked 
glycosylation, found in obese mice and cancer cells, are caused by higher mTORC1 activity 
(Park et al., 2014; Sodi et al., 2015; Very et al., 2018). 
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Proteasome inhibition and muscle proteostasis 
The muscle atrophy that occurs in catabolic states largely results from accelerated breakdown 
of long-lived myofibrillar proteins, such as actin or myosin, by the UPS (Mitch and Goldberg, 
1996). Therefore, proteasome inhibitors were tested to counteract muscle atrophy and several 
in vivo studies report beneficial effects on muscle proteostasis and atrophy by applying 
proteasome inhibitors on distinct catabolic states, such as sepsis (Fischer et al., 2000; Supinski 
et al., 2009), hindlimb casting (Krawiec et al., 2005; Vargas and Lang, 2008), hindlimb 
unloading (Jamart et al., 2011) and denervation (Beehler et al., 2006). A study in a murine 
model of hindlimb immobilization demonstrated that MG132 not only preserves muscle mass 
and increases cross-sectional area (CSA), but also decreased the expression of Atrogin-1 and 
MuRF1 and diminished the rehabilitation time of these mice (Caron et al., 2011). Importantly, 
proteasome inhibitors were also applied in mouse models of muscular dystrophies. MG132-
treatment of dy3K/dy3K mice, a mouse model for laminin-α2-related muscular dystrophy 
(LAMA2-MD), significantly improved the dystrophic phenotype of these mice (Carmignac et al., 
2011). Surprisingly, proteasome inhibition did not only improve muscle weight and CSA but 
also muscle histology, decreased marker of apoptosis and improved locomotion and lifespan 
(Carmignac et al., 2011). Similar results have been obtained by treating dy3K/dy3K mice with 
bortezomib, which increases the clinical relevance of such a treatment (Korner et al., 2014). 
Using bortezomib-treatment in a mouse model for spinal muscular atrophy (SMA) revealed an 
increase of the survival motor neuron 1 (SMN1) protein (Kwon et al., 2011). Decreased 
expression of this protein is the cause of SMA. Furthermore, bortezomib improved motor 
function, neuromuscular junction (NMJ) size and muscle pathology in these mice (Kwon et al., 
2011). Increased survival was only observed after combining the treatment with the histone 
deacetylase inhibitor trichostatin A (TSA), which is an inducer of Smn gene transcription (Kwon 
et al., 2011). 
Even though bortezomib can shift the balance of muscle proteostasis and can prevent muscle 
wasting in animal models (Beehler et al., 2006; Carmignac et al., 2011; Caron et al., 2011; 
Kwon et al., 2011), its use is not approved in patients for treatment of muscle atrophy. Indeed, 
clinical trials with bortezomib for the treatment of cancer cachexia have not shown consistent 
results (Madeddu and Mantovani, 2009; Penna et al., 2016). Proteasome inhibitors have 
various adverse effects and complete blockage of the UPS is detrimental for muscle fibers, as 
recently confirmed by a study investigating the effect of a Psmc4 knockout in murine muscles 
(Kitajima et al., 2014). These muscles showed dysregulated proteasomal activity, basophilic 
inclusions and disorganization of the sarcomeres in young adult mice, suggesting that 
appropriate proteasomal activity is important to maintain muscle homeostasis (Kitajima et al., 
2014). Therefore, it would be interesting to test the effect of dampening the UPS by  intermittent 
inactivation or destabilization of Nrf1 activity and its consequences on muscle proteostasis. 
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The role of the UPS and mTORC1 in regulating proteostasis in sarcopenia 
Sarcopenia is probably the most frequent but least understood type of systemic muscle loss. 
The muscle wasting that is characteristic for sarcopenia differs largely from other wasting 
conditions, as the muscle loss develops slowly and gradually over time (Cohen et al., 2015). 
Sarcopenia may affect as much as 15% of the population aged 65 years and above and 
approximately 50% of individuals aged over 80 years old (Cohen et al., 2015). This loss of 
muscle substantially reduces quality of life and physical activity and independence of older 
people and the increased frailty leads to falls, fractures and admission to hospitals and nursing 
homes (Cosqueric et al., 2006; Fielding et al., 2011). Investigating the underlying mechanisms 
of sarcopenia in patients but also in animal models is difficult. Several other diseases and co-
morbidities often accompany sarcopenia and precede or directly contribute to the muscle 
wasting. Therefore, muscle wasting in sarcopenia can be a combination of many factors and 
differs largely between individuals. Therefore, it is important to discriminate between age-
related and sarcopenic pathology. This might also explain the controversial findings about the 
state of muscle proteostasis and of the UPS in aging or sarcopenia. In many aging studies, the 
function of the UPS and the proteasome function in particular, was reported to decrease with 
age in various tissues and organs (Chondrogianni and Gonos, 2005; Dahlmann, 2007; 
Gaczynska et al., 2001; Tonoki et al., 2009), including decreased gene expression of 
proteasomal subunits in aging mice (Lee et al., 1999; Lee et al., 2000). Notably, UPS 
dysfunction is present in several age-related neurodegenerative disorders, such as 
Alzheimer’s (Keck et al., 2003), Parkinson’s (McNaught et al., 2003) or Huntington’s disease 
(Seo et al., 2004). In contrast, by focusing on sarcopenia, a study from aged, 30-month-old 
rats reported a marked loss of muscle mass accompanied by increased expression of 
proteasomal subunits, proteasome activity, ubiquitinylation and DUB-activity (Altun et al., 
2010). Nevertheless, expression of genes coding for the proteasomal subunits were not 
increased in aged rats and the expression of the atrogene program differed from the one of 
rapid atrophy (Altun et al., 2010). Although these findings indicate an increase of the UPS and 
increased overall protein degradation, there is currently no successful approach for using 
proteasome inhibitors to attenuate muscle wasting in sarcopenia. 
Besides increased proteolysis and muscle wasting, sarcopenic muscles are characterized by 
a loss of mitochondria, mitochondrial dysfunction, increased apoptosis, disrupted NMJs, 
increased fiber denervation and decreased rates of protein synthesis (Chai et al., 2011; 
Combaret et al., 2009; Deschenes et al., 2010; Ibebunjo et al., 2013). The observation that 
protein synthesis declines with age raises the question, whether activation of mTORC1 is 
beneficial for sarcopenic muscles and whether it helps to avoid age-related muscle wasting. 
The role of mTORC1 activity in sarcopenia is still controversially discussed. Several studies 
reported decreased activity of the Akt-mTORC1 pathway in older age groups compared to 
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younger groups (Cuthbertson et al., 2005; Leger et al., 2008; Pallafacchina et al., 2002). In 
contrast, however, recent studies observed hyperphosphorylation of mTORC1 in aged human 
muscles, but also in muscles of aged mice and rats (Joseph et al., 2019; Markofski et al., 2015; 
White et al., 2016). Importantly, TSCmKO mice develop precocious sarcopenia (Bentzinger et 
al., 2013; Castets et al., 2013; Guridi et al., 2015), characterized by fragmentation of the NMJ 
(Ham et al., 2019, in preparation), severe muscle wasting and progressive loss of muscle mass 
(Bentzinger et al., 2013; Castets et al., 2013), loss of muscle force (Bentzinger et al., 2013; 
Castets et al., 2013) and accumulation of misfolded proteins (Guridi et al., 2015). As mentioned 
above, treatment with rapamycin normalizes autophagy in TSCmKO mice and ameliorates 
many of the signs of the myopathy (Castets et al., 2013). This is in accordance with a recent 
study, that describes the beneficial effects of mTORC1 inhibition on muscle wasting observed 
in aged rats (Joseph et al., 2019). Hence, the understanding of the role of mTORC1 in 
regulating muscle proteostasis is also of fundamental importance to find means to mitigate 
sarcopenia. 
  | Rationale and objectives of the thesis | 
 
  34 
5. Rationale and objectives of the thesis 
Several lines of evidence points to an important role of mTORC1 in controlling muscle 
proteostasis. Based on its stimulation in nutrient-rich conditions and on its function in regulating 
translation and protein synthesis, the role of mTORC1 in mediating muscle anabolism is well 
established. In contrast, the exact mechanism of how mTORC1 stimulates and activates 
catabolic processes to induce muscle atrophy is unknown. The overall objective of my PhD 
thesis was to characterize the role of mTORC1 in maintaining muscle proteostasis in 
vivo.  
The first specific aim of my PhD study was to investigate the underlying mechanisms of the 
mTORC1-driven muscle atrophy observed in young TSCmKO mice. For this purpose, 
comprehensive analysis of whole-genome and proteome data of TSCmKO mice was analyzed 
to identify catabolic processes, which are activated in response to sustained activation of 
mTORC1. 
The identification, of the ubiquitin-proteasome-system (UPS) as major catabolic process, 
which is induced by sustained activation of mTORC1, in the first part of this thesis was then 
expanded into an extensive project to study the mTORC1-dependent induction of the UPS. 
Thus, the second specific aim of my PhD study was to determine if sustained activation of 
mTORC1 increases the UPS via the Akt-FoxO-signaling or by distinct other, unknown catabolic 
pathways. To test this, several distinct interventions and different mouse models, targeting 
specific parts of the mTORC1-Akt-FoxO-signaling, were carried out and led to the identification 
of Nrf1 as a mediator of mTORC1-driven muscle atrophy. 
Lastly, I investigated whether inactivation of Nrf1 is sufficient to disable the activation of the 
UPS in TSCmKO mice and if this would be sufficient to attenuate mTORC1-driven muscle 
atrophy 
Hence, during my PhD study, I aimed to understand all of how mTORC1 is involved in 
regulating catabolic processes and muscle proteostasis and thereby maintains body function 
and health. 
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6. Results and Discussion 
Part 1 - Manuscript: “mTORC1-dependent increase of the ubiquitin-proteasome 
system disturbs muscle proteostasis” 
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Abstract 
Skeletal muscle is crucial for human daily life, ensuring locomotion, breathing and affecting 
whole-body metabolism. The continuous adjustment of the balance in muscle proteostasis is 
essential for maintaining regular muscle growth during life. Perturbation of this balance by 
extrinsic factors, as for example seen in cachexia or in sarcopenia, is a main cause of loss of 
life quality and increased mortality. Thus, a better molecular understanding of muscle 
proteostasis is of fundamental importance to develop possible treatment strategies to 
counteract the above diseases. The mammalian (or mechanistic) target of rapamycin complex 
1 (mTORC1) has emerged as an important regulator of cellular growth. Because of its role in 
regulating translation and protein synthesis, mTORC1 was proposed as mediator of muscle 
hypertrophy. However and in striking contrast to the expected outcome of muscle gain, 
sustained activation of mTORC1 in muscle by knockout of its upstream inhibitor TSC1 
(TSCmKO mice) results in atrophy. The underlying mechanism of this mTORC1-driven atrophy 
remained unresolved. Here we demonstrate that sustained activation of mTORC1 in muscles 
of TSCmKO mice leads to a significant increase of the ubiquitin-proteasome system (UPS). 
Surprisingly, constitutive activation of Akt in muscle resulted in a similar induction of the UPS 
as observed in TSCmKO mice, suggesting an UPS activation mechanism, which is, at least in 
part, independent of the activation of FoxO transcription factors. Finally, we identify the 
transcription factor Nrf1 (also referred to as NFE2L1) as an important mediator of mTORC1-
driven activation of the UPS. Together, these results provide new information about the role of 
mTORC1 in regulating muscle proteostasis, which might help to develop new therapeutic 
agents that could slow-down muscle wasting. 
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Introduction 
Skeletal muscle wasting is a hallmark of neuromuscular diseases and is associated with many 
pathophysiological conditions, such as cancer, aging, AIDS and chronic diseases of the heart 
or kidney. The balance of muscle proteostasis ultimately determines muscle size: if overall 
rates of protein degradation are lower than the overall rates in protein synthesis muscle will 
grow (hypertrophy); if overall rates of protein degradation outstrips the overall rates in protein 
synthesis muscle shrinks (atrophy) (Sandri, 2013). 
Mammalian (or mechanistic) target of rapamycin (mTOR) is a protein serine/threonine kinase 
that assembles into two distinct multi-protein complexes, called mTORC1 and mTORC2 
(Laplante and Sabatini, 2012; Shimobayashi and Hall, 2014). Studies in mice have shown that 
mTOR function in skeletal muscle is largely based on the activity of mTORC1 and not of 
mTORC2 (Bentzinger et al., 2008; Risson et al., 2009). High doses of the name-giving drug 
rapamycin block mTORC1 instantaneously through direct binding of the FK506-binding protein 
1a (FKBP1A, also FKBP12)-rapamycin complex (Laplante and Sabatini, 2012). mTORC1 is 
activated by different cellular inputs, such as amino acids, insulin, growth factors and energy 
status, to drive cell growth through increasing protein translation and lipid synthesis or by 
activating energy metabolism, ATP production and glycolytic flux (Laplante and Sabatini, 
2012). Activation of mTORC1 involves Ragulator-Rag complex mediated amino acid sensing, 
which recruits and anchors mTORC1 to the lysosomal membranes (Sancak et al., 2010). In 
parallel, mTORC1 becomes fully activated by growth factors via the insulin receptor substrate 
1 (IRS1) – protein kinase B (PKB, hereafter called Akt) pathway (Inoki et al., 2002; Manning et 
al., 2002; Menon et al., 2014). A protein complex (the TSC complex) comprising TSC1, TSC2 
(tuberous sclerosis complex 1 and 2) and TBC1D7 (TBC1 domain family member 7) functions 
as an upstream inhibitor of mTORC1 and is essential for the growth factor-induced mTORC1 
activation (Inoki et al., 2002; Manning et al., 2002). mTORC1 controls protein synthesis by 
phosphorylating its targets S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1) (Ma and 
Blenis, 2009). Phosphorylation of 4E-BP1 leads to its dissociation from eukaryotic translation 
initiation factor 4E (eIF4E), which is essential to start the signaling cascade resulting in the 
assembly of the 48S pre-initiation complex (Ma and Blenis, 2009). Phosphorylation of S6K1 
promotes protein synthesis by activating ribosomal protein S6 (RPS6, hereafter called S6) and 
therefore ribosome biogenesis, and by regulating translation initiation factors (Ma and Blenis, 
2009). These activities make mTORC1 to a major hub for regulating mammalian cell size. 
Based on the function of mTORC1 in controlling protein synthesis, stimulation of mTORC1 
activity was described as mediator of muscle hypertrophy (Bodine et al., 2001; Ruegg and 
Glass, 2011; Sandri, 2013). 
The previous results obtained using mice in which Tsc1 is specifically deleted in skeletal 
muscle fibers (called TSCmKO mice), however, challenged this concept as most muscles are 
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atrophic at young age (Bentzinger et al., 2013) and because these mice develop a severe 
myopathy causing death at the age of approximately one year (Castets et al., 2013). The 
phenotypic similarity between skeletal muscles of mice that are deficient for a gene essential 
for autophagy (Masiero et al., 2009) and of the TSCmKO mice suggested that impairment of 
autophagy, a process that is essential for the clearing of aberrant proteins and cell organelles 
(Dikic, 2017), might be responsible for the late-onset myopathy in TSCmKO mice. Indeed, 
autophagy induction was completely blocked in TSCmKO mice and inhibition of mTORC1 
activation by rapamycin alleviated this blockage (Castets et al., 2013). While inhibition of 
autophagy can explain this late-onset myopathy in the TSCmKO mice, the muscle atrophy 
observed in young TSCmKO mice cannot be explained by this mechanism. Instead, overall 
protein degradation rates may exceed the rates in protein synthesis, resulting in an imbalanced 
proteostasis. One possibility for the increased protein degradation could be an overall 
dampening of Akt-signaling as a consequence of sustained mTORC1 activation. This inhibition 
of Akt could be based on a well-described feedback loop from mTORC1 via S6K1 and IRS1 
to Akt (Bentzinger et al., 2008; Harrington et al., 2004). Inhibition of Akt would then result in 
the activation of forkhead box O (FoxO) pathways, which in turn would result in the activation 
of the ubiquitin-proteasome system (UPS) and increased protein degradation. 
The UPS is the primary degradation system for short-lived, misfolded and damaged proteins 
(Dikic, 2017). The key component of the UPS for degradation is the 26S proteasome, a multi-
catalytic, ATP-dependent protein complex, composed of various subunits that are assembled 
into two distinct subcomplexes - the 20S core particle and the 19S regulatory particle, which is 
attached to both ends of the core particle (Finley et al., 2016). The 26S proteasome recognizes 
ubiquitinylated proteins that, upon ATP hydrolysis, translocate into the 20S core particle where 
they are degraded to short peptide fragments. Degradation requires three specific, 
proteolytically active subunits: PSMB5 (ꞵ5, chymotrypsin-like activity), PSMB6 (ꞵ1, caspase-
like activity) and PSMB7 (ꞵ2, trypsin-like activity) (Finley et al., 2016). Here we demonstrate 
that sustained activation of mTORC1 in muscles of young TSCmKO mice leads to a significant 
increase of the UPS, which is largely reversed by short-term application of rapamycin. 
Surprisingly, constitutive activation of Akt in muscle resulted in a similar induction of the UPS 
as observed in TSCmKO mice. Increased expression of genes coding for proteasomal 
subunits and multiple ubiquitin-E3-ligases are thought to be directly regulated by increased 
transcriptional activity of FoxO family members. In contrast, our results provide evidence that 
mTORC1 regulates the UPS, particularly the expression of proteasomal subunits, not solely 
by FoxO but by the transcription factor nuclear factor, erythroid derived 2, -like 1 (Nrf1, also 
referred to as NFE2L1). Together, these results demonstrate that mTORC1 activation is a 
major driver of the UPS in skeletal muscle and identified Nrf1 as an important mediator of this 
pathway. Both, mTORC1 signaling as well as the UPS are considered as potential treatment 
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targets in a large variety of distinct muscle wasting diseases. Therefore, understanding the 
underlying regulatory mechanisms of how mTORC1 controls muscle mass is of fundamental 
importance to eventually develop new therapeutic strategies to slow-down the massive muscle 
wasting observed in cachexia and sarcopenia.  
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Results 
Young TSCmKO mice display an atrophy-related gene expression signature 
TSCmKO mice are phenotypically indistinguishable from Control littermates at young age 
(Bentzinger et al., 2013). Nevertheless, despite the marked increase in protein synthesis due 
to sustained activation of mTORC1, most muscles of TSCmKO mice display reduced muscle 
weight and smaller type IIb fibers (Bentzinger et al., 2013). Within one year, they develop 
kyphosis and a severe myopathy, due to a blockage in autophagy induction, which is causing 
premature death (Castets et al., 2013). Young, 3-month-old TSCmKO mice have increased 
transcript levels of the two ubiquitin-E3-ligases F-box protein 32 (Fbxo32, hereafter called 
Atrogin-1) and Tripartite motif-containing 63 / Muscle ring finger 1 (Trim63, hereafter called 
MuRF1), indicating that muscle atrophy in these mice in young age precedes the severe 
myopathy observed around the age of one year (Bentzinger et al., 2013; Castets et al., 2013). 
While inhibition of autophagy can explain this late-onset myopathy in the TSCmKO mice, the 
muscle atrophy observed in young TSCmKO mice cannot be explained by this mechanism. 
Instead, overall protein degradation rates may exceed the rates in protein synthesis, resulting 
in an imbalanced proteostasis. 
To explore the molecular mechanism of muscle proteostasis and with the aim to identify new 
catabolic processes involved in muscle atrophy, we generated RNA-sequencing data from 3-
month-old TSCmKO mice and Control littermates. Principal component analysis (PCA) 
revealed a decent clustering of biological replicates (Figure S1A) and around 4,600 genes 
were significantly, differentially expressed (DE) between Control and TSCmKO mice (Figure 
S1B). Next, we compared the gene expression of TSCmKO mice with a previous cDNA 
microarray analysis describing a set of genes (designated as atrogins, hereafter called 
atrogenes), which are commonly regulated in different types of muscle atrophy (Lecker et al., 
2004). We found 91 of those atrogenes expressed in TSCmKO mice (Figure 1A). More than 
40% (38 out of 91) among these genes were significantly DE in young TSCmKO mice 
compared to Control littermates and were similarly increased/decreased as previously found 
in different types of muscle atrophy (Figure 1B, Table S1). The majority of these 38 atrogenes 
is involved either in protein degradation or in energy production (Lecker et al., 2004) (Figure 
S1C). To compare the gene expression profile of TSCmKO mice with the current knowledge 
about atrophy-related genes, we screened literature of the last decade for genes involved in 
at least one type of muscle atrophy. Thereby we created an unsupervised list of 249 so-called 
“atrophy-related genes” (Table S2). Interestingly, we found 103 out of these 249 atrophy-
related genes (41%) similarly increased/decreased in young TSCmKO mice (Figure 1C, Table 
S3). Similar to the previously described atrogenes, we found a majority of the annotated, 
atrophy-related genes to be involved in protein degradation (25%) (Figure 1D). Altogether, 
these results emphasize the large overlap of gene expression between TSCmKO mice and 
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any other type of muscle atrophy. This is a direct indication for increased protein degradation 
pathways in TSCmKO mice. 
 
Ubiquitin proteasome system is enriched in young TSCmKO mice 
After demonstrating that young TSCmKO indeed exhibit a large atrophy-related gene 
expression signature, we aimed to identify involved catabolic processes, which functionally 
could contribute to the mTORC1-driven muscle atrophy we observed in TSCmKO mice. For 
that reason, we generated proteomics data from 3-month-old TSCmKO mice and Control 
littermates. PANTHER pathway enrichment analysis (Mi et al., 2019; Mi et al., 2013) on all DE 
proteins showed the strongest pathway enrichment for the “Ubiquitin-proteasome pathway” 
(Figure 2A). Moreover, using DAVID enrichment analysis algorithms (Huang da et al., 2009a, 
b) on the same DE proteins, the “Proteasome” was found amongst the strongest enriched 
pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Figure 
2B). Similarly, DAVID functional annotation clustering (Huang da et al., 2009a, b) revealed a 
strong enrichment of a cluster of terms belonging to the “Proteasome” (Figure S2A). Thus, 
proteomics data of TSCmKO mice further supports the notion that sustained activation of 
mTORC1 leads to an induction of the ubiquitin-proteasome system (UPS) and in particular of 
the 26S proteasome. 
To test whether indeed the UPS is increased in TSCmKO mice, we started to examine the 
activation of the overall system. As we already have reported previously, we found increased 
transcript expression levels of the two ubiquitin-E3-ligases Atrogin-1 and MuRF1 in TSCmKO 
mice (Figure 2E). Concomitantly, TSCmKO mice showed increased levels of ubiquitinylated 
proteins compared to Control littermates (Figure 2D). Importantly, we found transcript and 
protein expression of various proteasomal subunits (PSM) from distinct proteasomal 
compartments of the 26S proteasome significantly increased in young TSCmKO mice (Figure 
2C, 2D). Finally, using a luminescence-based assay for measuring proteasome activity 
revealed an increase in TSCmKO mice for all of the three main catalytic enzymes (β5, β1 and 
β2) (Figure 2F). Therefore, the expression of proteasomal subunits correlates with the 
increased proteasome activity. Importantly, similar activation of the UPS was observed in 
different fast-twitch muscles of TSCmKO mice, independent of gender, age (Figure S3A-S3D) 
or the progression state of the myopathy (Figure S3E). Altogether, these results demonstrate 
that sustained activation of mTORC1 indeed leads to an overall induction of the UPS, which 
most likely results in increased protein degradation and in an imbalanced muscle proteostasis.  
 
Short-term inhibition with rapamycin reverses the increased UPS in TSCmKO mice 
To test if the induction of the UPS in TSCmKO mice is mTORC1-dependently regulated, we 
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treated young TSCmKO mice and Control littermates with rapamycin for three consecutive 
days. Successful inhibition of mTORC1 was confirmed by strong reduction of phosphorylated 
S6 and 4E-BP1 and restoration of Akt activity in TSCmKO mice treated with rapamycin (Figure 
S4A, S4B). Further confirming successful mTORC1 inhibition, we found both, reversed 
transcript expression and less expression of p62 upon rapamycin treatment in TSCmKO mice 
(Figure S4B, S4D). This is in line with the findings we have previously reported, that rapamycin 
is sufficient to normalize autophagy induction in TSCmKO mice (Castets et al., 2013).  
Interestingly, we found the expression of Atrogin-1 and MuRF1 (Figure 3A) and the protein 
expression of most proteasomal subunits (Figure 3D) completely reversed in TSCmKO mice 
treated with rapamycin. More importantly, also β5 and β1 proteasome activity was completely 
reversed, whereas β2 activity was not altered at all after rapamycin treatment in TSCmKO 
mice (Figure 3C). The latter is in strong contrast to the protein expression of its corresponding 
protein PSMB7 (Figure 3D). The amount of ubiquitinylated proteins remains elevated after 
rapamycin treatment in TSCmKO mice (Figure S4C). This suggests either increased 
degradation rates due to compensatory autophagy-lysosomal degradation or an accumulation 
of ubiquitinylated substrates, which cannot be degraded anymore. The finding that expression 
of p62 was completely absent after rapamycin treatment (Figure S4B) favors the first notion 
of intact degradation. Surprisingly, we did not found an overall reversing of the transcripts 
encoding for proteasomal subunits upon rapamycin treatment in TSCmKO mice (Figure 3B). 
Indeed, we found a group of PSM genes that was reversed or at least show a trend for this 
(Psmb5, Psmd8, Psme4), but we also found a group of PSM genes which was even further 
increased after rapamycin treatment (Psma1, Psma5, Psmc4, Psmd4, Psmd11) (Figure 3B). 
Since every PSM gene encodes for one individual proteasomal subunit, which is used to build 
up different parts of the 26S proteasome, it is well possible that multiple transcriptional 
regulators dynamically regulate PSM genes in a concerted but sequential manner. Therefore, 
rapamycin-induced inhibition of mTORC1 might not affect all of this transcription factors 
simultaneously. Together, these results demonstrate that the increase of the UPS observed in 
TSCmKO mice is a direct consequence of sustained activation of mTORC1, which is largely 
reversed by short-term inhibition of mTORC1 using rapamycin. Therefore, inhibition of 
mTORC1 by rapamycin not only restores autophagy flux and ameliorates myopathy in 
TSCmKO mice (Castets et al., 2013) but also reverses the induction of the UPS. 
 
Activation of mTORC1 for 21 days is sufficient to increase the UPS in adult muscle 
Next, we aimed to test if acute muscle-specific deletion of Tsc1 in adult muscles for 3 weeks 
would lead to a similar induction of the UPS as observed in TSCmKO mice. For that reason 
and to exclude any impact of pre-adult skeletal muscle development, we crossed Tsc1fl/fl mice 
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with HSA-mER-Cre-mER mice (McCarthy et al., 2012), which allowed us to induce Cre-
mediated ablation of Tsc1 in adult muscles upon tamoxifen treatment (iTSCmKO mice). First, 
we addressed the question if mTORC1 activation for 21 days leads to similar molecular and 
phenotypic characteristics as observed in young, constitutive TSCmKO mice. 21-day 
iTSCmKO mice showed reduced expression of TSC1 and strong activation of mTORC1, 
characterized by increased phosphorylation of its targets S6 and 4E-BP1 (Figure S5A). In 
addition, we also found increased translation initiation, represented by the ratio of 4E-BP1 and 
eIF4E bound to the eukaryotic 7-methylguanosine 5'-triphosphate (m7GTP)-cap (Figure S5E). 
21-day iTSCmKO mice further had decreased phosphorylation levels of Akt and its target 
PRAS40 (Figure S5B), increased expression of p62 (Figure S5B) and of many transcripts 
involved in autophagy-lysosomal degradation (Figure S5F). All fast-twitch, hindlimb muscles 
of 21-day iTSCmKO mice show significantly reduced or trends to decreased relative muscle 
weight, while none of the other organs show any decrease in relative weight (Figure S5C). In 
summary, these results demonstrate that activation of mTORC1 for 21 days exhibits similar 
characteristics as we previously described for young TSCmKO mice (Bentzinger et al., 2013; 
Castets et al., 2013; Guridi et al., 2015). 
The expression of Atrogin-1 and MuRF1 was increased in 21-day iTSCmKO mice (Figure 4A) 
and we found an increased number of ubiquitinylated proteins (Figure 4E). Both, transcript 
and protein expression of proteasomal subunits were significantly increased in 21-day 
iTSCmKO mice compared to Control littermates (Figure 4B, 4D). Similarly, proteasome 
activity of all three catalytic enzymes was significantly increased (Figure 4C). Altogether, these 
results clearly demonstrate that acute activation of mTORC1 in adult muscle for 21 days is 
sufficient to induce the UPS. Using iTSCmKO mice allowed us to compare different durations 
of mTORC1 activation. Therefore, we wondered whether the mTORC1-dependent increase in 
proteasome activity is progressive or stays constant over time. For that reason, we measured 
proteasome activity after 10 and 90 days of mTORC1 activation in adult muscles. Interestingly, 
we found a constant, similar increase of proteasome activity for 10-, 21- and 90-day iTSCmKO 
mice when compared to Control littermates (Figure S5D). This finding supports the hypothesis 
that sustained activation of mTORC1 in muscle results in a constant, but rather mild, increase 
of protein degradation rates. During days and months, this increase might results into a 
progressed atrophy and together with blockage of autophagy induction in the severe myopathy 
we previously described for 12-month-old TSCmKO mice (Castets et al., 2013). 
 
Hypertrophic soleus muscles are resistant to an mTORC1-dependent increase of the 
UPS 
Although, we demonstrated that sustained activation of mTORC1 induces the UPS to increase 
overall rates of protein degradation, it remains to be resolved if this increase of the UPS 
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effectively causes atrophy. As we already showed previously, all hindlimb muscles of young 
TSCmKO mice but not soleus (SOL) muscle undergo atrophy (Bentzinger et al., 2013). 
Instead, the soleus was shown to be atrophy-resistant, characterized by strong hypertrophy 
and increased muscle fiber size (Bentzinger et al., 2013). Similarly, acute activation of 
mTORC1 in adult muscles showed strongly increased relative muscle weight of the soleus in 
21-day iTSCmKO mice when compared with Control littermates (Figure S5C). 
Therefore, we aimed to test whether this atrophy-resistance is related to changes in the 
mTORC1-signaling or to alterations in the UPS induction. We found strongly increased 
phosphorylation of S6 and a clear trend for 4E-BP1 at their mTORC1-specific phosphorylation 
sites (Figure S5G), assuming similar activation of mTORC1 as found in tibialis anterior (TA) 
muscles of 21-day iTSCmKO mice (Figure S5A). Likewise, we found reduced phosphorylation 
levels of Akt and its target PRAS40 and increased expression of p62 in the soleus of 21-day 
iTSCmKO mice compared to Control littermates (Figure S5H). Up to that point, we could not 
find any differences in the mTORC1-Akt signaling of soleus muscles and we tested whether 
the UPS is similarly activated as in fast-twitch muscles. Importantly, we found proteasome 
activity of all three catalytic enzymes unaltered in the soleus muscle of 21-day iTSCmKO mice 
when compared with Control littermates (Figure 4F). Concomitantly, the induction of PSM 
genes and the expression of proteasomal subunits were blunted or much milder in the soleus 
(Figure 4H, 4I) in contrast to fast-twitch muscles (Figure 4B, 4D). Surprisingly, we found no 
transcriptional increase for Atrogin-1 and MuRF1 nor for other FoxO targets such as Atf4, 
Bnip3, Gadd45a or Ppp1r15a (Figure 4G, 4J). Thus, despite sustained activation of mTORC1 
and inactive Akt, FoxO transcription factors and the UPS as well, are not activated in soleus 
muscles of 21-day iTSCmKO mice, which could explain the atrophy-resistance and 
hypertrophy found in those muscles. Altogether, these results raised evidence for the 
hypothesis that an mTORC1-dependent induction of the UPS in fast-twitch muscles causes 
muscle atrophy. 
 
Constitutive activation of Akt induces proteasome activity similarly as in TSCmKO 
mice 
To further study the involvement of Akt-FoxO-signaling in regulating the UPS in mTORC1-
driven muscle atrophy, we aimed to investigate the mechanism of UPS activation in the 
absence of FoxO transcription factor activity. For that reason, we used mice with an inducible, 
muscle-specific, constitutively active form of Akt (hereafter called caAkt mice). We induced 
constitutive activation of Akt during 14 days and compared caAkt mice with TSCmKO mice 
and Control littermates. Because TSC2 is inactivated by Akt-dependent phosphorylation, 
which destabilizes TSC2 and disrupts the TSC complex (Inoki et al., 2002), constitutive 
mTORC1 activation should be similar as in TSCmKO mice. This is supported by previous 
  | Results - Part 1 - Manuscript | 
 
  45 
studies, which demonstrated that constitutive activation of Akt in murine skeletal muscle leads 
to constitutive activation of mTORC1, characterized by increased phosphorylation of S6K1, 
S6 and 4E-BP1 (Lai et al., 2004; Marabita et al., 2016). In contrast to TSCmKO mice, FoxO 
transcription factors are not active in caAkt mice. Indeed, we found transcript levels of Atrogin-
1 and MuRF1 not increased in muscles of caAkt mice, while TSCmKO mice displayed 
increased expression (Figure 5A). Similarly, the transcript expression of various FoxO targets 
was significantly increased in TSCmKO mice, whereas none of them was increased in caAkt 
mice (Figure 5B). To our surprise, we found proteasome activity for all three catalytic enzymes 
significantly increased in caAkt mice compared with Control littermates and similar to the 
activity measured in TSCmKO mice (Figure 5C). In addition, most PSM genes showed a 
similar trend for increased expression as observed in TSCmKO mice (Figure 5D). One 
exception is Psma1, a known FoxO-target (Milan et al., 2015), which is strongly increased in 
TSCmKO mice and not induced in caAkt mice (Figure 5D). Thus, FoxO transcription factors 
are not regulating the majority of PSM genes in caAkt mice. Altogether, these results 
demonstrate that sustained activation of mTORC1 induces PSM genes and therefore 
proteasomal biosynthesis and proteasome activity, independently of the activation status of 
FoxO transcription factors. Hence, this suggests that another transcription factor increases the 
expression of PSM genes upon sustained activation of mTORC1. 
 
Nrf1 is a key mediator of mTORC1-induced UPS 
For that reason, we aimed to identify a transcription factor, which is both, activated by 
mTORC1 and able to induce transcription of all PSM genes. The transcription factor Nrf1 was 
shown to increase all PSM genes as a “bounce-back” response to compromised proteasome 
function (Radhakrishnan et al., 2010; Sha and Goldberg, 2014; Steffen et al., 2010). Further 
demonstrating its important role in regulating proteasomal biosynthesis, tissue-specific 
knockout of Nrf1 in brain, liver and brown adipocytes leads to a dysregulation of proteasomal 
genes and function (Bartelt et al., 2018; Lee et al., 2013; Lee et al., 2011; Widenmaier et al., 
2017). Importantly, it was previously shown in mouse embryonic fibroblasts (MEFs) and in liver 
and brain tissue that sustained activation of mTORC1 increases the transcript levels of PSM 
genes via Nrf1 (Zhang et al., 2014). Therefore, Nrf1 fulfilled all the criteria as potential 
transcription factor for the mTORC1-dependent increase of the UPS. Therefore, we aimed to 
explore the role of Nrf1 in skeletal muscle and particularly if and how Nrf1 regulates muscle 
proteostasis. 
Indeed, we found transcript levels of Nrf1 significantly increased in young TSCmKO mice 
(Figure 6A, S6B), whereas short-term treatment with rapamycin reversed this increase 
(Figure 6A). NAD(P)H dehydrogenase, quinone 1 (NQO1), which is one of the best described 
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targets of Nrf1 involved in antioxidative response (Leung et al., 2003; Venugopal and Jaiswal, 
1998), was transcriptionally but also in protein expression significantly increased in young 
TSCmKO mice (Figure 6A, 6B, S6A, S6B). Surprisingly, we found transcript but not protein 
expression of NQO1 reversed by 3-day rapamycin treatment (Figure 6B). Another well-
described target and regulator of Nrf1, valosin containing protein (VCP, or p97) 
(Radhakrishnan et al., 2014; Sha and Goldberg, 2014), was transcriptionally increased in 
young TSCmKO mice with a trend of reversing by treating TSCmKO mice with rapamycin for 
3 days (Figure 6A, S6B). Importantly, we found genes encoding for two known positive 
regulators of Nrf1 significantly increased in young TSCmKO mice and reversed with rapamycin 
(Figure 6A, S6B). First, the gene encoding for protease DNA-damage inducible protein 2 
(Ddi2), which was shown to cleave Nrf1 allowing its translocation to the nucleus (Koizumi et 
al., 2016). Second, the gene encoding for O-linked N-acetylglucosamine transferase (Ogt), 
which was shown to catalyze O-GlcNacylation to stabilize Nrf1 and activate its transcriptional 
activity (Han et al., 2017; Sekine et al., 2018). Moreover, we found OGT expression 
significantly increased in young TSCmKO mice, whereas DDI2 at least showed a trend to be 
increased (Figure S6A). Many targets of Nrf1 were shown to be regulated under certain 
cellular stresses, particularly by another family member, namely nuclear factor erythroid-
derived 2-related factor 2 (NFE2L2, hereafter called Nrf2). To exclude any cross-regulation or 
compensatory mechanism, we tested the protein expression of Nrf2 and did not observe any 
increase (Figure S6C). Sustained activation of mTORC1 for 21 days was sufficient to increase 
the transcriptional expression of Nrf1, its targets and regulators in gastrocnemius (GAST) 
muscle (Figure 6C, 6D). In contrast, the transcriptional increase of Nrf1 and Nqo1 was 
completely blunted in the soleus muscle of 21-day iTSCmKO mice (Figure 6C). Similarly, we 
found significantly increased expression of NQO1 in TA muscle of 21-day iTSCmKO mice, but 
no induction in the soleus (Figure 6E). Finally, our experiments demonstrate that Nrf1, but not 
Nqo1, is transcriptionally increased upon constitutive activation of Akt (Figure 6F). Thus, our 
data clearly identifies Nrf1 as an mTORC1-dependent mediator of the UPS, which most likely 
regulates the expression of PSM genes and the UPS. 
 
Inactivation of Nrf1 in TSCmKO mice decreases the expression of PSM genes 
To test this Nrf1-dependent regulation of PSM genes in muscle, we aimed to inactivate Nrf1 in 
young TSCmKO mice. For that reason we designed a plasmid that drives expression of a 
shRNA directed to all existing transcript variants of Nrf1 (Nrf1 knock-down, Nrf1-kd). First, we 
tested Nrf1 inactivation in MEFs and treated them with the proteasome inhibitor bortezomib 
(BTZ), which should lead to a strong accumulation of cleaved Nrf1 (Nrf1 CL) (Radhakrishnan 
et al., 2014; Widenmaier et al., 2017). Indeed, we found Nrf1 FL and Nrf1 CL strongly 
accumulated in MEFs treated with BTZ compared with vehicle-treated MEFs (Figure 7A). This 
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accumulation was reduced in MEFs transfected with Nrf1-kd shRNA and even non-treated 
MEFs demonstrate a clear reduction of Nrf1 FL and Nrf1 CL comparing MEFs transfected with 
scramble shRNA and Nrf1-kd shRNA (Figure 7A). 
Next, we electroporated TA muscles of TSCmKO mice and Control littermates with plasmids 
driving scramble shRNA and Nrf1-kd shRNA, to inactivate Nrf1 specifically in muscle fibers for 
two weeks. Unfortunately, we realized that the most frequently used Nrf1-antibody for Western 
blot analysis (Cell Signaling Technology, #8052) but also other antibodies, displayed strong 
unspecific binding in skeletal muscle tissue on different molecular weights. This makes it 
almost impossible to detect and quantify differences in Nrf1 protein expression between 
different genotypes. In MEFs, we could not observe this effect, and it seems not to be the case 
for any other tissue, where this antibody was used before. Nevertheless, we confirmed 
successful inactivation of Nrf1 by strongly reduced expression of Nrf1 FL (~120kDa), Nrf1 CL 
(~85kDa) and locus control region-factor 1 (LCR-F1 or Nrf1β, ~55kDa) in muscles with Nrf1-
kd compared to muscles with scramble shRNA in Control and TSCmKO mice (Figure 7B). 
Further demonstrating successful inactivation of Nrf1, we found its transcript expression 
significantly decreased in TSCmKO mice and Control littermates (Figure 7D). Unfortunately, 
through electroporation, we slightly dampened the genotype-specific differences between 
muscles from Control and TSCmKO mice. This might be due to new and regenerative fibers, 
which do not express human skeletal ɑ-actin (HSA) yet and therefore do not have the ablation 
of TSC1. This was further supported by the fact that the expression of TSC1 was reduced in 
electroporated muscles of TSCmKO mice, but not as explicit as we normally observe in 
TSCmKO mice (Figure S7B) (Bentzinger et al., 2013; Castets et al., 2013). Significantly 
decreased relative muscle weight, found in the contralateral, sham-treated TA muscles of 
TSCmKO mice when compared with Control littermates (Figure S7A), further supports the 
notion that electroporation dampened genotype-specific differences. 
Interestingly, TA muscles of both, TSCmKO and Control mice transfected with Nrf1-kd shRNA, 
showed significantly decreased protein and transcript expression of most proteasomal 
subunits (Figure 7B, S7E). Only Psme4/PA200, which is a known FoxO-target (Milan et al., 
2015), displayed no decreased expression (Figure 7B, S7E). The protein expression of p97 
and DDI2 was significantly decreased with Nrf1 inactivation, whereas another potential target 
of Nrf1, glutamate-cysteine ligase, catalytic subunit (GCLC) was not altered and Nrf2 rather 
increased than decreased (Figure S7C). In contrast, transcript expression of Nrf2 was 
significantly decreased (Figure S7F), suggesting an Nrf1-dependent regulation which does 
not get functional relevance. Surprisingly, we found strong induction of NQO1, on protein and 
transcript levels, only in TSCmKO mice with Nrf1 inactivation (Figure S7C, S7F). Therefore, 
we assume that NQO1 is not solely regulated by Nrf1. In addition we found evidence, that 
inactivation of Nrf1 affects autophagy. Similarly to NQO1, p62 was transcriptionally and in 
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protein expression strongly increased in TSCmKO but not Control mice with Nrf1 inactivation 
(Figure S7C, S7F). In contrast, we observed less expression of BECN1 and LC3b upon Nrf1-
kd in Control and TSCmKO mice (Figure S7C). This implies that either the transcripts encoding 
for BECN1 / LC3b are direct targets of Nrf1 or that there is less induction of autophagosome 
formation. Interestingly, we found the amount of ubiquitinylated proteins significantly 
decreased in TSCmKO mice with Nrf1 inactivation (Figure S7D) and the expression of Atrogin-
1 and MuRF1 significantly further increased (Figure 7D). Both might be an indication for a 
compensatory mechanism induced by FoxO transcription factors. The finding that other FoxO 
targets, such as Psme4, Ppp1r15a and p62 are also significantly increased in the absence of 
Nrf1 in TSCmKO mice (Figure S7E, S7F), further supports the idea of a FoxO-driven 
compensatory mechanism. Altogether, these results demonstrate that Nrf1-inactivation is 
sufficient to decrease the expression of most proteasomal subunits. Moreover, inactivation of 
Nrf1 does not only affect proteasomal subunits, but also other parts of the UPS and autophagy-
lysosomal degradation, which needs further investigations. Hence, our data demonstrate that 
mTORC1 regulates the expression of proteasomal subunits and the UPS by a transcriptional 
increase of Nrf1.  
To link this mTORC1-dependent, Nrf1-induced increase of the UPS with muscle atrophy, we 
measured the body and muscle weight of contralateral, sham-treated and electroporated TA 
muscles in Control and TSCmKO mice. The body weight of these mice was not changed 
(Figure 7C). When we compared the ratio of muscle weight between electroporated and 
contralateral sham-treated muscles, we observed an almost significant, 10% increase in TA 
muscles of TSCmKO mice with inactivated Nrf1 compared to TSCmKO mice electroporated 
with scramble shRNA (Figure 7C). This data further supports the hypothesis that inactivation 
of Nrf1 could attenuate the muscle atrophy in TSCmKO mice. To demonstrate this, prolonged 
inactivation of Nrf1 and detailed analysis of the muscle histology must be performed.  
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Discussion 
Skeletal muscle size and therefore as well muscle wasting is ultimately determined by the 
muscle proteostasis. Activation of mTORC1 in skeletal muscle is generally associated with 
growth and with promoting anabolism. Because of its role in regulating translation and protein 
synthesis, mTORC1 was proposed as mediator of muscle hypertrophy (Bodine et al., 2001; 
Ruegg and Glass, 2011; Sandri, 2013; Schiaffino et al., 2013). Nevertheless, we previously 
showed in mice depleted for TSC1 in skeletal muscle (TSCmKO mice) that sustained 
activation of mTORC1 leads to atrophy, to a severe late-onset myopathy and to muscle 
weakness (Bentzinger et al., 2013; Castets et al., 2013). Particularly, the myopathic features 
of TSCmKO mice, such as vacuoles, damaged organelles and p62 aggregates, were 
explained by the blockage of autophagy induction (Castets et al., 2013). In contrast, the muscle 
atrophy, which is already observed in young TSCmKO mice, cannot be explained by this 
mechanism. In this study, we analyzed the atrophy of TSCmKO mice and identified a new 
mechanism of how mTORC1 regulates catabolic processes. This knowledge may help to 
attenuate mTORC1-driven muscle atrophy. 
One characteristic of muscle atrophy is the common expression of a set of genes called 
atrogenes (Lecker et al., 2004; Sacheck et al., 2007). Nevertheless, a recent study highlighted 
that even the expression of atrogenes vary between different types of muscle atrophy and that 
the signaling network controlling muscle atrophy is specific for each catabolic condition 
(Brocca et al., 2017). Additionally to the atrogenes, there is a huge variety of genes, which are 
related to only one or few specific types of muscle atrophy. Therefore, to understand the 
underlying gene expression program is essential for designing unique strategies to attenuate 
each specific type of muscle atrophy. Here, we present a new, unsupervised list of 249 
atrophy-related genes. These genes were at least once directly associated with muscle 
atrophy before. The large expression of atrogenes (40%) but also of atrophy-related genes 
(41%) we found in young TSCmKO mice is an indication of a prominent atrophy-related gene 
expression signature that is induced by sustained activation of mTORC1. Importantly, the 
majority of these genes are involved in protein degradation processes. Together, with the 
pathway enrichment of the ubiquitin-proteasome system and of the 26S proteasome we found 
in our proteomics data, this suggests that muscle atrophy in TSCmKO mice involves the 
activation of mTORC1-dependent catabolic processes. 
Indeed, we demonstrate in this study that sustained activation of mTORC1 in TSCmKO mice 
not only increases protein synthesis and blocks autophagy induction, but also induces the 
ubiquitin-proteasome system. This induction includes ubiquitin-E3-ligases, ubiquitinylation, 
transcriptional activation of proteasomal biosynthesis and increased proteasome activity. In 
addition to the current knowledge that the mTORC1-specific inhibitor rapamycin induces 
autophagy (Kim et al., 2011) and alleviates the blockage of autophagy induction in TSCmKO 
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mice (Castets et al., 2013), we found in this study evidence that short-term inhibition with 
rapamycin reverses the mTORC1-dependent increase of the UPS in young TSCmKO mice. 
The short-term characteristics of the rapamycin treatment definitely rules out that this induction 
of the UPS is caused by any pathological factors or occurs in response to extrinsic factors. 
Instead, we give evidence that the increase of the UPS, particularly the activation of PSM 
genes, is due to the activation of a signaling cascade resulting in the activation of Nrf1, as a 
direct consequence of sustained active mTORC1. By inducing a similar activation of the UPS, 
through activation of mTORC1 for only 21 days in adult muscles of iTSCmKO mice, we can 
exclude any impact caused by sustained active mTORC1 during pre-adult muscle 
development. Moreover, results from iTSCmKO mice again demonstrate that the increase of 
the UPS is based on mTORC1-Nrf1 signaling. Interestingly, proteasome activity is not further 
increased with prolonged activation of mTORC1 and is as well not further increased in 10-
month-old TSCmKO mice with severe myopathy. This finding favors the hypothesis that a 
relatively mild increase of the UPS slightly shift the balance of muscle proteostasis to the 
catabolic side. On this way, protein degradation in muscle still provides sufficient amino acids 
to avoid immediate detrimental effects to whole-body metabolism. On the other hand, a mild 
increase in protein degradation over days and months could still result in the accumulation of 
a more and more severe muscle atrophy. Therefore, dampening of this mTORC1-driven 
increase of the UPS, together with increased protein synthesis could potentially help to build 
up muscle mass. 
Skeletal muscles and muscle fiber types vary in their response to the same stimulus. For 
example, denervation in the rat diaphragm or any other fast-twitch muscle causes atrophy of 
the glycolytic, fast-twitch fibers type IIx and IIb, no changes in oxidative, fast-twitch fibers type 
IIa and hypertrophy of oxidative, slow-twitch type I fibers (Aravamudan et al., 2006; Schiaffino 
et al., 2013). In contrast, type I fibers of the slow-twitch muscle soleus show marked atrophy 
after denervation (Schiaffino et al., 2013). Thus, the same fiber type undergoes opposite 
changes in different muscles. Interestingly, the soleus muscle is also less sensitive to 
starvation and shows in general higher rates of protein synthesis and protein degradation 
compared to fast-twitch muscles (Li and Goldberg, 1976). Furthermore, hypertrophy of the 
soleus muscle induced by growth hormones, showed increased protein synthesis rates without 
any changes in protein degradation (Goldberg, 1969). Surprisingly, we previously found that 
the soleus muscle was the only muscle with increased relative muscle weight and fiber size 
upon sustained activation of mTORC1, although it displayed similar blockage of autophagy 
induction as observed for fast-twitch muscles (Bentzinger et al., 2013; Castets et al., 2013). 
Here, we demonstrated that activation of mTORC1 for only 21 days in iTSCmKO mice is 
sufficient to induce hypertrophy in the soleus muscle. Moreover, we showed that the soleus 
muscle is resistant to the mTORC1-Nrf1-dependent induction of the UPS. We have already 
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previously shown that the two ubiquitin-E3-ligases Atrogin-1 and MuRF1 were not increased 
in the soleus muscle of TSCmKO mice (Bentzinger et al., 2013). Here, we show in soleus 
muscle of 21-day iTSCmKO mice, despite decreased Akt activity caused by sustained 
activation of mTORC1, no alterations in the expression of Atrogin-1 and MuRF1 as well as of 
other FoxO targets, such as Atf4, Bnip3, Gadd45a and Ppp1r15a. Therefore, this could mean 
that in soleus muscles of TSCmKO mice rates of protein synthesis are increased via mTORC1 
but no changes in protein degradation rates because FoxO as well as Nrf1 are not increased. 
Similarly to how it was described earlier on (Goldberg, 1969), increased protein synthesis 
without any changes in protein degradation could result in the strong hypertrophy we observed 
in the soleus of TSCmKO and iTSCmKO mice. Why FoxO but also Nrf1 in the soleus of 
TSCmKO mice are not induced by mTORC1, needs further investigations. Interestingly, these 
results demonstrate that even if autophagy induction is blocked, and there is no increased 
UPS-activity either through Nrf1 or through FoxO, the soleus muscle is still able to undergo 
hypertrophy. 
Constitutive activation of Akt was shown to constitutively activate mTORC1 resulting in 
increased protein synthesis and ribosome biogenesis (Lai et al., 2004; Marabita et al., 2016). 
In addition, it was shown that constitutive activation of Akt leads to increased expression and 
to accumulations of p62 (Marabita et al., 2016). This indicates that constitutive activation of 
Akt and ablation of TSC1 leads to a similar activation of mTORC1 and to a similar blockage of 
autophagy induction. The big difference between constitutive activation of Akt and TSCmKO 
mice lies in the activation of FoxO transcription factors. In this study, we could show that caAkt 
mice have a similar increase of Nrf1 and proteasome activity as observed in TSCmKO mice. 
These results, together with the rapamycin treatment in TSCmKO mice and the short-term 
activation of mTORC1, explicitly means that the mTORC1-dependent induction of proteasomal 
biosynthesis and proteasome activity is mediated by Nrf1 and excludes involvement of FoxO-
signaling in this particular process. Nevertheless, the activity of FoxO is essential to induce a 
variety of ubiquitin-E3-ligases (Milan et al., 2015; Sacheck et al., 2004; Sandri et al., 2004; 
Sartori et al., 2013), which are needed for the ubiquitinylation of targets of the 26S proteasome. 
Therefore, if an mTORC1-Nrf1-driven increase of proteasomal biosynthesis and proteasome 
activity, without the induction of FoxO-dependent ubiquitin-E3-ligases, is sufficient to efficiently 
increase protein degradation rates, needs further investigations. Reduced protein degradation 
rates in mice with constitutive activation of Akt compared to TSCmKO mice, where FoxO and 
Nrf1 are active, might also explain the strong and fast hypertrophic response, which was shown 
for mice with constitutive activation of Akt (Lai et al., 2004; Marabita et al., 2016). 
In this study, we identify the transcription factor Nrf1 as key mediator of mTORC1-driven 
muscle atrophy, by transcriptionally regulating proteasomal biosynthesis. Nrf1 was previously 
associated with an mTORC1-dependent increase of genes encoding for proteasomal subunits 
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in TSC2-/- MEFs and in brain and liver lysates (Zhang et al., 2014). Here, we further support 
this finding and show comprehensive in-vivo data of skeletal muscle that an mTORC1-
dependent increase of Nrf1 leads to an increase of proteasomal biosynthesis and activity, and 
together with FoxO to an increase of the ubiquitin-proteasome system. Nrf1 was previously 
shown to be regulated by mTORC1 via SREBF1 (Zhang et al., 2014). If SREBF1 regulates 
Nrf1 in an mTORC1-dependent way in skeletal muscle, needs further investigations. 
Interestingly, not only Nrf1 but also some of its post-translational, positive regulators, namely 
p97, OGT and DDI2, are transcriptionally increased in an mTORC1-dependent manner. 
Increased expression of p97 was previously associated with muscle atrophy and accelerated 
degradation of myofibrillar proteins, whereas its inhibition caused rapid growth of myofibers 
(Piccirillo and Goldberg, 2012). More recently, p97 was identified as direct target of Nrf1 (Sha 
and Goldberg, 2014) and upon proteasome inhibition to be essential for the retrotranslocation 
of Nrf1 to the cytosolic side of the ER membrane (Radhakrishnan et al., 2014), where Nrf1 
escapes proteasomal degradation and is cleaved and activated by DDI2 (Koizumi et al., 2016). 
OGT was recently described to stabilize and activate Nrf1 upon O-GlcNacylation, which is a 
major feature of cancer cell metabolism (Sekine et al., 2018). Hence, our findings strongly 
suggests that sustained activation of mTORC1 leads to a transcriptional increase of Nrf1 but 
in parallel also to an increase of a variety of positive, post-translational regulators of Nrf1. 
Generally, an increase of Nrf1 is directly associated with the evolutionary conserved “bounce-
back” response upon proteasome inhibition to maintain cellular proteostasis (Radhakrishnan 
et al., 2010; Sha and Goldberg, 2014; Steffen et al., 2010). Proteasome inhibitors are used in 
clinical treatment of multiple myeloma (Adams and Kauffman, 2004; Richardson et al., 2005; 
Richardson et al., 2010). However, bortezomib alone or in combination with other drugs did 
not show its real efficacy in the clinical trials to treat solid tumors (Frankland-Searby and 
Bhaumik, 2012; Johnson, 2015). The observation that therapeutic proteasome inhibition 
promptly triggers the upregulation of PSM genes in malignant cells (Mitsiades et al., 2002), 
was associated with the Nrf1-induced “bounce-back” response. Hence, Nrf1 received 
significant medical relevance as regulator of an important compensatory response that 
promotes tumor cell survival and attenuates therapeutic efficacy (Yuan et al., 2018). In skeletal 
muscle, the role of Nrf1 is poorly described so far. One study reported that activation of Nrf1 
and Nrf2 improved the muscle histology in a mouse model for spinal and bulbar muscular 
atrophy (SBMA) (Bott et al., 2016). Nevertheless, this study focussed on the effect that Nrf1 
induced by regulating antioxidant enzymes and not on muscle proteostasis per se.  
Sustained activation of mTORC1 leads to increased expression of Nrf1 and increased 
expression of PSM genes. By inactivation of Nrf1 in Control and TSCmKO mice, we showed 
that Nrf1 regulates most PSM genes in muscle. Here, we present a mechanism in skeletal 
muscle, which functionally resembles the well-established “bounce-back” response but without 
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prior perturbation of proteasomes. Therefore, we raise evidence for the hypothesis that 
sustained active mTORC1 transcriptionally increases Nrf1 to increase the UPS and protein 
degradation rates, which results in muscle atrophy. Nrf1-inactivation in TSCmKO mice for only 
2 weeks with a minimal n number (n=3) shows a promising trend for increased muscle weight 
compared to Control mice. To elucidate the role of Nrf1 in regulating muscle proteostasis would 
require prolonged inactivation. At this stage, it would be interesting to compare the inactivation 
of Nrf1 in the presence / absence of proteasome inhibitors in TSCmKO mice. Whether this 
mechanism is effectively induced to regulate muscle proteostasis remains unresolved. It might 
well be that the initial role of this mechanism was to compensate for the block of autophagy 
induction, or to provide sufficient amino acids to fulfill increased protein synthesis rates or to 
deal with misfolded proteins and ER stress. Therefore, the activation of this mechanism needs 
further investigations. 
Altogether, the findings of this study help to understand and explore a new mechanism 
regulated by mTORC1 and Nrf1 that controls muscle proteostasis and muscle mass. In 
addition, this knowledge may lead to the identification of a new possible target to slow-down 
the massive muscle wasting observed in cachexia or sarcopenia.  
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Materials and methods 
Mice 
TSCmKO mice were obtained by crossing Tsc1-floxed mice (Kwiatkowski et al., 2002) from 
Jackson Laboratory with transgenic mice expressing Cre recombinase under the control of the 
human skeletal actin (HSA) promoter (Schwander et al., 2003). iTSCmKO mice were obtained 
by crossing Tsc1-floxed mice (Kwiatkowski et al., 2002) from Jackson Laboratory with 
transgenic, inducible mice expressing a chimeric Cre recombinase containing two mutated 
estrogen receptor ligand-binding domains (MerCreMer) under the control of the HSA promoter 
(McCarthy et al., 2012). caAkt mice were obtained from Dr. David Glass at Novartis Institutes 
for BioMedical Research (NIBR, Cambridge, MA, USA). These mice express a constitutively 
active form of Akt1/PKBα fused to enhanced green fluorescent protein (EGFP) and human 
estrogen receptor type 2 (ERt2) under the control of the HSA promoter. All mice were 
maintained in a licensed animal facility with a fixed 12 h dark-light cycle and were allowed for 
food and water ad libitum. All animal studies were performed under the guidelines and the law 
of the Swiss authorities and were regularly controlled and approved by the veterinary office. 
 
Animal experiments 
In some experiments mice were intraperitoneally injected with rapamycin (8 mg/kg; LC 
Laboratories) as previously described (Bentzinger et al., 2013) for three consecutive days. 
These mice were weighed before each injection. To induce ablation of Tsc1 in HSA-expressing 
muscle fibers, tamoxifen (2.5 mg/day; Sigma) diluted in corn oil (Sigma) was injected 
intraperitoneally for five consecutive days. To induce constitutive activation of Akt in HSA-
expressing muscles fibers, tamoxifen (40 mg/kg; Sigma) diluted in corn oil (Sigma) was 
injected intraperitoneally for five consecutive days, followed by three injections every 48 hours 
for one week more. In experiments using tamoxifen, only male mice were used. 
 
Cell culture 
SV40 immortalized mouse embryonic fibroblasts (MEFs) were maintained in Glutamax 
Dulbecco’s modified Eagle’s medium (DMEM Glutamax and pyruvate, Gibco) supplemented 
with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (pen/strep) on cell culture 
dishes in 37°C incubator with 5% CO2. For Nrf1-kd, MEFs were transfected with plasmids 
encoding for Nrf1-kd shRNA (see below) using Lipofectamin 2000 (Invitrogen). Lysis of the 
cells was started 48 hours after transfection. Cells were scraped and lysed in cold RIPA buffer 
(50 mM TrisHCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
ddH2O) supplemented with phosphatase and protease inhibitor cocktail tablets (Roche), DNA 
was sheared with a syringe (26G needle). Afterwards, the lysate was centrifuged at 16,000 g 
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for 20 min at 4°C. Supernatant (cleared lysates) were used to determine total protein amount 
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer’s 
protocol. Immunoblotting was performed as described below. For Nrf1 accumulation 
experiment, MEFs were treated with bortezomib (BTZ; 10 nM, Selleck Chemicals) or dimethyl 
sulfoxide (DMSO) as vehicle four hours prior to lysis. 
 
In vivo muscle transfection and electroporation 
The methods to construct plasmid vectors encoding shRNA have been described elsewhere 
(Kong et al., 2004). The murine 19 nucleotide target sequences correspond to: GGC CCG 
ATT GCT TCG AGA A (Nrf1). pRFP-C-RS scrambled shRNA plasmid vector was obtained 
from OriGene (TR30015). For analgesia, mice were injected subcutaneously with 
Buprenorphine (0.1 mg/kg) before and every 4 to 6 hours after electroporation. During night, 
Buprenorphine was given orally over the drinking water. Tibialis anterior (TA) muscle of 
anesthetized mice was exposed and injected with 50 μl (8 IU) of hyaluronidase (Sigma). Mice 
were returned to the cage for two hours. Then, TA muscle of anesthetized mice was injected 
with 50 μl of 2 μg/μl of the respective shRNA plasmid DNA. The electroporation was performed 
using an NEPA21 electroporation system (NepaGene). Three pulses lasting 30 ms with a 
pulse interval of 50 ms and the voltage set to 150 V/cm were applied. Mice were analyzed two 
to four weeks after electroporation. 
 
Transcript expression analysis (RNA extraction and RT-PCR) 
Dissected muscle was rapidly frozen in liquid nitrogen. Total RNA was extracted using the 
RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol. Equal amounts of RNA was 
transcribed into cDNA using the iScript cDNA Synthesis Kit (BioRad). Selected genes were 
amplified and detected using the Power SYBR Green PCR Master Mix (Applied Biosystems), 
quantitative expression was determined by StepOnePlus Real-Time PCR System (Applied 
Biosystems). Relative gene expression was determined with the StepOne software (v2.3) and 
normalized to the corresponding housekeeping gene as indicated and relative to expression 
in Control mice. All primers used for RT-qPCR are listed in Table S4. 
 
Western blot analysis 
Dissected muscle was rapidly frozen in liquid nitrogen. Frozen muscles were pulverized on a 
metal plate chilled in liquid nitrogen and directly snap-frozen as pellet in liquid nitrogen. 
Samples were lysed in cold RIPA buffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, ddH2O) supplemented with phosphatase and protease 
inhibitor cocktail tablets (Roche), incubated on a rotating wheel for 2 h at 4°C and sonicated 
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twice for 10 s. Afterwards, the lysate was centrifuged at 16,000 g for 20 min at 4°C. 
Supernatant (cleared lysates) were used to determine total protein amount using the Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer’s protocol. 
Proteins were separated on 4-12% Bis-Tris Protein Gels (NuPage Novex, Thermo Fisher 
Scientific) and transferred to nitrocellulose membrane (GE Healthcare Life Sciences, 
Amersham). The membrane was blocked with 5% BSA, 0.1% Tween-20, PBS for 1 h at room 
temperature. The primary antibody diluted in the blocking solution was incubated overnight at 
4°C with continuous shaking. The membranes were washed three times for 15 min with PBS-
T (0.1% Tween-20, PBS) and incubated with secondary horseradish peroxidase-conjugated 
(HRP) antibody for 1 h at room temperature. After washing with PBS-T, proteins were 
visualized by chemiluminescence (KPL LumiGLOⓇ, Seracare). Signal was captured on a 
Fusion Fx machine (VilberLourmat) and analyzed with FUSION Capt FX software. All 
antibodies used for immunoblotting are listed in Table S5. 
 
Ubiquitinylation analysis 
Dissected muscle was rapidly frozen in liquid nitrogen. Frozen muscles were pulverized on a 
metal plate chilled in liquid nitrogen and directly snap-frozen as pellet in liquid nitrogen. 
Samples were lysed in cold Ub-lysis-buffer (1 mM EDTA, 25 µM MG 132, 50 mM N-
ethylmaleimide, 50 mM TrisHCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, ddH2O) supplemented with phosphatase and protease inhibitor cocktail tablets 
(Roche), incubated on a rotating wheel for 2 h at 4°C and sonicated twice for 10 s. Afterwards, 
the lysate was centrifuged at 16,000 g for 20 min at 4°C. Supernatant (cleared lysates) were 
used to determine total protein amount using the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific) according to manufacturer’s protocol. Immunoblotting was performed as described 
above. 
 
Proteasome activity assay 
Proteasome activity assay was adapted from a protocol described previously (Strucksberg et 
al., 2010). Briefly, dissected extensor digitorum longus (EDL) or plantaris (PLA) muscles were 
rinsed in ice-cold PBS, immediately cut into 5-6 pieces and directly lysed in ice-cold PBS-E (5 
mM EDTA pH 8.0, PBS pH 7.2) and sonicated two times for 10 s. Afterwards, the lysate was 
centrifuged at 13,000 g for 5 min at 4°C. Supernatant (cleared lysates) were used to determine 
total protein amount using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) 
according to manufacturer’s protocol. Three individual luciferase-based Proteasome-GloTM 
Assay Systems (Promega) were used to measure the activity of each peptidase of the 
proteasome. Assay was performed on white, 96-well microplates (greiner BIO-ONE) and 
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luminescence was measured with Infinite M1000 (Tecan). Human, purified 20S proteasome 
(Enzo Life Sciences, BML-PW8720) was used as positive control. Proteasome inhibitor MG 
132 (50 µM, TOCRIS Biotechne) was used for measuring non-proteasomal activity in this 
assay, which was used for background subtraction. 
 
m7GTP pulldown 
Dissected muscle was rapidly frozen in liquid nitrogen. Frozen muscles were pulverized on a 
metal plate chilled in liquid nitrogen, before lysis in cold pull-down buffer (20 mM Hepes pH 
7.4, 50 mM KCl, 0.2 mM EDTA, 25 mM β-glycerophosphate, 0.5 mM sodium orthovanadate, 
1 mM dithiothreitol, 0.5% Triton X-100, and 50 mM sodium fluoride) supplemented with 
phosphatase and protease inhibitor cocktail tablets (Roche). Cells were disrupted by additional 
homogenization in a Potter homogenizer, incubated on ice for 10 min before centrifugation for 
10 min at 10,000 rpm at 4°C. Supernatant were used to determine total protein amount using 
the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer’s 
protocol. 400 µg of total lysate was used for m7GTP pull-down assay. After preclearing of the 
samples with agarose beads (Jena Bioscience) for 30 min at 4°C, 20 µl of a 50% slurry of γ-
Aminohexyl-m7GTP-Agarose (Jena Bioscience) was incubated with the precleared 
supernatant overnight at 4°C on a rotating wheel. After three washes, the samples were 
denatured for 10 min at 95°C before separation on 4-12% Bis-Tris Protein Gels (NuPage 
Novex, Thermo Fisher Scientific) and transferred to nitrocellulose membrane (GE Healthcare 
Life Sciences, Amersham). eIF4E and 4E-BP1 abundances on the m7GTP mimicking cap were 
visualized by chemiluminescence (KPL LumiGLOⓇ, Seracare). Signal was captured on a 
Fusion Fx machine (VilberLourmat) and analyzed with FUSION Capt FX software. 
 
RNA extraction for RNA-seq 
EDL muscles isolated from Control and TSCmKO mice, were used to generate the 
corresponding cDNA-libraries. Poly-A mRNA were directly isolated from frozen EDL samples 
by using the DynabeadsTM mRNA DIRECTTM Purification Kit (Invitrogen) with the Mini 
configuration followed by alkaline hydrolysis. To provide 5’ to 3’ directionality to fragmented 
samples, mRNA was treated with phosphatase and then with polynucleotide kinase (PNK). 
Further, 3’ and 5’ adaptors (Illumina) were ligated and the resulting product was reverse 
transcribed to generate cDNA by PCR. During PCR amplification, each prepared sample was 
uniquely indexed (barcoding) using index primer (Illumina) for multiplexing (differently indexed 
samples in one lane). PCR products have been purified twice with AMPure beads (Agencourt). 
The quality of the cDNA-library was verified and quantified by using a Bioanalyzer (Agilent 
Technologies). Illumina “HiSeq 2000” was used for sequencing at the Quantitative Genomics 
  | Results - Part 1 - Manuscript | 
 
  58 
Facility (QGF) at the Department of Biosystems Science and Engineering (D-BSSE) of the 
ETH Zürich in Basel. 
 
Protein isolation for Tandem Mass Tag (TMT)-LC-MS/MS 
Dissected muscle was rapidly frozen in liquid nitrogen. Frozen muscles were pulverized on a 
metal plate chilled in liquid nitrogen and directly snap-frozen as pellet in liquid nitrogen. 
Samples were lysed in cold lysis buffer (1% sodium deoxycholate, 100 mM 
ammoniumbicarbonate) and ultra sonicated twice for 10 s with VialTweeter (Hielscher). 
Afterwards, the lysate was centrifuged at 16,000 g for 10 min at 4°C. Supernatant (cleared 
lysates) were used to determine total protein amount using the Pierce BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to manufacturer’s protocol. Next, protein was reduced 
and alkylated. Afterwards, proteins were digested using Trypsin digestion at 37°C overnight. 
Samples were purified (solid phase extraction). labeled with TMT10plex Label Reagents 
(Thermo scientific) and then mixed before sample fractionation and clean-up. Labeled samples 
are analyzed by high resolution Orbitrap LC-MS/MS. 
 
Bioinformatics 
Paired-end sequencing reads were annotated and then aligned to the mouse reference 
genome (UCSC/mm10 and Refseq/GenBank annotation) using CLIPZ (Khorshid et al., 2011). 
From aligned reads, mRNA expression levels were estimated calculating the relative 
abundance of mRNA, based on the number of reads associated with a transcript and the 
transcript length (Jaskiewicz et al., 2012). Transcript counts of the two different genotypes 
have been analyzed and tested for differential expression by using R and Bioconductor 
software tools as previously described (Anders et al., 2013). Genes were considered as 
significantly differentially expressed with a confidence level of 0.05. Volcano plots and principal 
component analysis (PCA) plots were created using R. Mass-spectrometric data was further 
statistically validated by the in-house developed software tool SafeQuant (Glatter et al., 2012). 
Proteins were considered as significantly differentially expressed with a confidence level of 
0.05. Characterization and enrichment analysis of the differentially expressed proteins was 
done using PANTHER pathway enrichment analysis (Mi et al., 2019; Mi et al., 2013) and 
DAVID analysis and functional annotation clustering (Huang da et al., 2009a, b). 
 
Statistical analysis 
All experiments were performed on a minimum of n (number of individual experiments) ≥3 
independent biological samples. In all graphs, data are presented as the mean value and the 
respective standard error of the mean (SEM, error bars). Student’s t test was used when two 
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groups were compared to evaluate statistical significance. One-way or two-way analysis of 
variance (ANOVA) test with Tukey’s correction for multiple comparisons were used to compare 
more than two groups. A confidence level of 0.05 was accepted for statistical significance. 
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Figure 1. Young TSCmKO mice display an atrophy-related gene expression signature. 
(A) Identification of mTORC1-dependent atrogenes, comparing published mRNA expression 
data of atrogenes with RNA-sequencing data obtained from extensor digitorum longus (EDL) 
muscles from female, 3-month-old TSCmKO mice and Control littermates (n=5). (B) Volcano 
plot of previously described atrogenes found expressed in young TSCmKO mice. Colored 
circles indicate significantly (p<0.05), differentially expressed (DE) genes (green=upregulated, 
red=downregulated) between young TSCmKO mice and Control littermates, which are 
similarly regulated as in other types of muscle atrophy. Genes DE in young TSCmKO mice 
twofold or more, are labeled by their gene name. (C) Volcano plot of atrophy-related genes 
found expressed in young TSCmKO mice. Genes DE in young TSCmKO mice twofold or more, 
are labeled by their gene name. (D) Volcano plot of atrophy-related genes found expressed in 
young TSCmKO mice. Genes involved in protein degradation are labeled by their gene name.  
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Figure 2. Ubiquitin proteasome system is enriched in young TSCmKO mice. 
Significantly (p<0.05), differentially expressed (DE) proteins were obtained from proteomics 
data from tibialis anterior (TA) muscles of 3-month-old, male TSCmKO mice and Control 
littermates (n=4). (A) Bar diagram illustrates PANTHER pathway enrichment analysis done 
with DE proteins. (B) DAVID enrichment analysis algorithms were applied on DE proteins to 
determine the most enriched KEGG pathways. (C, E) Relative transcript expression was 
quantified by RT-qPCR in TA muscle from 2-month-old, female TSCmKO and Control mice, 
n=5. Transcript encoding ꞵ-tubulin was used as reference. (D) Western blot analysis of 
proteasomal subunits (PSM) in TA muscles from 2-month-old, female TSCmKO and Control 
mice, n=5. Western blot analysis of ubiquitinylated proteins in gastrocnemius (GAST) muscles 
from 3-month-old, male TSCmKO and Control mice, n=6. (F) Luciferase-based proteasome 
activity measurement in lysates of extensor digitorum longus (EDL) muscles from 4-month-old, 
male TSCmKO and Control mice, n=4. Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, 
*p ≤ 0.05, Student's t test.  
  | Results - Part 1 - Manuscript | 
 
  66 
 
Figure 3. Short-term inhibition with rapamycin reverses the increased UPS in 
TSCmKO mice. 
3-month-old Control and TSCmKO mice were treated with rapamycin (RAPA) or vehicle for 3 
days. (A, B) Relative transcript expression was quantified by RT-qPCR in gastrocnemius 
(GAST) muscle, n=5 (Control:RAPA), n = 6 (Control, TSCmKO, TSCmKO:RAPA). Transcript 
encoding ꞵ-actin was used as reference. (C) Luciferase-based proteasome activity 
measurement in lysates of plantaris (PLA) muscle, n=5 (Control:RAPA), n = 6 (Control, 
TSCmKO, TSCmKO:RAPA. (D) Western blot analysis of proteasomal subunits (PSM) in 
tibialis anterior (TA) muscle, n=4 (Control:RAPA), n = 6 (Control, TSCmKO, TSCmKO:RAPA). 
Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, One-way ANOVA test.  
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Figure 4. Activation of mTORC1 for 21 days is sufficient to increase the UPS in most 
adult muscles but not in soleus. 
In 3-month-old mice, Tsc1 deletion was induced in skeletal muscle (iTSCmKO mice) and mice 
were examined 21 days later. (A, B, J) Relative transcript expression was quantified by RT-
qPCR in gastrocnemius (GAST) muscle, n=5 (iTSCmKO), n=4 (Control). Transcript encoding 
ꞵ-tubulin was used as reference. (C) Luciferase-based proteasome activity measurement in 
lysates of extensor digitorum longus (EDL) muscle, n=4. (D) Western blot analysis of 
proteasomal subunits (PSM) in tibialis anterior (TA) muscle, n=4. (E) Western blot analysis of 
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ubiquitinylated proteins in GAST muscle, n=5 (iTSCmKO), n=4 (Control). The slow-twitch 
muscle soleus (SOL) is hypertrophic in iTSCmKO mice and displays no increase of the UPS. 
(F) Luciferase-based proteasome activity measurement in lysates of EDL and SOL muscle, 
n=4 (EDL), n=4 (SOL, Control), n=5 (SOL, iTSCmKO). (G, H, J) Relative transcript expression 
was quantified by RT-qPCR in SOL muscle, n=4. Transcript encoding ꞵ-actin was used as 
reference. (I) Western blot analysis of PSM in SOL muscle, n=4. Data represent means ± 
SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test.  
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Figure 5. Constitutive activation of Akt induces proteasome activity similarly as in 
TSCmKO mice. 
10-month-old Control, TSCmKO and caAkt mice were treated every 72 h with tamoxifen to 
induce a constitutive active form of Akt (caAkt mice) for 14 days. (A, B, D) Relative transcript 
expression was quantified by RT-qPCR in gastrocnemius (GAST) muscle, n=4 (TSCmKO), 
n=3 (caAkt, Control). Transcripts encoding the TATA box binding protein (TBP) was used as 
reference. (C) Luciferase-based proteasome activity measurement in lysates of plantaris (PLA) 
muscle, n=3 (caAkt, TSCmKO), n=4 (Control). Data represent means ± SEM, ***p ≤ 0.001, **p 
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Figure 6. Nrf1 is a key mediator of mTORC1-induced UPS. 
3-month-old Control and TSCmKO mice were treated with rapamycin (RAPA) or vehicle for 3 
days. (A) Relative transcript expression was quantified by RT-qPCR in gastrocnemius (GAST) 
muscle, n=5 (Control:RAPA), n = 6 (Control, TSCmKO, TSCmKO:RAPA). Transcript encoding 
ꞵ-actin was used as reference. (B) Western blot analysis of NQO1 in tibialis anterior (TA) 
muscle, n=4 (Control:RAPA), n = 6 (Control, TSCmKO, TSCmKO:RAPA). In 3-month-old mice, 
Tsc1 deletion was induced in skeletal muscle (iTSCmKO mice) and mice were examined 21 
days later. (C) Relative transcript expression was quantified by RT-qPCR in GAST or soleus 
(SOL) muscle, n=5 (GAST iTSCmKO), n=4 (GAST Control, SOL Control, SOL iTSCmKO). 
Transcripts encoding ꞵ-tubulin (GAST) or ꞵ-actin (SOL) were used as reference. (D) Relative 
transcript expression was quantified by RT-qPCR in GAST muscle, n=5 (iTSCmKO), n=4 
(Control). Transcript encoding ꞵ-tubulin was used as reference. (E) Western blot analysis of 
NQO1 in TA or SOL muscle, n=4. 10-month-old Control, TSCmKO and caAkt mice were 
treated every 72 h with tamoxifen to induce a constitutive active form of Akt (caAkt mice) for 
14 days. (F) Relative transcript expression was quantified by RT-qPCR in GAST muscle, n=4 
(TSCmKO), n=3 (caAkt, Control). Transcripts encoding TBP was used as reference. Data 
represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test (if two groups were 
compared), One-way ANOVA test (if more than two groups were compared).   
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Figure 7. Inactivation of Nrf1 in TSCmKO mice decreases the expression of PSM genes. 
(A) Western blot analysis of mouse embryonic fibroblasts (MEFs), transfected with plasmids 
driving the expression of a shRNA directed to Nrf1 (Nrf1-kd shRNA) or to a scramble sequence 
(Scramble shRNA), and treated with bortezomib (BTZ) in the last 4 hours before lysis. Nrf1 CL 
= Cleaved Nrf1; Nrf1 FL = Full-length Nrf1. Tibialis anterior (TA) muscle of 3-month-old Control 
and TSCmKO mice was electroporated with plasmids driving scramble or Nrf1-kd shRNA. 
Muscles were analyzed 2 weeks later. (B) Western blot analysis of proteasomal subunits 
(PSM), Nrf1 FL, Nrf1 CL and LCR-F1 (Nrf1ꞵ) in electroporated TA muscle, n=3. (C) Left: Delta 
of body weight between electroporated and the contralateral, sham-treated muscle, n=3. Right: 
Relative muscle weight ratio between electroporated and the contralateral, sham-treated 
muscle, n=3. (D) Relative transcript expression was quantified by RT-qPCR in electroporated 
TA muscles, n=3. Transcript encoding Desmin (DES) was used as reference. Data represent 
means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test (if two groups were 
compared), One-way ANOVA test (if more than two groups were compared). 
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Figure S1. Young TSCmKO mice display an atrophy-related gene expression signature. 
(A) Principal component analysis (PCA) of RNA-seq data obtained from extensor digitorum 
longus (EDL) muscles of 3-month-old TSCmKO mice and Control littermates (n=5). Plotting 
principal component 1 (PC1) versus principal component 2 (PC2) illustrates the clear genotype 
specific differentiation of TSCmKO mice and Control littermates. (B) Volcano plot of all genes 
expressed in TSCmKO mice and Control littermates. Red circles indicate significantly 
(p<0.05), DE genes. Blue lines represent a fold-change of +/- 2. The 15 most significantly, DE 
genes are labeled by their gene name. (C) Volcano plot of previously described atrogenes 
found expressed in young TSCmKO mice. Genes involved in protein degradation are labeled 
by their gene name.  
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Figure S2. Ubiquitin proteasome system is enriched in young TSCmKO mice. 
(A) Significantly (p<0.05) DE proteins were obtained from proteomics data from tibialis anterior 
(TA) muscles of 3-month-old, male TSCmKO mice and Control littermates (n=4). DAVID 
enrichment algorithms were applied on all DE proteins to calculate functional annotation 
clustering.  
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Figure S3. Ubiquitin proteasome system is enriched in young TSCmKO mice. 
(A, B) Relative transcript expression was quantified by RT-qPCR in gastrocnemius (GAST) 
muscle from 3-month-old, male TSCmKO and Control mice (n=6). Transcript encoding ꞵ-actin 
was used as reference. (C) Luciferase-based proteasome activity measurement in lysates of 
plantaris (PLA) muscles from 3-month-old, male TSCmKO and Control mice (n=6). (D) 
Western blot analysis of proteasomal subunits (PSM) in tibialis anterior (TA) muscles from 3-
month-old, male TSCmKO and Control mice (n=6). (E) Luciferase-based proteasome activity 
measurement in lysates of PLA muscles from 10-month-old, male TSCmKO (n=3) and Control 
mice (n=4). Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test.  
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Figure S4. Short-term inhibition with rapamycin reverses the increased UPS in 
TSCmKO mice. 
3-month-old Control and TSCmKO mice were treated with rapamycin (RAPA) or vehicle for 3 
days. (A, B) Western blot analysis of mTORC1-Akt-signaling in tibialis anterior (TA) muscle, 
n=4 (Control:RAPA), n = 6 (Control, TSCmKO, TSCmKO:RAPA). (C) Western blot analysis of 
ubiquitinylated proteins in TA muscles, n=4 (Control:RAPA), n = 6 (Control, TSCmKO, 
TSCmKO:RAPA). (D) Relative transcript expression was quantified by RT-qPCR in 
gastrocnemius (GAST) muscle, n=5 (Control:RAPA), n = 6 (Control, TSCmKO, 
TSCmKO:RAPA). Transcript encoding ꞵ-actin was used as reference. Data represent means 
± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, One-way ANOVA test.  
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Figure S5. Activation of mTORC1 for 21 days is sufficient to increase the UPS in most 
adult muscles but not in soleus. 
In 3-month-old mice, Tsc1 deletion was induced in skeletal muscle (iTSCmKO mice) and mice 
were examined 10, 21 or 90 days later, as indicated. (A, B) Western blot analysis of mTORC1-
Akt-signaling in tibialis anterior (TA) muscle, n=4. (C) Relative muscle and organ weight, n=4. 
(D) Luciferase-based proteasome activity measurement in lysates of extensor digitorum 
longus (EDL) muscles from 10-day and 90-day iTSCmKO mice, n=3 (10d Control), n=5 (10d 
iTSCmKO), n=4 (90d Control, 90d iTSCmKO). (E) Analysis of translation initiation using 
m7GTP binding assay in gastrocnemius (GAST) muscle, WCL = whole-cell-lysates, n=3 
(Control), n=4 (iTSCmKO). (F) Relative transcript expression was quantified by RT-qPCR in 
GAST muscle, n=4 (Control), n=5 (iTSCmKO). Transcript encoding ꞵ-tubulin was used as 
reference. (G, H) Western blot analysis of mTORC1/Akt-signaling in soleus (SOL) muscle, 
n=4. Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test. 
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Figure S6. Nrf1 is a key mediator of mTORC1-induced UPS. 
(A) Western blot analysis of NQO1, DDI2 and OGT in tibialis anterior (TA) muscles from 2-
month-old, female TSCmKO and Control mice, n=5. (B) Relative transcript expression was 
quantified by RT-qPCR in TA muscle from 2-month-old, female TSCmKO and Control mice, 
n=5. Transcript encoding ꞵ-tubulin was used as reference. (C) Western blot analysis of Nrf2 
in TA muscles from 2-month-old, female TSCmKO and Control mice, n=5. Data represent 
means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test.  
  | Results - Part 1 - Manuscript | 
 
  80 
 
Figure S7. Inactivation of Nrf1 in TSCmKO mice decreases the expression of PSM 
genes. 
Tibialis anterior (TA) muscle of 3-month-old Control and TSCmKO mice was electroporated 
with plasmids driving scramble or Nrf1-kd shRNA. Muscles were analyzed 2 weeks later. (B, 
C) Western blot analysis of TSC1, proposed targets of Nrf1 and proteins involved in 
autophagy-lysosomal degradation in electroporated TA muscle, n=3. (D) Western blot analysis 
of ubiquitinylated proteins in electroporated TA muscle, n=3. (E, F) Relative transcript 
expression was quantified by RT-qPCR in electroporated TA muscles, n=3. Transcript 
encoding Desmin was used as reference. Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 
0.01, *p ≤ 0.05, Student's t test (if two groups were compared), One-way ANOVA test (if more 
than two groups were compared).  
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Table S1. DE genes (TSCmKO vs. Control), previously described as atrogenes. 
Identification of mTORC1-dependent atrogenes, comparing published mRNA expression data 
of atrogenes with RNA-sequencing data obtained from extensor digitorum longus (EDL) 
muscles from female, 3-month-old TSCmKO mice and Control littermates (n=5). Table of 
previously described atrogenes found expressed in young TSCmKO mice, which are similarly 
regulated as in other types of muscle atrophy (indicated in column “as atrogene”).  
  
Gene Symbol Reference Category as atrogene FC: TSCmKO vs. Control PValue
Atp5a1 Lecker et al. (2004) Energy production Decreased 0.772 0.00083482
Dera Lecker et al. (2004) Energy production Increased 1.845 0.006017387
Dlat Lecker et al. (2004) Energy production Decreased 0.800 0.004699766
Eno3 Lecker et al. (2004) Energy production Decreased 0.760 0.002031758
Glul Lecker et al. (2004) Energy production Increased 2.168 1.09583E-10
Gpd1 Lecker et al. (2004) Energy production Decreased 0.768 0.008314873
Ldha Lecker et al. (2004) Energy production Decreased 0.629 1.28988E-08
Ndufs1 Lecker et al. (2004) Energy production Decreased 0.692 5.17327E-06
Pgam2 Lecker et al. (2004) Energy production Decreased 0.771 0.01473967
Sat1 Lecker et al. (2004) Energy production Increased 1.695 4.34812E-07
Slc25a26 Lecker et al. (2004) Energy production Decreased 0.693 0.000494468
Slc35f5 Lecker et al. (2004) Energy production Increased 2.202 1.34076E-09
Slc7a8 Lecker et al. (2004) Energy production Increased 1.835 0.002277851
Tpi1 Lecker et al. (2004) Energy production Decreased 0.802 0.005044593
Fn1 Lecker et al. (2004) Extracellular matrix Decreased 0.655 0.033173145
Igfbp5 Lecker et al. (2004) Extracellular matrix Decreased 0.563 4.20694E-05
Srl Lecker et al. (2004) Extracellular matrix Decreased 0.689 6.46397E-06
Fam134b Lecker et al. (2004) Miscellaneous Increased 1.704 0.000481954
Hectd1 Lecker et al. (2004) Miscellaneous Increased 1.373 1.58486E-05
Itm2a Lecker et al. (2004) Miscellaneous Decreased 0.341 2.47776E-25
Mt1 Lecker et al. (2004) Miscellaneous Increased 2.333 0.016068802
Nptn Lecker et al. (2004) Miscellaneous Increased 1.265 0.006382659
Nrep Lecker et al. (2004) Miscellaneous Decreased 0.320 1.46442E-12
Ppp1r15a Lecker et al. (2004) Miscellaneous Increased 2.030 5.22626E-13
Sesn1 Lecker et al. (2004) Miscellaneous Increased 2.272 8.65483E-15
Tfrc Lecker et al. (2004) Miscellaneous Decreased 0.639 0.000571293
Txnl1 Lecker et al. (2004) Miscellaneous Increased 1.386 0.00066842
Bnip3 Lecker et al. (2004) Protein degradation Increased 1.687 4.1557E-06
Ctsl Lecker et al. (2004) Protein degradation Increased 1.796 2.47539E-11
Fbxo32 Lecker et al. (2004) Protein degradation Increased 1.994 3.55098E-06
Gabarapl1 Lecker et al. (2004) Protein degradation Increased 1.689 1.07322E-07
Psma5 Lecker et al. (2004) Protein degradation Increased 1.293 0.008270969
Psmc4 Lecker et al. (2004) Protein degradation Increased 1.384 0.000480621
Psmd8 Lecker et al. (2004) Protein degradation Increased 2.227 3.71704E-14
Psme4 Lecker et al. (2004) Protein degradation Increased 2.907 1.03993E-37
Ubb Lecker et al. (2004) Protein degradation Increased 1.661 0.023369007
Ube4b Lecker et al. (2004) Protein degradation Increased 1.312 0.001313838
Eif4ebp1 Lecker et al. (2004) Translation Increased 1.522 0.000538631
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Gene Symbol Reference Category as atrogene FC: TSCmKO vs. Control PValue Direction
Ampd3 Lecker et al. (2004) Energy production Increased 1.164 0.38831336 No
Atp5a1 Lecker et al. (2004) Energy production Decreased 0.772 0.00083482 Yes
Ckmt2 Lecker et al. (2004) Energy production Decreased 1.056 0.626484025 No
Cox7b Sacheck et al. (2007) Energy production Decreased 1.051 0.73402195 No
Dera Lecker et al. (2004) Energy production Increased 1.845 0.006017387 Yes
Dlat Lecker et al. (2004) Energy production Decreased 0.800 0.004699766 Yes
Eno3 Lecker et al. (2004) Energy production Decreased 0.760 0.002031758 Yes
Gclm Sacheck et al. (2007) Energy production Increased 1.073 0.465862491 No
Glul Lecker et al. (2004) Energy production Increased 2.168 1.09583E-10 Yes
Gpd1 Lecker et al. (2004) Energy production Decreased 0.768 0.008314873 Yes
Hadh Sacheck et al. (2007) Energy production Decreased 0.891 0.261879895 No
Idh3b Sacheck et al. (2007) Energy production Decreased 0.749 0.012297508 Yes
Impdh2 Lecker et al. (2004) Energy production Increased 0.739 0.008613491 Opposite
Kctd9 Lecker et al. (2004) Energy production Increased 0.784 0.009665123 Opposite
Ldha Lecker et al. (2004) Energy production Decreased 0.629 1.28988E-08 Yes
Mdh1 Lecker et al. (2004) Energy production Decreased 1.100 0.353706328 No
Ndufa5 Sacheck et al. (2007) Energy production Decreased 0.742 0.010223395 Yes
Ndufb5 Lecker et al. (2004) Energy production Decreased 1.070 0.636153621 No
Ndufb8 Lecker et al. (2004) Energy production Decreased 1.200 0.071159872 No
Ndufs1 Lecker et al. (2004) Energy production Decreased 0.692 5.17327E-06 Yes
Ndufv2 Lecker et al. (2004) Energy production Decreased 0.872 0.177964839 No
Oxct1 Lecker et al. (2004) Energy production Decreased 1.299 0.001993086 Opposite
Pfkfb3 Lecker et al. (2004) Energy production Increased 1.440 0.208317063 No
Pgam2 Lecker et al. (2004) Energy production Decreased 0.771 0.01473967 Yes
Phkg1 Lecker et al. (2004) Energy production Decreased 0.884 0.172463855 No
Sat1 Lecker et al. (2004) Energy production Increased 1.695 4.34812E-07 Yes
Slc25a26 Lecker et al. (2004) Energy production Decreased 0.693 0.000494468 Yes
Slc35f5 Lecker et al. (2004) Energy production Increased 2.202 1.34076E-09 Yes
Slc3a1 Sacheck et al. (2007) Energy production Increased 0.722 0.0593756 No
Slc7a8 Lecker et al. (2004) Energy production Increased 1.835 0.002277851 Yes
Tpi1 Lecker et al. (2004) Energy production Decreased 0.802 0.005044593 Yes
Uqcrc2 Sacheck et al. (2007) Energy production Decreased 0.765 0.000701771 Yes
Col15a1 Lecker et al. (2004) Extracellular matrix Decreased 0.928 0.582998902 No
Col1a1 Lecker et al. (2004) Extracellular matrix Decreased 0.685 0.065231847 No
Col3a1 Lecker et al. (2004) Extracellular matrix Decreased 0.923 0.598449306 No
Col5a2 Lecker et al. (2004) Extracellular matrix Decreased 0.895 0.352859889 No
Fbn1 Lecker et al. (2004) Extracellular matrix Decreased 0.735 0.067117416 No
Fn1 Lecker et al. (2004) Extracellular matrix Decreased 0.655 0.033173145 Yes
Igfbp5 Lecker et al. (2004) Extracellular matrix Decreased 0.563 4.20694E-05 Yes
Lgals1 Lecker et al. (2004) Extracellular matrix Decreased 1.355 0.005441938 Opposite
Postn Lecker et al. (2004) Extracellular matrix Decreased 0.706 0.113889861 No
Smoc2 Lecker et al. (2004) Extracellular matrix Decreased 1.058 0.637320122 No
Srl Lecker et al. (2004) Extracellular matrix Decreased 0.689 6.46397E-06 Yes
Aco2 Raffaello et al. (2006) Miscellaneous Decreased 1.034 0.676217745 No
Actn3 Raffaello et al. (2006) Miscellaneous Increased 0.917 0.460427268 No
Adss Raffaello et al. (2006) Miscellaneous Decreased 0.766 0.016490552 Yes
Ak1 Raffaello et al. (2006) Miscellaneous Decreased 0.698 2.79561E-06 Yes
Apln Coelho et al. (2019) Miscellaneous Increased 0.579 0.010344633 Opposite
Asb15 Coelho et al. (2019) Miscellaneous Increased 3.312 7.17011E-17 Yes
Atp2a1 Raffaello et al. (2006) Miscellaneous Decreased 0.786 0.020388257 Yes
Atp5b Raffaello et al. (2006) Miscellaneous Decreased 0.889 0.115238536 No
Bcat2 Shimizu et al. (2011) Miscellaneous Increased 1.766 5.76154E-06 Yes
Bin1 Raffaello et al. (2006) Miscellaneous Increased 1.167 0.036377463 Yes
Cald1 Raffaello et al. (2006) Miscellaneous Decreased 0.709 0.000964215 Yes
Cap2 Sacheck et al. (2007) Miscellaneous Increased 1.269 0.0031167 Yes
Car3 Raffaello et al. (2006) Miscellaneous Increased 2.875 0.00013848 Yes
Cd68 Sacheck et al. (2007) Miscellaneous Increased 1.811 0.038466052 Yes
Cebpb Schakman et al. (2008) Miscellaneous Increased 1.331 0.027296303 Yes
Cggbp1 Raffaello et al. (2006) Miscellaneous Decreased 1.070 0.35854888 No
Chchd10 Raffaello et al. (2006) Miscellaneous Decreased 0.986 0.880580117 No
Chrna1 Sacheck et al. (2007) Miscellaneous Increased 0.783 0.009504591 Opposite
Cpe Lecker et al. (2004) Miscellaneous Decreased 2.532 1.18252E-18 Opposite
Cryab Raffaello et al. (2006) Miscellaneous Increased 0.905 0.385363655 No
Cs Raffaello et al. (2006) Miscellaneous Decreased 0.799 0.001384295 Yes
Csnk2a2 Lecker et al. (2004) Miscellaneous Increased 1.136 0.182987498 No
Csrp3 Raffaello et al. (2006) Miscellaneous Increased 1.859 0.034243374 Yes
Ctso Raffaello et al. (2006) Miscellaneous Decreased 0.677 8.35026E-05 Yes
Ddit4 Shimizu et al. (2011) Miscellaneous Increased 9.700 1.86346E-09 Yes
Dhrs7c Raffaello et al. (2006) Miscellaneous Decreased 0.670 1.05494E-05 Yes
Dusp5 Coelho et al. (2019) Miscellaneous Increased 1.119 0.807201442 No
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Dysf Sacheck et al. (2007) Miscellaneous Increased 1.059 0.610991092 No
Eef1a1 Raffaello et al. (2006) Miscellaneous Increased 0.862 0.189121727 No
eIF4E3 Soares et al. (2014) Miscellaneous Decreased 1.345 0.002107236 Opposite
Ep300 Schakman et al. (2008) Miscellaneous Increased 1.032 0.689880821 No
Fam134b Lecker et al. (2004) Miscellaneous Increased 1.704 0.000481954 Yes
Fhl1 Raffaello et al. (2006) Miscellaneous Increased 1.147 0.463284408 No
Fst Schiaffino et al. (2013) Miscellaneous Decreased 0.463 2.84293E-05 Yes
Fth1 Raffaello et al. (2006) Miscellaneous Increased 1.786 3.18599E-12 Yes
Gadd45a Raffaello et al. (2006) Miscellaneous Increased 3.928 1.1915E-11 Yes
Gstm1 Raffaello et al. (2006) Miscellaneous Increased 0.992 0.929999747 No
H3f3a Raffaello et al. (2006) Miscellaneous Increased 0.903 0.404957632 No
Hectd1 Lecker et al. (2004) Miscellaneous Increased 1.373 1.58486E-05 Yes
Hes6 Raffaello et al. (2006) Miscellaneous Decreased 2.031 4.95818E-08 Opposite
Hmox1 Kang et al. (2013) Miscellaneous Increased 1.596 0.006936233 Yes
Hopx Coelho et al. (2019) Miscellaneous Decreased 0.933 0.623848781 No
Hspb1 Raffaello et al. (2006) Miscellaneous Increased 2.792 2.51072E-10 Yes
Ifrd1 Lecker et al. (2004) Miscellaneous Increased 1.117 0.429392576 No
Igf1 Coelho et al. (2019) Miscellaneous Decreased 0.611 0.004585933 Yes
Igfbp3 Coelho et al. (2019) Miscellaneous Increased 1.346 0.018578147 Yes
Itm2a Lecker et al. (2004) Miscellaneous Decreased 0.341 2.47776E-25 Yes
Jph2 Lecker et al. (2004) Miscellaneous Decreased 1.261 0.023089985 Opposite
Kcnn3 Sacheck et al. (2007) Miscellaneous Increased 1.943 1.84182E-06 Yes
Kif21b Sacheck et al. (2007) Miscellaneous Decreased 1.469 0.074344807 No
Klf15 Coelho et al. (2019) Miscellaneous Increased 1.535 0.000877052 Yes
Klhl38 Coelho et al. (2019) Miscellaneous Increased 1.246 0.093665245 No
Larp7 Raffaello et al. (2006) Miscellaneous Decreased 0.983 0.847942237 No
Ldb3 Lecker et al. (2004) Miscellaneous Decreased 1.018 0.836238007 No
Lpin1 Lecker et al. (2004) Miscellaneous Increased 0.861 0.151153513 No
Lpp Raffaello et al. (2006) Miscellaneous Increased 0.860 0.089639333 No
Luc7l3 Sacheck et al. (2007) Miscellaneous Decreased 0.932 0.443688011 No
Map1lc3a Raffaello et al. (2006) Miscellaneous Increased 1.546 1.50194E-06 Yes
Mb Raffaello et al. (2006) Miscellaneous Increased 0.851 0.249883454 No
Mbnl1 Raffaello et al. (2006) Miscellaneous Decreased 1.060 0.449247942 No
Mbtd1 Raffaello et al. (2006) Miscellaneous Decreased 0.874 0.156738318 No
Mdh2 Raffaello et al. (2006) Miscellaneous Decreased 0.995 0.963469091 No
Mkl1 Coelho et al. (2019) Miscellaneous Increased 0.948 0.697651339 No
Mmp14 Raffaello et al. (2006) Miscellaneous Increased 0.826 0.137235476 No
Mstn Schiaffino et al. (2013) Miscellaneous Increased 0.938 0.669427386 No
Mt1 Lecker et al. (2004) Miscellaneous Increased 2.333 0.016068802 Yes
mt-Co1 Raffaello et al. (2006) Miscellaneous Decreased 0.947 0.615225242 No
mt-Cytb Raffaello et al. (2006) Miscellaneous Decreased 0.896 0.388008783 No
mt-Nd2 Raffaello et al. (2006) Miscellaneous Decreased 0.970 0.818536604 No
mt-Nd5 Raffaello et al. (2006) Miscellaneous Decreased 0.666 0.000107085 Yes
Mybpc1 Raffaello et al. (2006) Miscellaneous Decreased 0.962 0.719353331 No
Mybpc2 Raffaello et al. (2006) Miscellaneous Decreased 0.674 0.002652255 Yes
Mybph Raffaello et al. (2006) Miscellaneous Increased 0.292 0.003384344 Opposite
Myh4 Raffaello et al. (2006) Miscellaneous Decreased 0.867 0.315484196 No
Myl12a Raffaello et al. (2006) Miscellaneous Increased 1.745 4.95958E-06 Yes
Myl2 Lecker et al. (2004) Miscellaneous Decreased 4.570 1.04916E-05 Opposite
Myom2 Raffaello et al. (2006) Miscellaneous Decreased 1.050 0.692661649 No
Myoz1 Raffaello et al. (2006) Miscellaneous Decreased 0.876 0.093446236 No
Ncam1 Sacheck et al. (2007) Miscellaneous Increased 0.858 0.332660521 No
Nedd4 McClung et al. (2010) Miscellaneous Increased 0.963 0.631656764 No
Nptn Lecker et al. (2004) Miscellaneous Increased 1.265 0.006382659 Yes
Nr1d1 Mayeuf-Louchart et al. (2017) Miscellaneous Decreased 1.069 0.634223225 No
Nrep Lecker et al. (2004) Miscellaneous Decreased 0.320 1.46442E-12 Yes
Pdcd10 Soares et al. (2014) Miscellaneous Decreased 1.046 0.638777982 No
Pdk4 Schakman et al. (2008) Miscellaneous Increased 1.666 0.058119185 No
Pgf Coelho et al. (2019) Miscellaneous Decreased 1.270 0.455643324 No
Pi15 Coelho et al. (2019) Miscellaneous Decreased 0.673 0.002164032 Yes
Pik3c3 Schiaffino et al. (2013) Miscellaneous Increased 0.926 0.45080135 No
Pik3ip1 Coelho et al. (2019) Miscellaneous Increased 1.787 2.4321E-08 Yes
Por Sacheck et al. (2007) Miscellaneous Increased 1.038 0.708727788 No
Ppargc1a Wang et al. (2016) Miscellaneous Decreased 0.439 0.001114996 Yes
Ppp1r15a Lecker et al. (2004) Miscellaneous Increased 2.030 5.22626E-13 Yes
Prnp Sacheck et al. (2007) Miscellaneous Increased 1.154 0.127525651 No
Ptges3 Lecker et al. (2004) Miscellaneous Increased 0.682 0.000155724 Opposite
Pvalb Lecker et al. (2004) Miscellaneous Decreased 0.929 0.45201604 No
Pygm Raffaello et al. (2006) Miscellaneous Decreased 0.851 0.091416563 No
Rpl3 Raffaello et al. (2006) Miscellaneous Increased 0.962 0.733378031 No
Rplp0 Raffaello et al. (2006) Miscellaneous Increased 1.429 0.00067187 Yes
Rplp2 Raffaello et al. (2006) Miscellaneous Increased 0.895 0.460539409 No
Rps18 Raffaello et al. (2006) Miscellaneous Increased 0.777 0.074997948 No
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Rps20 Raffaello et al. (2006) Miscellaneous Increased 0.960 0.684467534 No
S1pr2 Pierucci et al. (2018) Miscellaneous Increased 1.051 0.811661646 No
Sesn1 Lecker et al. (2004) Miscellaneous Increased 2.272 8.65483E-15 Yes
Sh3glb1 Lecker et al. (2004) Miscellaneous Decreased 0.962 0.601217438 No
Slc25a4 Raffaello et al. (2006) Miscellaneous Decreased 0.766 0.000775653 Yes
Sln Sacheck et al. (2007) Miscellaneous Increased 0.902 0.763342753 No
Smpx Raffaello et al. (2006) Miscellaneous Increased 0.890 0.323925335 No
Spns2 Pierucci et al. (2018) Miscellaneous Increased 1.154 0.348541319 No
Tfrc Lecker et al. (2004) Miscellaneous Decreased 0.639 0.000571293 Yes
Tnfrsf12a Hindi et al. (2013) Miscellaneous Increased 5.565 3.47268E-09 Yes
Tnfsf12 Hindi et al. (2013) Miscellaneous Increased 1.619 0.000110984 Yes
Trib3 Choi et al. (2019) Miscellaneous Increased 2.282 0.000129242 Yes
Ttn Raffaello et al. (2006) Miscellaneous Decreased 0.733 0.025587052 Yes
Txnl1 Lecker et al. (2004) Miscellaneous Increased 1.386 0.00066842 Yes
Vdac1 Raffaello et al. (2006) Miscellaneous Decreased 0.842 0.025290137 Yes
Asb2 Bello et al. (2009) Protein degradation Increased 1.321 0.009001682 Yes
Becn1 Mammucari et a. (2017) Protein degradation Increased 1.354 0.000168687 Yes
Bnip3 Lecker et al. (2004) Protein degradation Increased 1.687 4.1557E-06 Yes
Cblb Abe et al. (2013) Protein degradation Increased 0.898 0.232509032 No
Ctsl Lecker et al. (2004) Protein degradation Increased 1.796 2.47539E-11 Yes
Fbxo21 Milan et al. (2015) Protein degradation Increased 1.001 0.997889878 No
Fbxo30 Sartori et al. (2013) Protein degradation Increased 1.626 1.60955E-07 Yes
Fbxo31 Milan et al. (2015) Protein degradation Increased 1.206 0.026383022 Yes
Fbxo32 Lecker et al. (2004) Protein degradation Increased 1.994 3.55098E-06 Yes
Fbxo40 Shi et al. (2011) Protein degradation Increased 1.551 2.55245E-08 Yes
Fbxw7 Shin et al. (2018) Protein degradation Increased 0.974 0.753865897 No
Gabarapl1 Lecker et al. (2004) Protein degradation Increased 1.689 1.07322E-07 Yes
Itch Milan et al. (2015) Protein degradation Increased 1.092 0.211436357 No
Map1lc3b Lecker et al. (2004) Protein degradation Increased 0.914 0.36067096 No
Mdm2 Ramos et al. (2017) Protein degradation Increased 1.313 0.000652836 Yes
Mul1 Lokireddy et al. (2012)* Protein degradation Increased 1.193 0.027112398 Yes
Nsfl1c Piccirillo et al. (2012) Protein degradation Increased 1.262 0.077212307 No
Psma1 Lecker et al. (2004) Protein degradation Increased 1.095 0.42336849 No
Psma5 Lecker et al. (2004) Protein degradation Increased 1.293 0.008270969 Yes
Psmb3 Lecker et al. (2004) Protein degradation Increased 1.048 0.713956947 No
Psmb4 Lecker et al. (2004) Protein degradation Increased 1.097 0.286246068 No
Psmc4 Lecker et al. (2004) Protein degradation Increased 1.384 0.000480621 Yes
Psmd11 Lecker et al. (2004) Protein degradation Increased 1.171 0.15167781 No
Psmd8 Lecker et al. (2004) Protein degradation Increased 2.227 3.71704E-14 Yes
Psme4 Lecker et al. (2004) Protein degradation Increased 2.907 1.03993E-37 Yes
Rps27a Lecker et al. (2004) Protein degradation Increased 1.517 0.051734756 No
Sqstm1 Milan et al. (2015) Protein degradation Increased 2.244 5.98994E-14 Yes
Traf6 Paul et al. (2010) Protein degradation Increased 1.533 2.61125E-09 Yes
Trim32 Kudryashova et al. (2005) Protein degradation Increased 1.422 0.000957328 Yes
Trim54 Centner et al. (2001) Protein degradation Increased 1.243 0.02174058 Yes
Trim55 Centner et al. (2001) Protein degradation Increased 1.174 0.076953289 No
Trim63 Bodine et al. (2001) Protein degradation Increased 2.904 2.25452E-12 Yes
Uba52 Lecker et al. (2004) Protein degradation Increased 0.990 0.966865453 No
Ubb Lecker et al. (2004) Protein degradation Increased 1.661 0.023369007 Yes
Ubc Lecker et al. (2004) Protein degradation Increased 0.983 0.909831012 No
Ube2j1 Lecker et al. (2004) Protein degradation Increased 0.989 0.869643757 No
Ube3b Kerksick et al. (2013) Protein degradation Increased 1.445 2.67442E-06 Yes
Ube4b Lecker et al. (2004) Protein degradation Increased 1.312 0.001313838 Yes
Usp14 Lecker et al. (2004) Protein degradation Increased 1.085 0.433941799 No
Vcp Piccirillo et al. (2012) Protein degradation Increased 1.366 0.008145317 Yes
Acvr2b Magnusson et al. (2005) Signaling Decreased 1.116 0.376621915 No
Adam19 Magnusson et al. (2005) Signaling Increased 0.846 0.218395967 No
Cacng1 Magnusson et al. (2005) Signaling Increased 0.683 0.000879977 Opposite
Camk2d Magnusson et al. (2005) Signaling Increased 0.716 0.000737603 Opposite
Cd82 Magnusson et al. (2005) Signaling Increased 0.524 6.67257E-06 Opposite
Cdkn1a Magnusson et al. (2005) Signaling Increased 1.693 0.002236232 Yes
Ctgf Magnusson et al. (2005) Signaling Increased 1.017 0.933616501 No
Cyr61 Magnusson et al. (2005) Signaling Increased 2.252 2.38375E-09 Yes
Frat2 Magnusson et al. (2005) Signaling Decreased 0.558 2.45013E-06 Yes
Fzd9 Magnusson et al. (2005) Signaling Decreased 1.354 0.036636756 Opposite
Kcna7 Magnusson et al. (2005) Signaling Decreased 1.171 0.243068306 No
Kcnj12 Magnusson et al. (2005) Signaling Decreased 1.054 0.61204453 No
Maged1 Magnusson et al. (2005) Signaling Increased 0.934 0.460836399 No
Mt2 Magnusson et al. (2005) Signaling Increased 1.962 0.06660961 No
Pick1 Magnusson et al. (2005) Signaling Decreased 1.777 7.50285E-12 Opposite
Ptp4a3 Magnusson et al. (2005) Signaling Decreased 0.923 0.334983044 No
Ramp1 Magnusson et al. (2005) Signaling Decreased 0.815 0.082733961 No
Rrad Magnusson et al. (2005) Signaling Increased 2.544 0.002218105 Yes
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Table S2. Unsupervised list of atrophy-related genes (01.01.2019) 
Unsupervised list of atrophy-related genes found in literature, compared with RNA-sequencing 
data obtained from extensor digitorum longus (EDL) muscles from female, 3-month-old 
TSCmKO mice and Control littermates (n=5). Table of atrophy-related genes found expressed 
in young TSCmKO mice. Reference marked with asterisk (*) was retracted (but not regarding 
the findings that describe Mul1 as atrophy-related gene). 
  
Timp1 Magnusson et al. (2005) Signaling Increased 1.111 0.718537876 No
Vegfa Magnusson et al. (2005) Signaling Decreased 0.519 5.70648E-12 Yes
Atf4 Lecker et al. (2004) Transcription Increased 0.957 0.593093155 No
Atf6b Sacheck et al. (2007) Transcription Increased 1.384 0.001401524 Yes
Carm1 Sacheck et al. (2007) Transcription Increased 0.951 0.597099318 No
Cdr2 Magnusson et al. (2005) Transcription Increased 1.155 0.450692469 No
Eftud2 Sacheck et al. (2007) Transcription Increased 1.259 0.013000071 Yes
Ezh1 Lecker et al. (2004) Transcription Increased 1.124 0.126129871 No
Foxo1 Lecker et al. (2004) Transcription Increased 0.893 0.416926684 No
Foxo3 Ikeda et al. (2016) Transcription Increased 1.362 0.000350273 Yes
Id2 Magnusson et al. (2005) Transcription Increased 0.803 0.178071666 No
Junb Lecker et al. (2004) Transcription Decreased 1.296 0.158282182 No
Maf Lecker et al. (2004) Transcription Decreased 0.971 0.811361363 No
Max Lecker et al. (2004) Transcription Increased 1.020 0.835456848 No
Myc Magnusson et al. (2005) Transcription Increased 0.440 6.50308E-07 Opposite
Myog Sacheck et al. (2007) Transcription Increased 0.550 0.028922574 Opposite
Nfe2l2 Lecker et al. (2004) Transcription Increased 1.181 0.075743435 No
Nr4a1 Magnusson et al. (2005) Transcription Decreased 0.840 0.41505349 No
Ppp5c Sacheck et al. (2007) Transcription Increased 1.005 0.971384063 No
Prmt1 Magnusson et al. (2005) Transcription Increased 0.901 0.27035962 No
Rb1 Magnusson et al. (2005) Transcription Increased 1.024 0.765237484 No
Sap30 Magnusson et al. (2005) Transcription Increased 2.068 1.40071E-07 Yes
Srcap Lecker et al. (2004) Transcription Decreased 0.996 0.961149347 No
Tgif1 Lecker et al. (2004) Transcription Increased 0.929 0.919115536 No
Zbtb16 Magnusson et al. (2005) Transcription Decreased 0.977 0.833279877 No
Ddx42 Lecker et al. (2004) Translation Increased 0.860 0.038221699 Opposite
Ddx6 Sacheck et al. (2007) Translation Increased 0.778 0.003429638 Opposite
Eif4a2 Lecker et al. (2004) Translation Increased 0.755 0.001221286 Opposite
Eif4ebp1 Lecker et al. (2004) Translation Increased 1.522 0.000538631 Yes
Eif4g2 Lecker et al. (2004) Translation Increased 0.780 0.000114349 Opposite
Ncl Lecker et al. (2004) Translation Increased 0.881 0.154441289 No
Rpl12 Lecker et al. (2004) Translation Increased 0.545 0.013551729 Opposite
Rrp9 Sacheck et al. (2007) Translation Increased 1.169 0.150852367 No
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Gene Symbol Reference Category as atrogene FC: TSCmKO vs. Control PValue
Ldha Lecker et al. (2004) Energy production Decreased 0.629 1.28988E-08
Ndufs1 Lecker et al. (2004) Energy production Decreased 0.692 5.17327E-06
Slc25a26 Lecker et al. (2004) Energy production Decreased 0.693 0.000494468
Eno3 Lecker et al. (2004) Energy production Decreased 0.760 0.002031758
Gpd1 Lecker et al. (2004) Energy production Decreased 0.768 0.008314873
Pgam2 Lecker et al. (2004) Energy production Decreased 0.771 0.01473967
Atp5a1 Lecker et al. (2004) Energy production Decreased 0.772 0.00083482
Dlat Lecker et al. (2004) Energy production Decreased 0.800 0.004699766
Tpi1 Lecker et al. (2004) Energy production Decreased 0.802 0.005044593
Slc35f5 Lecker et al. (2004) Energy production Increased 2.202 1.34076E-09
Glul Lecker et al. (2004) Energy production Increased 2.168 1.09583E-10
Dera Lecker et al. (2004) Energy production Increased 1.845 0.006017387
Slc7a8 Lecker et al. (2004) Energy production Increased 1.835 0.002277851
Sat1 Lecker et al. (2004) Energy production Increased 1.695 4.34812E-07
Ndufa5 Sacheck et al. (2007) Energy production Decreased 0.742 0.010223395
Idh3b Sacheck et al. (2007) Energy production Decreased 0.749 0.012297508
Uqcrc2 Sacheck et al. (2007) Energy production Decreased 0.765 0.000701771
Igfbp5 Lecker et al. (2004) Extracellular matrix Decreased 0.563 4.20694E-05
Fn1 Lecker et al. (2004) Extracellular matrix Decreased 0.655 0.033173145
Srl Lecker et al. (2004) Extracellular matrix Decreased 0.689 6.46397E-06
Bcat2 Shimizu et al. (2011) Miscellaneous Increased 1.766 5.76154E-06
Nrep Lecker et al. (2004) Miscellaneous Decreased 0.320 1.46442E-12
Itm2a Lecker et al. (2004) Miscellaneous Decreased 0.341 2.47776E-25
Tfrc Lecker et al. (2004) Miscellaneous Decreased 0.639 0.000571293
Mt1 Lecker et al. (2004) Miscellaneous Increased 2.333 0.016068802
Sesn1 Lecker et al. (2004) Miscellaneous Increased 2.272 8.65483E-15
Ppp1r15a Lecker et al. (2004) Miscellaneous Increased 2.030 5.22626E-13
Fam134b Lecker et al. (2004) Miscellaneous Increased 1.704 0.000481954
Txnl1 Lecker et al. (2004) Miscellaneous Increased 1.386 0.00066842
Hectd1 Lecker et al. (2004) Miscellaneous Increased 1.373 1.58486E-05
Nptn Lecker et al. (2004) Miscellaneous Increased 1.265 0.006382659
Igf1 Coelho et al. (2019) Miscellaneous Decreased 0.611 0.004585933
Pi15 Coelho et al. (2019) Miscellaneous Decreased 0.673 0.002164032
Asb15 Coelho et al. (2019) Miscellaneous Increased 3.312 7.17011E-17
Pik3ip1 Coelho et al. (2019) Miscellaneous Increased 1.787 2.4321E-08
Igfbp3 Coelho et al. (2019) Miscellaneous Increased 1.346 0.018578147
mt-Nd5 Raffaello et al. (2006) Miscellaneous Decreased 0.666 0.000107085
Dhrs7c Raffaello et al. (2006) Miscellaneous Decreased 0.670 1.05494E-05
Mybpc2 Raffaello et al. (2006) Miscellaneous Decreased 0.674 0.002652255
Ctso Raffaello et al. (2006) Miscellaneous Decreased 0.677 8.35026E-05
Ak1 Raffaello et al. (2006) Miscellaneous Decreased 0.698 2.79561E-06
Cald1 Raffaello et al. (2006) Miscellaneous Decreased 0.709 0.000964215
Ttn Raffaello et al. (2006) Miscellaneous Decreased 0.733 0.025587052
Slc25a4 Raffaello et al. (2006) Miscellaneous Decreased 0.766 0.000775653
Adss Raffaello et al. (2006) Miscellaneous Decreased 0.766 0.016490552
Atp2a1 Raffaello et al. (2006) Miscellaneous Decreased 0.786 0.020388257
Cs Raffaello et al. (2006) Miscellaneous Decreased 0.799 0.001384295
Vdac1 Raffaello et al. (2006) Miscellaneous Decreased 0.842 0.025290137
Gadd45a Raffaello et al. (2006) Miscellaneous Increased 3.928 1.1915E-11
Car3 Raffaello et al. (2006) Miscellaneous Increased 2.875 0.00013848
Hspb1 Raffaello et al. (2006) Miscellaneous Increased 2.792 2.51072E-10
Csrp3 Raffaello et al. (2006) Miscellaneous Increased 1.859 0.034243374
Fth1 Raffaello et al. (2006) Miscellaneous Increased 1.786 3.18599E-12
Myl12a Raffaello et al. (2006) Miscellaneous Increased 1.745 4.95958E-06
Rplp0 Raffaello et al. (2006) Miscellaneous Increased 1.429 0.00067187
Bin1 Raffaello et al. (2006) Miscellaneous Increased 1.167 0.036377463
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Table S3. DE genes (TSCmKO vs. Control), found as atrophy-related genes 
Identification of mTORC1-dependent atrophy-related genes, comparing a unsupervised list of 
atrophy-related genes with RNA-sequencing data obtained from extensor digitorum longus 
(EDL) muscles from female, 3-month-old TSCmKO mice and Control littermates (n=5). Table 
of previously described atrophy-related genes found expressed in young TSCmKO mice, 
which are similarly regulated as in other types of muscle atrophy (indicated in column “as 
atrogene”). Reference marked with asterisk (*) was retracted (but not regarding the findings 
that describe Mul1 as atrophy-related gene).  
Cebpb Schakman et al. (2008) Miscellaneous Increased 1.331 0.027296303
Ppargc1a Wang et al. (2016) Miscellaneous Decreased 0.439 0.001114996
Fst Schiaffino et al. (2013) Miscellaneous Decreased 0.463 2.84293E-05
Kcnn3 Sacheck et al. (2007) Miscellaneous Increased 1.943 1.84182E-06
Cd68 Sacheck et al. (2007) Miscellaneous Increased 1.811 0.038466052
Cap2 Sacheck et al. (2007) Miscellaneous Increased 1.269 0.0031167
Hmox1 Kang et al. (2013) Miscellaneous Increased 1.596 0.006936233
Tnfrsf12a Hindi et al. (2013) Miscellaneous Increased 5.565 3.47268E-09
Tnfsf12 Hindi et al. (2013) Miscellaneous Increased 1.619 0.000110984
Trib3 Choi et al. (2019) Miscellaneous Increased 2.282 0.000129242
Klf15 Coelho et al. (2019) Miscellaneous Increased 1.535 0.000877052
Ddit4 Shimizu et al. (2011) Miscellaneous Increased 9.700 1.86346E-09
Map1lc3a Raffaello et al. (2006) Protein degradation Increased 1.546 1.50194E-06
Mul1 Lokireddy et al. (2012)* Protein degradation Increased 1.193 0.027112398
Gabarapl1 Lecker et al. (2004) Protein degradation Increased 1.689 1.07322E-07
Bnip3 Lecker et al. (2004) Protein degradation Increased 1.687 4.1557E-06
Becn1 Mammucari et a. (2017) Protein degradation Increased 1.354 0.000168687
Sqstm1 Milan et al. (2015) Protein degradation Increased 2.244 5.98994E-14
Vcp Piccirillo et al. (2012) Protein degradation Increased 1.366 0.008145317
Trim63 Bodine et al. (2001) Protein degradation Increased 2.904 2.25452E-12
Trim54 Centner et al. (2001) Protein degradation Increased 1.243 0.02174058
Ube3b Kerksick et al. (2013) Protein degradation Increased 1.445 2.67442E-06
Trim32 Kudryashova et al. (2005) Protein degradation Increased 1.422 0.000957328
Psme4 Lecker et al. (2004) Protein degradation Increased 2.907 1.03993E-37
Psmd8 Lecker et al. (2004) Protein degradation Increased 2.227 3.71704E-14
Fbxo32 Lecker et al. (2004) Protein degradation Increased 1.994 3.55098E-06
Ctsl Lecker et al. (2004) Protein degradation Increased 1.796 2.47539E-11
Ubb Lecker et al. (2004) Protein degradation Increased 1.661 0.023369007
Psmc4 Lecker et al. (2004) Protein degradation Increased 1.384 0.000480621
Ube4b Lecker et al. (2004) Protein degradation Increased 1.312 0.001313838
Psma5 Lecker et al. (2004) Protein degradation Increased 1.293 0.008270969
Traf6 Paul et al. (2010) Protein degradation Increased 1.533 2.61125E-09
Mdm2 Ramos et al. (2017) Protein degradation Increased 1.313 0.000652836
Fbxo30 Sartori et al. (2013) Protein degradation Increased 1.626 1.60955E-07
Asb2 Bello et al. (2009) Protein degradation Increased 1.321 0.009001682
Fbxo31 Milan et al. (2015) Protein degradation Increased 1.206 0.026383022
Fbxo40 Shi et al. (2011) Protein degradation Increased 1.551 2.55245E-08
Foxo3 Ikeda et al. (2016) Protein degradation Increased 1.362 0.000350273
Vegfa Magnusson et al. (2005) Signaling Decreased 0.519 5.70648E-12
Frat2 Magnusson et al. (2005) Signaling Decreased 0.558 2.45013E-06
Rrad Magnusson et al. (2005) Signaling Increased 2.544 0.002218105
Cyr61 Magnusson et al. (2005) Signaling Increased 2.252 2.38375E-09
Cdkn1a Magnusson et al. (2005) Signaling Increased 1.693 0.002236232
Sap30 Magnusson et al. (2005) Transcription Increased 2.068 1.40071E-07
Atf6b Sacheck et al. (2007) Transcription Increased 1.384 0.001401524
Eftud2 Sacheck et al. (2007) Transcription Increased 1.259 0.013000071
Eif4ebp1 Lecker et al. (2004) Translation Increased 1.522 0.000538631
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Gene Forward primer Reverse primer 
Actb 
(B-actin) CAGCTTCTTTGCAGCTCCTT GCAGCGATATCGTCATCCA 
Atf4 AGCAAAACAAGACAGCAGCC ACTCTCTTCTTCCCCCTTGC 
Bnip3 TTCCACTAGCACCTTCTGATGA GAACACCGCATTTACAGAACAA 
Ctsd CGTCTTGCTGCTCATTCTCGGCC GCCGCCCACCTCCGTCATAGT 
Ctsl GTGGACTGTTCTCACGCTCA TCCGTCCTTCGCTTCATAGG 
Ddi2 TGAACGGGCATCCTGTGAAA AATTGAGAAGGAGCACGCCA 
Des GAGGTTGTCAGCGAGGCTAC CTTCAGGAGGCAGTGAGGAC 
Fbxo32 
(Atrogin-1) CTCTGTACCATGCCGTTCCT GGCTGCTGAACAGATTCTCC 
Gabarapl1 CATCGTGGAGAAGGCTCCTA ATACAGCTGGCCCATGGTAG 
Gadd45a CCGAAAGGATGGACACGGTG TTATCGGGGTCTACGTTGAGC 
Map1lc3b 
(LC3b) CACTGCTCTGTCTTGTGTAGGTTG TCGTTGTGCCTTTATTAGTGCATC 
MuRF1 
(Trim63) ACCTGCTGGTGGAAAACA AGGAGCAAGTAGGCACCTCA 
Nfe2l1 
(Nrf1) CCCTACTCACCCAGTCAGTATG CATCGTGCGAGGAATGAGGA 
Nfe2l2 
(Nrf2) GCCCACATTCCCAAACAAGAT CCAGAGAGCTATTGAGGGACTG 
Nqo1 TTCTCTGGCCGATTCAGAG GGCTGCTTGGAGCAAAATAG 
Ogt TTCGGGAATCACCCTACTTCA TACCATCATCCGGGCTCAA 
Ppp1r15a 
(Gadd34) GACCCCTCCAACTCTCCTTC CTTCCTCAGCCTCAGCATTC 
Psma1 CCTCAGGGCAGGATTCATCAA GAGCGGCAAGCTCTGACTG 
Psma5 AGCAATTGGCTCTGCTTCAG GCATTCAGCTTCTCCTCCAT 
Psmb5 AGGAGCCGCGAATCGAAATG CCAGAAGGTACGGGTTGATCTC 
Psmb6 CTGGGAAAACCGGGAAGTCTC GAGTCCGCTCCTAGAACCAC 
Psmb7 GTGTCGGTGTTTCAGCCAC TCCGCTTCCAAGACAGCATT 
Psmc1 AAGGGGGTCATTCTCTACGG AAGCTCTGAGCCAACCACTC 
Psmc4 TGGTCATCGGTCAGTTCTTG CGGTCGATGGTACTCAGGAT 
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Psmd11 AGGCAGACAGAAGCATTGAAA GGTCCAAAATCCCATGAAACT 
Psmd4 TCTCCTATTCTGGCTGGTGAA CATGCTGCTTAGGTCTGGAAG 
Psmd8 GCCTCAATCTCCTCTTCCTGCTATC GTCTGTCATCTTTTTGGGTGTGC 
Psme4 AGCGTCAACAAGATAAGAATGCT GCCCGATTCCTATATGCTCAAA 
Sqstm1 
(p62) AGGGAACACAGCAAGCTCAT GACTCAGCTGTAGGGCAAGG 
Tbp TGCTGTTGGTGATTGTTGGT CTGGCTTGTGTGGGAAAGAT 
Tubb 
(B-tubulin) GAAGCTGACCACACCCACCT TGAAGAAGTGCAGGCGTGGG 
Vcp 
(p97) GGTTGGGGTTAGAGCAGCTT GCGACTAATCAAACGACGGC 
Table S4: Primers used for quantitative PCR analysis 
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Protein Ab No Company Dilution 
4E-BP1 #9452 Cell Signaling Technology 1:1000 
4E-BP1 p-S65 #9451 Cell Signaling Technology 1:1000 
a-actinin A7732 Sigma 1:5000 
Akt #9272 Cell Signaling Technology 1:1000 
Akt p-S473 #9271 Cell Signaling Technology 1:1000 
BECN1 #3495 Cell Signaling Technology 1:1000 
DDI2 ab197081 Abcam 1:2000 
eIF4E #2067 Cell Signaling Technology 1:1000 
GAPDH #2118 Cell Signaling Technology 1:5000 
GCLC ab41463 Abcam 1:1000 
GFP 11 814 460 001 Roche 1:1000 
LC3B #2775 Cell Signaling Technology 1:1000 
Ubiquitin BML-PW8810 Enzo 1:500 
NFE2L1 (Nrf1) #8052 Cell Signaling Technology 1:1000 
NFE2L2 (Nrf2) #12721 Cell Signaling Technology 1:1000 
NQO1 ab2346 Abcam 1:5000 
OGT #24083 Cell Signaling Technology 1:1000 
SQSTM1 (p62) GP62-C Progen 1:1000 
PA200 18799-1-AP Proteintech 1:500 
PRAS40 #2610 Cell Signaling Technology 1:1000 
PRAS40 p-T246 #2997 Cell Signaling Technology 1:1000 
PSMA* 
(PSMA1,2,3,5,6,7) 
BML-PW8195 Enzo 1:1000 
PSMB5 ab3330 Abcam 1:1000 
PSMB6 #13267 Cell Signaling Technology 1:1000 
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PSMB7 #13207 Cell Signaling Technology 1:1000 
PSMC1 ab140450 Abcam 1:2000 
PSMC5 ab140450 Abcam 1:2000 
S6 #2217 Cell Signaling Technology 1:1000 
S6 p-S235-S236 #2211 Cell Signaling Technology 1:1000 
S6 p-S240-S244 #5364 Cell Signaling Technology 1:1000 
TSC1 A300-316A Bethyl 1:5000 
VCP (p97) #2648 Cell Signaling Technology 1:1000 
Table S5: Primary antibodies used for immunoblotting 
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Part 2 - “Proteasome inhibition in Control and TSCmKO mice” 
Proteasome inhibition has mainly been studied in the context of cancer treatment and 
neurodegenerative diseases because of its anti-inflammatory activity and its ability to induce 
cellular apoptosis and to shift the equilibrium of proteostasis towards cell death (Manasanch 
and Orlowski, 2017). Currently, the three proteasome inhibitors bortezomib (BTZ), carfilzomib 
and ixazomib are approved for the treatment of adult patients with multiple myeloma (Adams 
and Kauffman, 2004; Meng et al., 1999; Richardson et al., 2014; Richardson et al., 2015; 
Richardson et al., 2005; Richardson et al., 2010; Wang et al., 2013). In parallel to the studies 
in cancer treatment, proteasome inhibitors were tested to counteract muscle atrophy by 
reducing accelerated protein degradation. Indeed, several in vivo studies reported beneficial 
effects on muscle proteostasis and atrophy by applying proteasome inhibitors on distinct 
catabolic states, such as sepsis, hindlimb casting and unloading, denervation, immobilization 
or in animal models for muscular dystrophies (Beehler et al., 2006; Carmignac et al., 2011; 
Caron et al., 2011; Fischer et al., 2000; Jamart et al., 2011; Korner et al., 2014; Krawiec et al., 
2005; Supinski et al., 2009; Vargas and Lang, 2008). Although it was shown that BTZ affects 
muscle proteostasis and at least can partially prevent muscle wasting in animal models, its use 
was never approved in patients for treatment of muscle atrophy. In addition, clinical trials with 
BTZ for the treatment of cancer cachexia have not shown consistent results (Madeddu and 
Mantovani, 2009; Penna et al., 2016). 
In this thesis, we investigated the role of mTORC1 in regulating muscle proteostasis and we 
identified the mTORC1-Nrf1-signaling as an important mediator of increasing proteasomal 
biosynthesis and inducing the UPS. To elucidate the role of the 26S proteasome in this 
mechanism and to test if proteasome inhibition is sufficient to attenuate muscle atrophy in 
TSCmKO mice, we recently started to explore the usage of BTZ in skeletal muscle. BTZ 
belongs to the proteasome inhibitor group of boronates, dipeptidyl boronic acids, which 
reversibly bind and inhibit the β5 catalytic enzyme of the 26S proteasome (Adams et al., 1998). 
Unfortunately, there is not much data about the efficacy and the duration of effect of BTZ in 
murine skeletal muscle. Therefore, we first tested the response of BTZ (1 mg/kg) to the 
proteasome activity in skeletal muscles of Control mice. Confirming proper application and 
successful targeting of skeletal muscle, we found a 50% reduction in β5-activity 6 hours after 
BTZ treatment in lysates of plantaris (PLA) muscle (Figure 4A). Interestingly, β5-activity was 
completely restored after 48 hours (Figure 4A). Surprisingly, we found an even more 
pronounced inhibition of the β1-activity, with 75% reduction after 6 hours maintained over 72 
hours ending still with more than 50% reduction (Figure 4A). Finally, β2 activity was not 
affected by proteasome inhibition using BTZ (Figure 4A). 
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Figure 4. Proteasome inhibition using bortezomib in skeletal muscle of Control and TSCmKO mice. 
3-month-old Control mice were treated once with bortezomib (BTZ) or vehicle and have been dissected after 6, 24, 
48 or 72 hours. (A) Luciferase-based proteasome activity measurement in lysates of extensor digitorum longus 
(EDL) muscles. (B) Western blot analysis of ubiquitinylated proteins in tibialis anterior (TA) muscles. 3-month-old 
TSCmKO and Control mice were treated every 72 h with BTZ or vehicle for 4 weeks, n=3. (C) Progression of 
relative fat mass between start and end of the treatment. (D) Progression of relative lean mass between start and 
end of the treatment. (E) Body weight was measured every 6th day and at the last day of treatment. Asterisk 
indicating where body weight was significantly different between Control and Control:BTZ. (F) Relative muscle 
weight after BTZ treatment. (G) Muscle fatigue depicted in percentage of peak force for each contraction (tetani). 
Asterisk indicating significance levels at the last contraction. (H) Peak tetanic force (absolute force) and peak 
specific force (absolute force normalized to cross-sectional area) after BTZ treatment. Data represent means ± 
SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test (if two groups were compared), One-way ANOVA test (if 
more than two groups were compared), Two-way ANOVA test (if multiple time points and more than two groups 
were compared). 
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Accumulation of ubiquitinylated proteins is a direct and functional indication for proteasome 
inhibition. We found the strongest accumulation of ubiquitinylated proteins 24 hours after the 
BTZ treatment (Figure 4B). These findings lead to the assumption that decreased proteasome 
activity precedes the accumulation of ubiquitinylated proteins, and that decreased β5-activity 
is required and as well the limiting factor, for proteasomal degradation in skeletal muscle. 
These preliminary experiments were performed with n=1 (6 h, 24 h and 48 h) and with n=2 (72 
h) to study the response of BTZ prior to a long-term treatment in Control and TSCmKO mice. 
Therefore, higher n number would be necessary to make statistics and to make conclusive 
statements. 
To test if proteasome inhibition is sufficient to attenuate muscle atrophy in TSCmKO mice, we 
subjected young TSCmKO and Control mice to a 4-week proteasome inhibition using BTZ (1 
mg/kg, every 72 hours, intraperitoneally injections). Both, Control and TSCmKO mice, lost 
body mass upon proteasome inhibition, due to a strong decrease in fat mass (Figure 4C, 4E). 
Lean mass showed a trend to be decreased in Control mice but not in TSCmKO mice with BTZ 
(Figure 5D). We found a trend to decreased relative muscle weight in TSCmKO and Control 
mice with BTZ (Figure 4F). As we previously showed, peak tetanic and specific force were 
significantly decreased in TSCmKO mice (Castets et al., 2013) and we did rather observe a 
trend to decreased than improved tetanic force after the BTZ treatment in Control and 
TSCmKO mice (Figure 4H). Nevertheless, we found a weak trend to increased peak specific 
force in TSCmKO mice with BTZ compared to vehicle-treated TSCmKO mice (Figure 4H). 
Because absolute force was rather decreased and specific force shows a trend to be 
increased, we assume alterations to the cross-sectional area of TSCmKO mice treated with 
BTZ. Interestingly, we found a significant improvement in fatigue resistance of young TSCmKO 
mice compared to Control littermates, and even more improved fatigue resistance upon 
proteasome inhibition in TSCmKO mice but not in Control mice (Figure 4G). This is on one 
side an indication for more oxidative fibers and on the other hand, it could mean that fast fibers 
are less atrophic. Altogether, these data suggest rather mild changes to the muscle histology 
and physiology in Control and TSCmKO mice after 4 weeks of BTZ treatment. Important to 
note is, that we performed this experiments with n=3, which is not enough statistical power to 
properly analyze histological and physiological data. Moreover, we will have to analyze fiber 
size and cross-sectional area, fiber type distribution and the ubiquitin-proteasome system. 
Since Nrf1 was described as a key-driver of the “bounce-back” response upon proteasome 
inhibition (Radhakrishnan et al., 2010; Sha and Goldberg, 2014; Steffen et al., 2010), it will be 
interesting to test how Nrf1 is regulated in skeletal muscle of Control and TSCmKO mice. 
Therefore, Nrf1-activity could also explain a rather mild response to the BTZ treatment, 
assuming continual restoration of proteasome function, due to newly synthesized proteasomal 
subunits. 
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In addition, we assume that proteasome inhibition using BTZ (1 mg/kg) in skeletal muscle, 
completely blocks proteasome degradation only during the first 24 hours. Therefore, in a 72-
hours treatment during 4 weeks there will be alternating states of active and inhibited 
proteasome degradation.  Finally, the increase of the UPS in TSCmKO mice is relatively mild 
compared to other catabolic conditions, such as starvation or denervation. We assume that a 
mild increase of the UPS, over days and month, is the reason for the atrophy in TSCmKO 
mice. Therefore, proteasome inhibition in alternating states of active and inactive degradation 
during four weeks may lead to marginally improvements in muscle mass but might also be a 
good option for therapeutic strategies. Even though longer treatment durations are difficult to 
perform because of the whole-body adverse effects of proteasome inhibitors, there might be 
possibilities to dampen, but not inactivate, proteasome degradation. 
 
Results - Part 2 - Material and Methods 
Mice 
All mice were maintained in a licensed animal facility with a fixed 12 h dark-light cycle and 
were allowed for food and water ad libitum. All animal studies were performed under the 
guidelines and the law of the Swiss authorities and were regularly controlled and approved by 
the veterinary office. 
 
Animal experiments 
In some experiments mice were intraperitoneally injected with bortezomib (BTZ; 1 mg/kg; 
Selleck Chemicals) diluted in saline every 72 hours for four consecutive weeks. This mice were 
weighed before each injection. For the time course study of BTZ in skeletal muscle, BTZ (1 
mg/kg; Selleck Chemicals) diluted in saline was once intraperitoneally injected. 
 
In vitro muscle force 
In vitro force measurements of extensor digitorum longus (EDL) muscles were conducted as 
described previously (Bentzinger et al., 2008). Muscle fatigue was measured by repeated 
stimulation (number of contractions) at 200 Hz every 8 s and then recorded by using the Aurora 
Scientific Inc. Model 610A Dynamic Muscle Control Software. Graph displays maximal peak 
force of each contraction. 
 
Ubiquitinylation analysis 
Dissected muscle was rapidly frozen in liquid nitrogen. Frozen muscles were pulverized on a 
metal plate chilled in liquid nitrogen and directly snap-frozen as pellet in liquid nitrogen. 
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Samples were lysed in cold Ub-lysis-buffer (1 mM EDTA, 25 µM MG 132, 50 mM N-
ethylmaleimide, 50 mM TrisHCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% SDS, ddH2O) supplemented with phosphatase and protease inhibitor cocktail tablets 
(Roche), incubated on a rotating wheel for 2 h at 4°C and sonicated twice for 10 s. Afterwards, 
the lysate was centrifuged at 16,000 g for 20 min at 4°C. Supernatant (cleared lysates) were 
used to determine total protein amount using the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific) according to manufacturer’s protocol. Immunoblotting was performed as described 
above. 
 
Proteasome activity assay 
Proteasome activity assay was adapted from a protocol described previously (Strucksberg et 
al., 2010). Briefly, dissected EDL muscles were rinsed in ice-cold PBS, immediately cut into 5-
6 pieces and directly lysed in ice-cold PBS-E (5 mM EDTA pH 8.0, PBS pH 7.2) and sonicated 
two times for 10 s. Afterwards, the lysate was centrifuged at 13,000 g for 5 min at 4°C. 
Supernatant (cleared lysates) were used to determine total protein amount using the Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer’s protocol. Three 
individual luciferase-based Proteasome-GloTM Assay Systems (Promega) were used to 
measure the activity of each peptidase of the proteasome. Assay was performed on white, 96-
well microplates (greiner BIO-ONE) and luminescence was measured with Infinite M1000 
(Tecan). Human, purified 20S proteasome (Enzo Life Sciences, BML-PW8720) was used as 
positive control. Proteasome inhibitor MG 132 (50 µM, TOCRIS Biotechne) was used for 
measuring non-proteasomal activity in this assay, which was used for background subtraction. 
 
Statistical analysis 
Data are presented as the mean value and the respective standard error of the mean (SEM, 
error bars). Student’s t test was used when two groups were compared to evaluate statistical 
significance. One-way or two-way analysis of variance (ANOVA) test with Tukey’s correction 
for multiple comparisons were used to compare more than two groups. A confidence level of 
0.05 was accepted for statistical significance.
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Part 3 - “Proteasome activity in sarcopenia” 
Similar to what we observe in TSCmKO mice, the muscle loss that is characteristic for 
sarcopenia develops slowly and gradually over time (Cohen et al., 2015). However, this 
process is strongly accelerated in TSCmKO mice, as these mice undergo many symptoms of 
precocious sarcopenia (Bentzinger et al., 2013; Castets et al., 2013; Guridi et al., 2015). 
In this thesis we investigated the role of mTORC1 in regulating muscle proteostasis and we 
identified the mechanism that sustained active mTORC1 induces the ubiquitin-proteasome 
system (UPS) via the transcriptional regulator Nrf1. Both, the mTORC1 signaling as well as 
the UPS are considered as potential treatment targets in sarcopenia (Cohen et al., 2015; Yoon, 
2017). The role of mTORC1 activity in sarcopenia is still controversially discussed. Several 
studies described reduced mTORC1 activity and decreased protein synthesis rates as the 
main reason for muscle wasting in the elderly (Cuthbertson et al., 2005; Leger et al., 2008; 
Pallafacchina et al., 2002). However, recent studies observed hyper-phosphorylation of 
mTORC1 in aged human muscles, but also in muscles of aged mice and rats (Joseph et al., 
2019; Markofski et al., 2015; White et al., 2016). Importantly, a recent study reported beneficial 
effects for mTORC1 inhibition on muscle wasting in aged rats (Joseph et al., 2019). 
Since muscles of TSCmKO mice and sarcopenic muscles share many common characteristics 
but also share a strong activation of the mTORC1-signaling, we wondered if the UPS is 
induced in sarcopenic muscles as well. For that reason, we measured proteasome activity for 
all three catalytic enzymes of the 26S proteasome in plantaris muscles of young, 8-month-old 
mice and compared them with plantaris muscles of sarcopenic, 28-month-old mice. 
Chymotrypsin-like (β5) activity was not altered between 8- and 28-month-old mice (Figure 5A). 
We found caspase-like (β1) activity significantly decreased and trypsin-like (β2) activity 
significantly increased in 28-month-old, sarcopenic mice compared to young 8-month-old mice 
(Figure 5A). Therefore, we found ambiguous results about the proteasome activity in 
sarcopenic mice. There is a thin line between normally aged muscles and sarcopenic muscles, 
which somewhen rapidly start to loose muscle mass. By normalizing the body weight to the 
muscle weight, we calculated a factor that is representative for the relative muscle wasting of 
the plantaris in a particular mouse. We found in the 28-month-old mice a separation of four 
mice with a mild or no muscle wasting, similar to young mice and a group of four mice with 
strong muscle wasting (Figure 5B, 5C, 5D). By correlating this wasting factor with the 
proteasome activity revealed that the decrease in β1-activity was specific for muscles with mild 
wasting (Figure 5C). Instead, muscles with stronger wasting displayed similar proteasome 
activity as found in muscles of young mice (Figure 5C). Similar correlation was obtained for 
β5-activity (Figure 5B).  
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Figure 5. Proteasome activity in sarcopenic muscles 
Proteasome activity was measured in plantaris (PLA) muscle of young 8-month-old, aged 24-month-old and 
sarcopenic 28-month-old mice. (A) Luciferase-based proteasome activity measurement in lysates of PLA muscles, 
n=10 (8 month, 24 month), n=8 (28 month). (B) Linear regression and correlation of proteasome activity and relative 
muscle wasting for β5-activity, n=10 (8 month, 24 month), n=8 (28 month). (C) Linear regression and correlation of 
proteasome activity and relative muscle wasting for β1-activity, n=10 (8 month, 24 month), n=8 (28 month). (D) 
Linear regression and correlation of proteasome activity and relative muscle wasting for β2-activity, n=10 (8 month, 
24 month), n=8 (28 month). Data represent means ± SEM, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, Student's t test (if 
two groups were compared), Pearson correlation coefficients (if correlation was analyzed). 
 
The significant increase found for β2-activity in 28-month-old mice compared with 8-month-old 
mice is also due to muscles, which undergo stronger wasting (Figure 5D). Surprisingly, we 
almost found significant correlation for β2-activity and the muscle wasting in 28-month-old, 
sarcopenic mice (Figure 5D). Interestingly, β2-activity of the 26S proteasome was also slightly 
stronger increased in young TSCmKO mice (Manuscript Figure 2F) and even more stronger 
increased in 10-month-old TSCmKO mice (Manuscript Figure S3E) with muscles displaying 
strong muscle wasting and myopathy (Castets et al., 2013). Moreover, β2-activity was not 
reversed in young TSCmKO mice treated with rapamycin for 3 days (Manuscript Figure 3C). 
In contrast, muscles with constitutive activation of Akt, which are hypertrophic and have no 
signs of muscle wasting or myopathy, had a normal, mild activation of β2-activity as observed 
for β1- and β5-activity (Manuscript Figure 5C). Altogether, our data demonstrates that β2-
activity of the proteasome is characteristically increased in muscles undergoing wasting, 
atrophy, myopathy and sarcopenia. Since we measure proteasome activity in lysates of muscle 
tissue, one explanation for this observation could be the invasion of muscle fibers by other cell 
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types (i.e. inflammatory cells), which may display distinct proteasome activity than muscle 
fibers. To make a statement about the activity of the UPS in sarcopenia and whether mTORC1 
regulates the UPS in sarcopenic muscles or not would need further investigations. However, 
our results clearly demonstrate that proteasome activity is not similarly increased as in 
TSCmKO mice. Nevertheless, sarcopenic muscles, characterized by pronounced muscle 
wasting show a clear trend for increased proteasome β2-activity. 
Besides, it would be interesting to test if Nrf1 regulates proteasomal biosynthesis in sarcopenic 
muscles. Dampening of the Nrf1-activity could be a possibility to make muscle proteostasis 
more sensitive for proteasome inhibition. Unfortunately, there is no approach for using 
proteasome inhibitors in sarcopenia. On the other hand, many aging studies reported a 
decrease of PSM genes, proteasome function and the UPS with age in different tissues and 
organs (Chondrogianni and Gonos, 2005; Dahlmann, 2007; Gaczynska et al., 2001; Lee et al., 
1999; Lee et al., 2000; Tonoki et al., 2009). Overexpression or activating Nrf1 might contribute 
to restore proteasomal function with age. Particularly, in age-related neurodegenerative 
disorders, such as Alzheimer’s (Keck et al., 2003), Parkinson’s (McNaught et al., 2003) or 
Huntington’s disease (Seo et al., 2004), malfunctioning of the UPS could be overcome by 
activating Nrf1. 
 
Results - Part 3 - Material and Methods 
Mice 
All mice were maintained in a licensed animal facility with a fixed 12 h dark-light cycle and 
were allowed for food and water ad libitum. All mice of the aging study were fed with a semi-
purified diet called AIN93M (KLIBA NAFAG). All animal studies were performed under the 
guidelines and the law of the Swiss authorities and were regularly controlled and approved by 
the veterinary office. 
 
Proteasome activity assay 
Proteasome activity assay was adapted from a protocol described previously (Strucksberg et 
al., 2010). Briefly, dissected plantaris (PLA) muscles were rinsed in ice-cold PBS, immediately 
cut into 5-6 pieces and directly lysed in ice-cold PBS-E (5 mM EDTA pH 8.0, PBS pH 7.2) and 
sonicated two times for 10 s. Afterwards, the lysate was centrifuged at 13,000 g for 5 min at 
4°C. Supernatant (cleared lysates) were used to determine total protein amount using the 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer’s protocol. 
Three individual luciferase-based Proteasome-GloTM Assay Systems (Promega) were used to 
measure the activity of each peptidase of the proteasome. Assay was performed on white, 96-
well microplates (greiner BIO-ONE) and luminescence was measured with Infinite M1000 
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(Tecan). Human, purified 20S proteasome (Enzo Life Sciences, BML-PW8720) was used as 
positive control. Proteasome inhibitor MG 132 (50 µM, TOCRIS Biotechne) was used for 
measuring non-proteasomal activity in this assay, which was used for background subtraction. 
 
Statistical analysis 
All experiments were performed on a minimum of n (number of individual experiments) ≥3 
independent biological samples. In all graphs, data are presented as the mean value and the 
respective standard error of the mean (SEM, error bars). Student’s t test was used when two 
groups were compared to evaluate statistical significance. Pearson correlation was used to 
statistically analyze correlation betwenn proteasome activity and muscle wasting. A confidence 
level of 0.05 was accepted for statistical significance. 
  | Conclusions and future prospects | 
 
  101 
7. Conclusions and future prospects 
Activation of mTORC1 in skeletal muscle is generally associated with growth, increasing 
translation and protein synthesis, promoting anabolism and mediating hypertrophy. In contrast, 
sustained activation of mTORC1 in skeletal muscles was previously shown to cause a 
blockage in autophagy induction and muscle atrophy, resulting in a severe muscle wasting and 
myopathy. 
In this thesis, mice with a muscle-specific ablation of TSC1 (TSCmKO mice), which leads to 
sustained activation of mTORC1, were used as a model to explore the role of mTORC1 in 
regulating muscle proteostasis. It was demonstrated that TSCmKO mice express a large set 
of atrophy-related genes, mainly involved in protein degradation processes. This strong, 
atrophic response in transcriptional regulation, highlighted the importance to explore new 
mechanisms of how mTORC1 controls catabolic processes to regulate muscle proteostasis. 
This thesis revealed that sustained activation of mTORC1 leads to an overall induction of the 
ubiquitin-proteasome system (UPS). This induction includes ubiquitin-E3-ligases, 
ubiquitinylation, transcriptional activation of proteasomal biosynthesis and increased 
proteasome activity. However, if the increase of the UPS also effectively increases overall 
protein degradation rates, remains to be tested. This would be essential for associating 
induced UPS activity with muscle atrophy. 
Furthermore, distinct interventions were used to identify the prerequisites and to dissect the 
mechanism leading to an increased UPS in TSCmKO mice. It was demonstrated that short-
term treatment with rapamycin hinders the induction of the UPS, and that short-term activation 
of mTORC1 during 21 days is sufficient to induce it. The identification of a new mechanism 
regulating muscle proteostasis revealed that an mTORC1-dependent activation of the UPS is 
mediated by the transcription factor Nrf1. Taken together, it appears that sustained activation 
of mTORC1-signaling induces the UPS via two separate catabolic processes: First, by 
transcriptionally inducing proteasomal biosynthesis mediated through Nrf1. Second, by the 
feedback mechanism leading to deceased Akt activity and increased FoxO transcription factor 
activity, which results in the activation of an atrophy-related gene program, increased 
expression of various ubiquitin-E3-ligases and increased ubiquitinylation. Further 
investigations are needed to ascertain if the increase of Nrf1 is regulated in an mTORC1-direct 
manner or if it is increased as an acute response to a secondary consequence, such as 
increased protein synthesis, blocked autophagy induction or accumulation of misfolded 
proteins and increased ER-stress. In either case, it remains to elucidate if mTORC1 regulates 
Nrf1 via SREBF1 or by a completely unknown, new mechanism. 
This thesis further demonstrated that the slow-twitch muscle soleus strongly varies in the 
response to sustained activation of mTORC1. Similar to fast-twitch muscles, the soleus muscle 
  | Conclusions and future prospects | 
 
  102 
of TSCmKO mice displays increased protein synthesis but in contrast no activation of the UPS. 
Why Nrf1 as well as FoxO transcription factors were not induced in the soleus muscles of 
TSCmKO mice, remains obscure and needs further investigations. One possible explanation 
for the “FoxO-part” would be that the status of Akt phosphorylation is not the limiting factor of 
FoxO phosphorylation in these muscles. FoxO was also shown to be regulated by post-
translational modifications, such as acetylation, ubiquitinylation and methylation. Similarly, one 
possible explanation for the “Nrf1-part” would be that one of the post-translational regulators 
of Nrf1 (i.e. p97, OGT, DDI2), which were shown in this thesis to be regulated in an mTORC1-
dependent way in fast-twitch muscles, repress the activity of Nrf1 in the soleus. Nevertheless, 
this would not explain the absence of the transcriptional increase of Nrf1 observed in fast-
twitch muscles. Another possibility is, that the basal activity of mTORC1 and the rates in protein 
synthesis are highly different between slow and fast-twitch muscles and therefore a potential 
threshold to induce a catabolic response could be completely different. 
In addition, this thesis showed that inactivation of Nrf1 for two weeks in TSCmKO mice strongly 
decreases the expression of proteasomal subunits and shows a trend for increased muscle 
weight. These results have to be confirmed in TSCmKO mice with prolonged inactivation of 
Nrf1. We hypothesize that prolonged inactivation of Nrf1 will result in an attenuation of the 
muscle atrophy in TSCmKO mice, which in parallel will demonstrate that an mTORC1-Nrf1-
dependent increase of the UPS causes muscle atrophy in TSCmKO mice. 
Increased Nrf1-activtiy is generally directly associated with an evolutionary conserved 
response mechanism upon proteasome perturbation to increase proteasomal biosynthesis and 
to maintain cellular proteostasis. Thus, Nrf1 received significant medical relevance as regulator 
of this important compensatory response that promotes tumor cell survival and attenuates 
therapeutic efficacy. Therefore, active Nrf1 in muscle might reduce the efficacy of proteasome 
inhibitors in the treatment of muscle wasting, as for example seen in sarcopenia. Indeed, this 
thesis demonstrated that TSCmKO mice show neither an attenuation of muscle atrophy nor 
an improvement of muscle function after bortezomib treatment. Nevertheless, extensive 
experiments are necessary to completely characterize the application of bortezomib in 
TSCmKO mice. Particularly, describing the role of Nrf1, in muscles of TSCmKO mice, in 
mediating proteasomal biosynthesis upon bortezomib treatment, would be interesting for future 
therapeutic strategies. 
The results presented in this thesis unraveled a new mechanism of how mTORC1 regulates 
the ubiquitin-proteasome system. In addition, these findings may lead to the thorough 
characterization of Nrf1 as a new possible target to slow-down the massive muscle wasting 
observed in cachexia or sarcopenia. 
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